PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 17532782-7 2007 CONCLUSIONS: CD patients with BB genotype of HSP70-2 polymorphism tend to experience a more severe clinical course and allele A is associated with more severe UC. boeravinone B 30-32 heat shock protein family A (Hsp70) member 2 Homo sapiens 45-52 17557252-3 2007 RESULTS: The frequencies of the VDR Tru I genotype in the groups were: TT 68.7%, Tt 26.3%, tt 5.0%; VDR Bsm I were: BB 6.2%, Bb 52.5%, bb 41.3%; Both polymorphisms were under Hardy-Weinberg equilibrium. boeravinone B 116-118 vitamin D receptor Homo sapiens 32-35 17557252-3 2007 RESULTS: The frequencies of the VDR Tru I genotype in the groups were: TT 68.7%, Tt 26.3%, tt 5.0%; VDR Bsm I were: BB 6.2%, Bb 52.5%, bb 41.3%; Both polymorphisms were under Hardy-Weinberg equilibrium. boeravinone B 116-118 vitamin D receptor Homo sapiens 100-103 17557252-3 2007 RESULTS: The frequencies of the VDR Tru I genotype in the groups were: TT 68.7%, Tt 26.3%, tt 5.0%; VDR Bsm I were: BB 6.2%, Bb 52.5%, bb 41.3%; Both polymorphisms were under Hardy-Weinberg equilibrium. boeravinone B 125-127 vitamin D receptor Homo sapiens 32-35 17557252-3 2007 RESULTS: The frequencies of the VDR Tru I genotype in the groups were: TT 68.7%, Tt 26.3%, tt 5.0%; VDR Bsm I were: BB 6.2%, Bb 52.5%, bb 41.3%; Both polymorphisms were under Hardy-Weinberg equilibrium. boeravinone B 135-137 vitamin D receptor Homo sapiens 32-35 17538237-10 2007 Based on the present findings, it was suggested that Mrp3 in the phase III reaction (drug elimination) contributed to the resistance to BB hepatotoxicity in addition to the suppression of the phase I reaction (metabolic activation) and the induction of the phase II reaction (detoxification). boeravinone B 136-138 ATP binding cassette subfamily C member 3 Rattus norvegicus 53-57 16760468-3 2006 In this report we demonstrate that JNK activity is necessary for platelet-derived growth factor (PDGF)-BB-induced chemotaxis of primary foreskin fibroblasts and in other cell types. boeravinone B 103-105 mitogen-activated protein kinase 8 Homo sapiens 35-38 17379004-0 2007 Limitation by p70 S6 kinase of platelet-derived growth factor-BB-induced interleukin 6 synthesis in osteoblast-like MC3T3-E1 cells. boeravinone B 62-64 interleukin 6 Mus musculus 73-86 17239832-5 2007 This is in accord with previous results demonstrating the presence of isoform BB, but not MM, in the few GP-containing brain and spinal cord neurons and in vagus nerve axons. boeravinone B 78-80 glycogen phosphorylase L Rattus norvegicus 105-107 16871271-7 2007 The frequency of the ec-NOS gene intron 4 genotype were found as bb=41.7%, ab=50% and aa=8.3% in the sildenafil responders and bb=93.5% and ba=6.5% in the sildenafil non-responders. boeravinone B 65-67 nitric oxide synthase 3 Homo sapiens 21-27 16871271-7 2007 The frequency of the ec-NOS gene intron 4 genotype were found as bb=41.7%, ab=50% and aa=8.3% in the sildenafil responders and bb=93.5% and ba=6.5% in the sildenafil non-responders. boeravinone B 127-129 nitric oxide synthase 3 Homo sapiens 21-27 17216280-11 2007 CONCLUSIONS/INTERPRETATION: The results support a role for post-translational modifications and PIMT in the development of type 1 diabetes in the diabetes-prone BB rat, and perhaps also in humans. boeravinone B 161-163 protein-L-isoaspartate (D-aspartate) O-methyltransferase 1 Rattus norvegicus 96-100 17316105-5 2007 Insulin glulisine complements insulin glargine (21(A)-Gly30(Ba)-L-Arg-30(Bb)-L-Arg-human insulin), the first long-acting basal insulin analog that displays a smoothed time-action profile with a 24-h duration of action. boeravinone B 73-75 insulin Homo sapiens 0-7 17316105-5 2007 Insulin glulisine complements insulin glargine (21(A)-Gly30(Ba)-L-Arg-30(Bb)-L-Arg-human insulin), the first long-acting basal insulin analog that displays a smoothed time-action profile with a 24-h duration of action. boeravinone B 73-75 insulin Homo sapiens 89-96 17316105-5 2007 Insulin glulisine complements insulin glargine (21(A)-Gly30(Ba)-L-Arg-30(Bb)-L-Arg-human insulin), the first long-acting basal insulin analog that displays a smoothed time-action profile with a 24-h duration of action. boeravinone B 73-75 insulin Homo sapiens 89-96 17202743-7 2007 The VDR polymorphisms among cases (BB 3%, Bb 18%, bb 80%; AA 15%, Aa 38%, aa 47%; and TT 81%, Tt 17%, tt 3%) did not differ significantly from those among controls (BB 1%, Bb 13%, bb 86%; AA 16%, Aa 46%, aa 38%; and TT 86%, Tt 13%, tt 1%). boeravinone B 42-44 vitamin D receptor Homo sapiens 4-7 17202743-7 2007 The VDR polymorphisms among cases (BB 3%, Bb 18%, bb 80%; AA 15%, Aa 38%, aa 47%; and TT 81%, Tt 17%, tt 3%) did not differ significantly from those among controls (BB 1%, Bb 13%, bb 86%; AA 16%, Aa 46%, aa 38%; and TT 86%, Tt 13%, tt 1%). boeravinone B 50-52 vitamin D receptor Homo sapiens 4-7 18336098-14 2007 The distribution of VDR alleles in patients with urolithiasis was similar to controls, although after grouping genotypes, a lower distribution of BB and tt polymorphisms were observed in patients suffering from urolithiasis. boeravinone B 146-148 vitamin D receptor Homo sapiens 20-23 16972262-5 2006 We found that islets of non-diabetic BB rats became positive to both IL-1beta and IL-4 very early on, confirming a local but intense production of both cytokines within the islets during the initial non-diabetic period. boeravinone B 37-39 interleukin 1 beta Rattus norvegicus 69-77 16972262-5 2006 We found that islets of non-diabetic BB rats became positive to both IL-1beta and IL-4 very early on, confirming a local but intense production of both cytokines within the islets during the initial non-diabetic period. boeravinone B 37-39 interleukin 4 Rattus norvegicus 82-86 17082646-3 2006 Furthermore, we observed that pancreatic islets of DRlyp/lyp rats as well as those of diabetes-inducible BB DR(+/+) rats potentially recruit innate cells through eotaxin expression. boeravinone B 105-107 C-C motif chemokine ligand 11 Rattus norvegicus 162-169 17064701-0 2006 Eosinophilic bowel disease controlled by the BB rat-derived lymphopenia/Gimap5 gene. boeravinone B 45-47 GTPase, IMAP family member 5 Rattus norvegicus 72-78 16879805-6 2006 This is in agreement with the occurrence of solely the BB isoform in the few brain and spinal cord neurons that contain GP. boeravinone B 55-57 glycogen phosphorylase L Rattus norvegicus 120-122 16818425-2 2006 Results showed that the PRLR and NCOA1 loci exerted the greatest impact on litter size: the average TNB from genotype AA was 2.28-3.33 more than that from BB (P<0.01) and the average NBA from AA was 1.57-3.30 more than that from BB (P<0.01). boeravinone B 155-157 prolactin receptor Sus scrofa 24-28 16805958-7 2006 These results suggest that calophyllolide (2) and mammea B/ BB (3) induced apoptosis in HL-60 cells through activation of the caspase-9/caspase-3 pathway, which is triggered by mitochondrial dysfunction. boeravinone B 60-62 caspase 9 Homo sapiens 126-135 16805958-7 2006 These results suggest that calophyllolide (2) and mammea B/ BB (3) induced apoptosis in HL-60 cells through activation of the caspase-9/caspase-3 pathway, which is triggered by mitochondrial dysfunction. boeravinone B 60-62 caspase 3 Homo sapiens 136-145 18943752-9 2006 We conclude that the pyramid line containing genes Xa4, xa5, and Xa21 would be the most promising and valuable genotype for improving Korean japonica cultivars for BB resistance. boeravinone B 164-166 transcription initiation factor IIA subunit 2 Oryza sativa Japonica Group 56-59 18943752-9 2006 We conclude that the pyramid line containing genes Xa4, xa5, and Xa21 would be the most promising and valuable genotype for improving Korean japonica cultivars for BB resistance. boeravinone B 164-166 receptor kinase-like protein Xa21 Oryza sativa Japonica Group 65-69 16818425-2 2006 Results showed that the PRLR and NCOA1 loci exerted the greatest impact on litter size: the average TNB from genotype AA was 2.28-3.33 more than that from BB (P<0.01) and the average NBA from AA was 1.57-3.30 more than that from BB (P<0.01). boeravinone B 155-157 nuclear receptor coactivator 1 Sus scrofa 33-38 16818425-2 2006 Results showed that the PRLR and NCOA1 loci exerted the greatest impact on litter size: the average TNB from genotype AA was 2.28-3.33 more than that from BB (P<0.01) and the average NBA from AA was 1.57-3.30 more than that from BB (P<0.01). boeravinone B 232-234 prolactin receptor Sus scrofa 24-28 16818425-2 2006 Results showed that the PRLR and NCOA1 loci exerted the greatest impact on litter size: the average TNB from genotype AA was 2.28-3.33 more than that from BB (P<0.01) and the average NBA from AA was 1.57-3.30 more than that from BB (P<0.01). boeravinone B 232-234 nuclear receptor coactivator 1 Sus scrofa 33-38 16507161-6 2006 The distribution of VDR genotyping in the control group was 1.03% for BB, 15.98% for Bb, and 82.99% for bb. boeravinone B 70-72 vitamin D receptor Homo sapiens 20-23 16339176-7 2006 MHC isoform distribution was shifted towards 2X fibres in BB. boeravinone B 58-60 major histocompatibility complex, class I, C Homo sapiens 0-3 16507161-6 2006 The distribution of VDR genotyping in the control group was 1.03% for BB, 15.98% for Bb, and 82.99% for bb. boeravinone B 85-87 vitamin D receptor Homo sapiens 20-23 16507161-5 2006 The distribution of VDR genotyping in patients with SLE was 1.9% for BB (non-excisable allele homozygote), 21.78% for Bb (heterozygote), and 76.23% for bb (excisable allele homozygote). boeravinone B 69-71 vitamin D receptor Homo sapiens 20-23 16507161-6 2006 The distribution of VDR genotyping in the control group was 1.03% for BB, 15.98% for Bb, and 82.99% for bb. boeravinone B 104-106 vitamin D receptor Homo sapiens 20-23 16203908-11 2005 Cx43 colocalized with Cx40 and Cx45 only in the very distal BB. boeravinone B 60-62 gap junction protein, alpha 3 Mus musculus 0-4 16014574-10 2005 These results indicate that the expression of CYP4A protein and the renal formation of 20-HETE are elevated in the kidney of BB rats due to a lack of vasopressin and that chronic blockade of the formation of 20-HETE and EETs with ABT promotes water excretion in vasopressin-deficient BB rats by reducing the circulating levels of oxytocin, which is a weak vasopressin agonist. boeravinone B 125-127 arginine vasopressin Rattus norvegicus 262-273 16014574-10 2005 These results indicate that the expression of CYP4A protein and the renal formation of 20-HETE are elevated in the kidney of BB rats due to a lack of vasopressin and that chronic blockade of the formation of 20-HETE and EETs with ABT promotes water excretion in vasopressin-deficient BB rats by reducing the circulating levels of oxytocin, which is a weak vasopressin agonist. boeravinone B 125-127 arginine vasopressin Rattus norvegicus 262-273 16253955-6 2005 Increasing the amounts of the hydrophobic solvent, BB, in formulations demonstrated a 1.2-4.4-fold increase in CT release. boeravinone B 51-53 calcitonin related polypeptide alpha Homo sapiens 111-113 16014574-5 2005 Chronic treatment of BB rats with a vasopressin type 2 receptor agonist for 1 wk normalized the renal production of 20-HETE. boeravinone B 21-23 arginine vasopressin Rattus norvegicus 36-47 16817144-3 2005 MATERIAL AND METHODS: We identified 58 patients with hyperprolactinaemia, in whom BB-PRL consisted>or=60% of the total PRL concentration. boeravinone B 82-84 prolactin Homo sapiens 85-88 16200423-3 2005 Our conjecture is that this relationship describes a condition of predominant sympathetic activation, from which it is hypothesized that selective beta1-adrenergic blockade (BB) would reduce O(2) delivery (QaO(2)) and QvO(2). boeravinone B 174-176 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 147-152 16279400-8 2005 Despite the finding of in vitro biological activity in all macroprolactinemic sera tested, our results suggest a variable in vivo bioactivity of bb-PRL, probably related to a reduced capacity to cross vascular endothelium. boeravinone B 145-147 prolactin Homo sapiens 148-151 16279400-9 2005 In this study, we demonstrated that in 12 out of 13 samples (85%), bb-PRL consisted of PRL-IgG complexes. boeravinone B 67-69 prolactin Homo sapiens 70-73 16279400-9 2005 In this study, we demonstrated that in 12 out of 13 samples (85%), bb-PRL consisted of PRL-IgG complexes. boeravinone B 67-69 prolactin Homo sapiens 87-90 16817144-9 2005 In hyperprolactinaemic patients with predominance of BB-PRL, there was no direct correlation between the presence of clinical features and the concentration of residual "free" PRL. boeravinone B 53-55 prolactin Homo sapiens 56-59 16817144-13 2005 During the short time of metoclopramide stimulation test, there was a marked rise mainly of the total and "free" PRL concentrations, and, in some tested subjects, the predominance of BB-PRL was lost temporally for 1 to 2 hours. boeravinone B 183-185 prolactin Homo sapiens 186-189 16132691-0 2005 MCP-1 and MIP-2 expression and production in BB diabetic rat: effect of chronic hypoxia. boeravinone B 45-47 mast cell protease 1-like 1 Rattus norvegicus 0-5 16114990-3 2005 Quantitatively, BB gelatin stimulated adherent PEC of C3H/HeN mice to secrete interleukin (IL)-12 (+p40), TNF-alpha, and IL-6 but not IL-1beta, IL-2, IL-10, and IFN-gamma. boeravinone B 16-18 interleukin 12b Mus musculus 100-103 16114990-3 2005 Quantitatively, BB gelatin stimulated adherent PEC of C3H/HeN mice to secrete interleukin (IL)-12 (+p40), TNF-alpha, and IL-6 but not IL-1beta, IL-2, IL-10, and IFN-gamma. boeravinone B 16-18 tumor necrosis factor Mus musculus 106-115 16114990-3 2005 Quantitatively, BB gelatin stimulated adherent PEC of C3H/HeN mice to secrete interleukin (IL)-12 (+p40), TNF-alpha, and IL-6 but not IL-1beta, IL-2, IL-10, and IFN-gamma. boeravinone B 16-18 interleukin 2 Mus musculus 144-148 16114990-3 2005 Quantitatively, BB gelatin stimulated adherent PEC of C3H/HeN mice to secrete interleukin (IL)-12 (+p40), TNF-alpha, and IL-6 but not IL-1beta, IL-2, IL-10, and IFN-gamma. boeravinone B 16-18 interleukin 10 Mus musculus 150-155 16114990-3 2005 Quantitatively, BB gelatin stimulated adherent PEC of C3H/HeN mice to secrete interleukin (IL)-12 (+p40), TNF-alpha, and IL-6 but not IL-1beta, IL-2, IL-10, and IFN-gamma. boeravinone B 16-18 interferon gamma Mus musculus 161-170 16132691-0 2005 MCP-1 and MIP-2 expression and production in BB diabetic rat: effect of chronic hypoxia. boeravinone B 45-47 C-X-C motif chemokine ligand 2 Rattus norvegicus 10-15 15849448-9 2005 In contrast, BB ameliorated calcium handling, as shown by the increased ratio of SERCA2 to phospholamban protein, despite having little effect on the histology. boeravinone B 13-15 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 Rattus norvegicus 81-87 16090161-1 2005 We present measurements of the B --> eta(")K branching fractions; for B(+) --> eta(")K(+) we measure also the time-integrated charge asymmetry Alpha(ch), and for B(0) --> eta(")K(0)(S) the time-dependent CP-violation parameters S and C. The data sample corresponds to 232 x 10(6) BB pairs produced by e(+)e(-) annihilation at the Upsilon (4S). boeravinone B 289-291 endothelin receptor type A Homo sapiens 85-88 16090161-1 2005 We present measurements of the B --> eta(")K branching fractions; for B(+) --> eta(")K(+) we measure also the time-integrated charge asymmetry Alpha(ch), and for B(0) --> eta(")K(0)(S) the time-dependent CP-violation parameters S and C. The data sample corresponds to 232 x 10(6) BB pairs produced by e(+)e(-) annihilation at the Upsilon (4S). boeravinone B 289-291 endothelin receptor type A Homo sapiens 85-88 15147345-0 2004 The roles of interleukin-18 in collagen-induced arthritis in the BB rat. boeravinone B 65-67 interleukin 18 Rattus norvegicus 13-27 15710870-4 2005 In the BB diabetic-prone rat model of T1D, intestinal intraluminal zonulin levels were elevated 35-fold compared to control BB diabetic-resistant rats. boeravinone B 7-9 haptoglobin Rattus norvegicus 67-74 15710870-9 2005 Combined together, these findings suggest that the zonulin-induced loss in small intestinal barrier function is involved in the pathogenesis of T1D in the BB diabetic-prone animal model. boeravinone B 155-157 haptoglobin Rattus norvegicus 51-58 15536079-3 2005 In the presence of Mg(2+), DAF bound Bb or the von Willebrand factor type A subunit of Bb with higher affinities (K(D), 1.3 +/- 0.5 and 2.2 +/- 0.1 microm, respectively). boeravinone B 37-39 CD55 molecule (Cromer blood group) Homo sapiens 27-30 15536079-7 2005 DAF did not bind cobra venom factor, implying that Bb decay is accelerated, at least in part, through DAF binding of this subunit. boeravinone B 51-53 CD55 molecule (Cromer blood group) Homo sapiens 0-3 15536079-7 2005 DAF did not bind cobra venom factor, implying that Bb decay is accelerated, at least in part, through DAF binding of this subunit. boeravinone B 51-53 CD55 molecule (Cromer blood group) Homo sapiens 102-105 15467010-2 2004 We previously showed that impaired NO synthesis in the spontaneously diabetic BB (BBd) rat is due to decreased levels of tetrahydrobiopterin (BH4), secondary to decreased expression of GTP cyclohydrolase I (GTPCH). boeravinone B 78-80 GTP cyclohydrolase 1 Rattus norvegicus 185-205 15123616-6 2004 The BB loop contains a hydrogen bond unique to IL-1RAPL between Thr residues at the 8th and 10th positions. boeravinone B 4-6 interleukin 1 receptor accessory protein like 1 Homo sapiens 47-55 15239135-5 2004 We thus evaluated the influence of BB-3644 on the efficacy of the anti-CD30 single-chain immunotoxin Ki-3(scFv)-ETA". boeravinone B 35-37 TNF receptor superfamily member 8 Homo sapiens 71-75 15239135-5 2004 We thus evaluated the influence of BB-3644 on the efficacy of the anti-CD30 single-chain immunotoxin Ki-3(scFv)-ETA". boeravinone B 35-37 immunglobulin heavy chain variable region Homo sapiens 106-110 15239135-5 2004 We thus evaluated the influence of BB-3644 on the efficacy of the anti-CD30 single-chain immunotoxin Ki-3(scFv)-ETA". boeravinone B 35-37 endothelin receptor type A Homo sapiens 112-115 15239135-6 2004 In vitro, the addition of BB-3644 augmented the antitumor effect of Ki-3(scFv)-ETA" against Hodgkin-derived L540Cy cells by a factor of 2.75. boeravinone B 26-28 immunglobulin heavy chain variable region Homo sapiens 73-77 15239135-6 2004 In vitro, the addition of BB-3644 augmented the antitumor effect of Ki-3(scFv)-ETA" against Hodgkin-derived L540Cy cells by a factor of 2.75. boeravinone B 26-28 endothelin receptor type A Homo sapiens 79-82 15239135-8 2004 One single nontoxic dose of BB-3644 increased the mean survival time of animals treated concomitantly with Ki-3(scFv)-ETA" to 93 days as compared with 35 days in the control (p = 0.0017). boeravinone B 28-30 immunglobulin heavy chain variable region Homo sapiens 112-116 15239135-8 2004 One single nontoxic dose of BB-3644 increased the mean survival time of animals treated concomitantly with Ki-3(scFv)-ETA" to 93 days as compared with 35 days in the control (p = 0.0017). boeravinone B 28-30 endothelin receptor type A Homo sapiens 118-121 15262416-6 2004 In addition, higher BET of the carriers, lower pH value and lower temperature prolonged BB release from PHSN, while stirring speed showed little influence on the release behavior. boeravinone B 88-90 delta/notch like EGF repeat containing Homo sapiens 20-23 15100275-10 2004 Prediabetic BBDP and diabetes-resistant BB animals also exhibited defective IENK cell function, including decreased NK cell cytotoxicity and reduced secretion of IL-4 and IFN-gamma. boeravinone B 12-14 interleukin 4 Rattus norvegicus 162-166 15105991-11 2004 CONCLUSIONS/INTERPRETATION: IL-1 beta-induced protein expression changes in islets in vitro also occur in vivo and change in a complex pattern during the development of diabetes in the BB-DP rat. boeravinone B 185-187 interleukin 1 beta Rattus norvegicus 28-37 15100275-10 2004 Prediabetic BBDP and diabetes-resistant BB animals also exhibited defective IENK cell function, including decreased NK cell cytotoxicity and reduced secretion of IL-4 and IFN-gamma. boeravinone B 12-14 interferon gamma Rattus norvegicus 171-180 12649542-0 2003 BB genotype of the vitamin D receptor gene polymorphism postpones parathyroidectomy in hemodialysis patients. boeravinone B 0-2 vitamin D receptor Homo sapiens 19-37 15225773-7 2004 The prevalence of the three BsmI VDR genotypes was 19.1, 44.9 and 36.0% for BB, Bb and bb, respectively. boeravinone B 76-78 vitamin D receptor Homo sapiens 33-36 15225773-7 2004 The prevalence of the three BsmI VDR genotypes was 19.1, 44.9 and 36.0% for BB, Bb and bb, respectively. boeravinone B 80-82 vitamin D receptor Homo sapiens 33-36 15225773-7 2004 The prevalence of the three BsmI VDR genotypes was 19.1, 44.9 and 36.0% for BB, Bb and bb, respectively. boeravinone B 87-89 vitamin D receptor Homo sapiens 33-36 15079808-3 2004 RESULTS: The HSP70-hom genotypes in the AS patients consisted of homozygote AA (60.2%) and BB(4.1%), and heterozygote(35.7%), while the HSP70-hom genotypes in the controls were composed of AA(58.6%), BB(2.9%) and heterozygote(38.6%). boeravinone B 91-93 heat shock protein family A (Hsp70) member 1 like Homo sapiens 13-22 15079808-3 2004 RESULTS: The HSP70-hom genotypes in the AS patients consisted of homozygote AA (60.2%) and BB(4.1%), and heterozygote(35.7%), while the HSP70-hom genotypes in the controls were composed of AA(58.6%), BB(2.9%) and heterozygote(38.6%). boeravinone B 200-202 heat shock protein family A (Hsp70) member 1 like Homo sapiens 13-22 15079808-5 2004 The frequencies of HSP70-hom alleles in AS patients were 77.9%(AA) and 22.1%(BB), while they were 78.1% and 21.9% in the controls. boeravinone B 77-79 heat shock protein family A (Hsp70) member 1 like Homo sapiens 19-28 14966047-8 2004 CONCLUSIONS: The non-BB genotype of the ecNOS 4a/4b gene polymorphism is a protective factor against the development of ACS. boeravinone B 21-23 nitric oxide synthase 3 Homo sapiens 40-45 14966047-9 2004 The GG genotype of the ecNOS Glu298Asp polymorphism exerts a benefit in addition to the non-BB genotype in the Korean population. boeravinone B 92-94 nitric oxide synthase 3 Homo sapiens 23-28 14561755-3 2003 In a previous investigation, we obtained evidence implicating the alpha4/5 region of the type A domain of Bb (especially Tyr338) in decay acceleration of C3bBb and proposed this site as a potential interaction point with DAF and long homologous repeat A of CR1. boeravinone B 106-108 complement C3b/C4b receptor 1 (Knops blood group) Homo sapiens 257-260 14682408-6 2003 On comparing pulmonary artery pressures in different eNOS genotypes, the mean pulmonary artery pressure (Ppa) in patients with the BB genotype was significantly higher than in patients with the nonBB genotypes (41.3 +/- 17.7 mmHg vs. 27.3 +/- 11.2 mmHg, P = 0.02). boeravinone B 131-133 nitric oxide synthase 3 Homo sapiens 53-57 12713516-7 2003 Phosphorylation of e-jun NH2-terminal kinase (JNK) and extracellular regulated kinase (ERK) increased significantly in the BB (226 and 200%, respectively; P < 0.05) but not in the VL, indicating activation of these pathways only after the resistance exercise. boeravinone B 123-125 mitogen-activated protein kinase 8 Homo sapiens 19-44 12713516-7 2003 Phosphorylation of e-jun NH2-terminal kinase (JNK) and extracellular regulated kinase (ERK) increased significantly in the BB (226 and 200%, respectively; P < 0.05) but not in the VL, indicating activation of these pathways only after the resistance exercise. boeravinone B 123-125 mitogen-activated protein kinase 8 Homo sapiens 46-49 12713516-7 2003 Phosphorylation of e-jun NH2-terminal kinase (JNK) and extracellular regulated kinase (ERK) increased significantly in the BB (226 and 200%, respectively; P < 0.05) but not in the VL, indicating activation of these pathways only after the resistance exercise. boeravinone B 123-125 mitogen-activated protein kinase 1 Homo sapiens 55-85 12713516-7 2003 Phosphorylation of e-jun NH2-terminal kinase (JNK) and extracellular regulated kinase (ERK) increased significantly in the BB (226 and 200%, respectively; P < 0.05) but not in the VL, indicating activation of these pathways only after the resistance exercise. boeravinone B 123-125 mitogen-activated protein kinase 1 Homo sapiens 87-90 14691685-4 2004 VDR allelic variants were: BB, 31.6%; Bb, 44.7%; and bb, 23.7% in the osteomalacia patients and BB, 19.4%; Bb, 61.3%; and bb, 19.4% in the controls. boeravinone B 27-29 vitamin D receptor Homo sapiens 0-3 14691685-4 2004 VDR allelic variants were: BB, 31.6%; Bb, 44.7%; and bb, 23.7% in the osteomalacia patients and BB, 19.4%; Bb, 61.3%; and bb, 19.4% in the controls. boeravinone B 38-40 vitamin D receptor Homo sapiens 0-3 14691685-4 2004 VDR allelic variants were: BB, 31.6%; Bb, 44.7%; and bb, 23.7% in the osteomalacia patients and BB, 19.4%; Bb, 61.3%; and bb, 19.4% in the controls. boeravinone B 53-55 vitamin D receptor Homo sapiens 0-3 14691685-4 2004 VDR allelic variants were: BB, 31.6%; Bb, 44.7%; and bb, 23.7% in the osteomalacia patients and BB, 19.4%; Bb, 61.3%; and bb, 19.4% in the controls. boeravinone B 96-98 vitamin D receptor Homo sapiens 0-3 14691685-4 2004 VDR allelic variants were: BB, 31.6%; Bb, 44.7%; and bb, 23.7% in the osteomalacia patients and BB, 19.4%; Bb, 61.3%; and bb, 19.4% in the controls. boeravinone B 107-109 vitamin D receptor Homo sapiens 0-3 14691685-4 2004 VDR allelic variants were: BB, 31.6%; Bb, 44.7%; and bb, 23.7% in the osteomalacia patients and BB, 19.4%; Bb, 61.3%; and bb, 19.4% in the controls. boeravinone B 122-124 vitamin D receptor Homo sapiens 0-3 12958689-6 2003 Correlations were found between VDR genotypes and BMD at lumbar spine L2-L4, (ss versus LL, P = 0.03 and BB versus bb, P = 0.02, respectively), with a similar pattern concerning total hip (ss versus LL, P = 0.12 and BB versus bb, P = 0.16 respectively). boeravinone B 105-107 vitamin D receptor Homo sapiens 32-35 12958689-6 2003 Correlations were found between VDR genotypes and BMD at lumbar spine L2-L4, (ss versus LL, P = 0.03 and BB versus bb, P = 0.02, respectively), with a similar pattern concerning total hip (ss versus LL, P = 0.12 and BB versus bb, P = 0.16 respectively). boeravinone B 115-117 vitamin D receptor Homo sapiens 32-35 12958689-6 2003 Correlations were found between VDR genotypes and BMD at lumbar spine L2-L4, (ss versus LL, P = 0.03 and BB versus bb, P = 0.02, respectively), with a similar pattern concerning total hip (ss versus LL, P = 0.12 and BB versus bb, P = 0.16 respectively). boeravinone B 216-218 vitamin D receptor Homo sapiens 32-35 12958689-6 2003 Correlations were found between VDR genotypes and BMD at lumbar spine L2-L4, (ss versus LL, P = 0.03 and BB versus bb, P = 0.02, respectively), with a similar pattern concerning total hip (ss versus LL, P = 0.12 and BB versus bb, P = 0.16 respectively). boeravinone B 226-228 vitamin D receptor Homo sapiens 32-35 12958689-7 2003 After corrections for age, height, fat and lean mass, the VDR BsmI genotype was still associated to BMD at the lumbar spine (BB versus bb, P = 0.03). boeravinone B 125-127 vitamin D receptor Homo sapiens 58-61 12958689-7 2003 After corrections for age, height, fat and lean mass, the VDR BsmI genotype was still associated to BMD at the lumbar spine (BB versus bb, P = 0.03). boeravinone B 135-137 vitamin D receptor Homo sapiens 58-61 12786678-9 2003 RESULTS: In young males with low physical activity (n = 752) gene carriers with the VDR genotype BB (n = 137) have significantly (P < 0.001) higher levels of fasting glucose (5.61 +/- 0.49 mmol/l) than gene carriers with the genotype Bb (n = 370; 5.44 +/- 0.44 mmol/l) or bb (n = 245; 5.38 +/- 0.44 mmol/l). boeravinone B 275-277 vitamin D receptor Homo sapiens 84-87 12792298-3 2003 RESULTS: The distribution of ER PvuII and XbaI and VDR BsmI restriction fragment length polymorphisms was as follows: pp, 30.2%; Pp, 49.7%; PP, 20.1%; xx, 71.8%; Xx, 22.5%; XX, 2.7%; bb, 76.5%; Bb, 22.2%; and BB, 1.3%. boeravinone B 183-185 estrogen receptor 1 Homo sapiens 29-31 12792298-3 2003 RESULTS: The distribution of ER PvuII and XbaI and VDR BsmI restriction fragment length polymorphisms was as follows: pp, 30.2%; Pp, 49.7%; PP, 20.1%; xx, 71.8%; Xx, 22.5%; XX, 2.7%; bb, 76.5%; Bb, 22.2%; and BB, 1.3%. boeravinone B 194-196 estrogen receptor 1 Homo sapiens 29-31 12792298-3 2003 RESULTS: The distribution of ER PvuII and XbaI and VDR BsmI restriction fragment length polymorphisms was as follows: pp, 30.2%; Pp, 49.7%; PP, 20.1%; xx, 71.8%; Xx, 22.5%; XX, 2.7%; bb, 76.5%; Bb, 22.2%; and BB, 1.3%. boeravinone B 209-211 estrogen receptor 1 Homo sapiens 29-31 12778851-11 2003 SBP was higher in men with bb genotype than in the other genotypes (p: 0.007). boeravinone B 27-29 selenium binding protein 1 Homo sapiens 0-3 12778851-14 2003 Moreover, men with bb genotype have the highest levels of SBP. boeravinone B 19-21 selenium binding protein 1 Homo sapiens 58-61 22061069-2 2002 Catalase and GSH-Px activities were higher in boston butt (BB) than in longissimus dorsi (LD), whereas lipid oxidation measured by 2-thiobarbituric acid substances (TBARS) content was higher in LD. boeravinone B 59-61 catalase Homo sapiens 0-8 22061069-3 2002 Catalase activity was stable in both BB and LD during 4-day storage; GSH-Px activity decreased in LD. boeravinone B 37-39 catalase Homo sapiens 0-8 11820863-2 2002 The hepatoprotective activity was evaluated in the bromobenzene- (BB-) induced hepatotoxicity model in mice through the measurement of the serum levels of alanine-aminotransferase (ALT) and aspartate transaminase (AST), thiobarbituric acid reacting substances (TBARS) and glutathione levels. boeravinone B 66-68 glutamic pyruvic transaminase, soluble Mus musculus 155-179 12134949-7 2002 The Papp BB-to-AP/Papp AP-to-BL ratios were >116, 35.1, 21.2, and 12.6 in Caco-2, MDCK-MDR1, MDCK-MRP2, and MDCK-WT cells, respectively. boeravinone B 9-11 ATP binding cassette subfamily C member 2 Canis lupus familiaris 96-105 11939260-10 2002 The ABO genotypes of the known 101 samples were as follows: AA, 4.30%; AO, 24.41%; BB, 4.16%; BO, 24.2%; AB, 8.46%; and 00, 34.65%. boeravinone B 83-85 ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase Homo sapiens 4-7 11694537-9 2002 Mutations at the C3b.Bb interface interfere with the normal dissociation of C3b from Bb, whether it is spontaneous or promoted by DAF, CR1, or factor H. boeravinone B 21-23 complement C3 Homo sapiens 17-20 11694537-9 2002 Mutations at the C3b.Bb interface interfere with the normal dissociation of C3b from Bb, whether it is spontaneous or promoted by DAF, CR1, or factor H. boeravinone B 21-23 complement C3 Homo sapiens 76-79 11694537-9 2002 Mutations at the C3b.Bb interface interfere with the normal dissociation of C3b from Bb, whether it is spontaneous or promoted by DAF, CR1, or factor H. boeravinone B 21-23 complement C3b/C4b receptor 1 (Knops blood group) Homo sapiens 135-138 11694537-9 2002 Mutations at the C3b.Bb interface interfere with the normal dissociation of C3b from Bb, whether it is spontaneous or promoted by DAF, CR1, or factor H. boeravinone B 21-23 complement factor H Homo sapiens 143-151 11694537-9 2002 Mutations at the C3b.Bb interface interfere with the normal dissociation of C3b from Bb, whether it is spontaneous or promoted by DAF, CR1, or factor H. boeravinone B 85-87 complement C3 Homo sapiens 17-20 11694537-9 2002 Mutations at the C3b.Bb interface interfere with the normal dissociation of C3b from Bb, whether it is spontaneous or promoted by DAF, CR1, or factor H. boeravinone B 85-87 complement C3b/C4b receptor 1 (Knops blood group) Homo sapiens 135-138 11694537-9 2002 Mutations at the C3b.Bb interface interfere with the normal dissociation of C3b from Bb, whether it is spontaneous or promoted by DAF, CR1, or factor H. boeravinone B 85-87 complement factor H Homo sapiens 143-151 11903042-1 2002 Previously we have demonstrated that the phosphoinositide 3-kinase (PI-3K) signal-transduction pathway mediates platelet-derived growth factor (PDGF)-BB-induced glycosaminoglycan (GAG) synthesis in fetal lung fibroblasts. boeravinone B 150-152 phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta Homo sapiens 41-66 11843060-3 2002 METHODS: The influence of oral supplementation with L. acidophilus NCFB 1748 and B. longum BB 536 on the uptake and distribution of 14C-labelled Trp-P-2 in several mouse tissues was quantified by liquid scintillation measurements and examined by tape section autoradiography (gives an unbiased qualitative registration of differences in overall tissue distribution) in the present investigation. boeravinone B 91-93 polycystin 2, transient receptor potential cation channel Mus musculus 145-152 11820863-2 2002 The hepatoprotective activity was evaluated in the bromobenzene- (BB-) induced hepatotoxicity model in mice through the measurement of the serum levels of alanine-aminotransferase (ALT) and aspartate transaminase (AST), thiobarbituric acid reacting substances (TBARS) and glutathione levels. boeravinone B 66-68 glutamic pyruvic transaminase, soluble Mus musculus 181-184 11820863-3 2002 The aqueous extract of the aerial parts of A. satureioides administered before BB, at the dose of 300 mg kg(-1)p.o., demonstrated significant inhibition (P< 0.01) in the BB increase of liver ALT and AST and in the BB-induced increase of liver TBARS content. boeravinone B 173-175 glutamic pyruvic transaminase, soluble Mus musculus 194-197 11820863-3 2002 The aqueous extract of the aerial parts of A. satureioides administered before BB, at the dose of 300 mg kg(-1)p.o., demonstrated significant inhibition (P< 0.01) in the BB increase of liver ALT and AST and in the BB-induced increase of liver TBARS content. boeravinone B 173-175 solute carrier family 17 (anion/sugar transporter), member 5 Mus musculus 202-205 11820863-3 2002 The aqueous extract of the aerial parts of A. satureioides administered before BB, at the dose of 300 mg kg(-1)p.o., demonstrated significant inhibition (P< 0.01) in the BB increase of liver ALT and AST and in the BB-induced increase of liver TBARS content. boeravinone B 173-175 glutamic pyruvic transaminase, soluble Mus musculus 194-197 11820863-3 2002 The aqueous extract of the aerial parts of A. satureioides administered before BB, at the dose of 300 mg kg(-1)p.o., demonstrated significant inhibition (P< 0.01) in the BB increase of liver ALT and AST and in the BB-induced increase of liver TBARS content. boeravinone B 173-175 solute carrier family 17 (anion/sugar transporter), member 5 Mus musculus 202-205 11845290-0 2001 An F344 rat congenic for BB/DP rat-derived diabetes susceptibility loci Iddm1 and Iddm2. boeravinone B 25-27 Insulin dependent diabetes mellitus QTL 1 Rattus norvegicus 72-77 11918278-10 2001 The present study demonstrated an increase in superoxide dismutase and catalase activities, as well as PON1 activities, in subjects with the BB allele. boeravinone B 141-143 catalase Homo sapiens 71-79 11918278-10 2001 The present study demonstrated an increase in superoxide dismutase and catalase activities, as well as PON1 activities, in subjects with the BB allele. boeravinone B 141-143 paraoxonase 1 Homo sapiens 103-107 14558674-8 2002 Six patients had normal L PRL levels, and their hyper PRL was due to excess BPRL or BB PRL. boeravinone B 84-86 prolactin Homo sapiens 54-57 14558674-8 2002 Six patients had normal L PRL levels, and their hyper PRL was due to excess BPRL or BB PRL. boeravinone B 84-86 prolactin Homo sapiens 54-57 11729524-5 2001 RESULTS: The respective frequencies of VDR genotypes were BB 18.6%, Bb 27.8% and bb 53.6%. boeravinone B 68-70 vitamin D receptor Homo sapiens 39-42 11845290-0 2001 An F344 rat congenic for BB/DP rat-derived diabetes susceptibility loci Iddm1 and Iddm2. boeravinone B 25-27 Insulin dependent diabetes mellitus QTL 2 Rattus norvegicus 82-87 11431473-5 2001 Ectopic expression of the RhoGAP domain as well as the full-length protein interfered with platelet-derived growth factor BB-induced membrane ruffling, but not with serum-induced stress fiber formation, further emphasizing the notion that, in vivo, RICH-1 is a GAP for Cdc42 and Rac1. boeravinone B 122-124 Rho GTPase activating protein 1 Homo sapiens 26-32 11461072-5 2001 The VDR polymorphism Bsm I, an intronic 3" gene variant, was significantly associated with increased breast cancer risk: odds ratio bb vs BB genotype = 2.32 (95% CI, 1.23-4.39). boeravinone B 132-134 vitamin D receptor Homo sapiens 4-7 11485976-8 2001 Furthermore, increases in both vessel density and blood perfusion indexes at day 28 in IL-10(-/-) mice were abolished after treatment with BB-94 (0.78+/-0.06 versus 1.17+/-0.09 and 0.62+/-0.02 versus 0.88+/-0.04, for vessel density and blood perfusion ratio, respectively, in IL-10(-/-) mice treated with BB-94 versus untreated IL-10(-/-) mice, P<0.05). boeravinone B 139-141 interleukin 10 Mus musculus 87-92 11485976-8 2001 Furthermore, increases in both vessel density and blood perfusion indexes at day 28 in IL-10(-/-) mice were abolished after treatment with BB-94 (0.78+/-0.06 versus 1.17+/-0.09 and 0.62+/-0.02 versus 0.88+/-0.04, for vessel density and blood perfusion ratio, respectively, in IL-10(-/-) mice treated with BB-94 versus untreated IL-10(-/-) mice, P<0.05). boeravinone B 139-141 interleukin 10 Mus musculus 276-281 11485976-8 2001 Furthermore, increases in both vessel density and blood perfusion indexes at day 28 in IL-10(-/-) mice were abolished after treatment with BB-94 (0.78+/-0.06 versus 1.17+/-0.09 and 0.62+/-0.02 versus 0.88+/-0.04, for vessel density and blood perfusion ratio, respectively, in IL-10(-/-) mice treated with BB-94 versus untreated IL-10(-/-) mice, P<0.05). boeravinone B 139-141 interleukin 10 Mus musculus 276-281 11485976-8 2001 Furthermore, increases in both vessel density and blood perfusion indexes at day 28 in IL-10(-/-) mice were abolished after treatment with BB-94 (0.78+/-0.06 versus 1.17+/-0.09 and 0.62+/-0.02 versus 0.88+/-0.04, for vessel density and blood perfusion ratio, respectively, in IL-10(-/-) mice treated with BB-94 versus untreated IL-10(-/-) mice, P<0.05). boeravinone B 305-307 interleukin 10 Mus musculus 87-92 11461072-5 2001 The VDR polymorphism Bsm I, an intronic 3" gene variant, was significantly associated with increased breast cancer risk: odds ratio bb vs BB genotype = 2.32 (95% CI, 1.23-4.39). boeravinone B 138-140 vitamin D receptor Homo sapiens 4-7 11335187-5 2001 In linear regression models to control for covariates, VDR genotype (BB and Bb vs. bb), blood lead, tibia lead, and DMSA-chelatable lead were all positive predictors of systolic blood pressure. boeravinone B 69-71 vitamin D receptor Homo sapiens 55-58 11683379-7 2001 Basal levels of soluble ART2 varied greatly among strains of rats and were lowest in the diabetes-prone BB (BBDP/Wor) rat. boeravinone B 104-106 ADP-ribosyltransferase 2b Rattus norvegicus 24-28 11392075-3 2001 In subjects exhibiting XX genotype of the estrogen receptor gene or bb genotype of the vitamin D receptor gene, erbB-2 expression was significantly lower compared to those with xx, Xx or BB, Bb (6/56 and 11/56 vs. 31/56 and 26/56; p = 0.0043 and 0.041). boeravinone B 191-193 vitamin D receptor Homo sapiens 87-105 11335187-5 2001 In linear regression models to control for covariates, VDR genotype (BB and Bb vs. bb), blood lead, tibia lead, and DMSA-chelatable lead were all positive predictors of systolic blood pressure. boeravinone B 76-78 vitamin D receptor Homo sapiens 55-58 11335187-5 2001 In linear regression models to control for covariates, VDR genotype (BB and Bb vs. bb), blood lead, tibia lead, and DMSA-chelatable lead were all positive predictors of systolic blood pressure. boeravinone B 83-85 vitamin D receptor Homo sapiens 55-58 10876047-3 2000 Specific ((125)I-Tyr(0),Bpa(4))BB binding was inhibited with high affinity by BB, BW2258U89, GRP, GRP(14-27) and NMB (IC(50) values of 10, 2, 15, 20, and 150 nM)but not GRP(1-16) (IC(50) value of > 1000 nM). boeravinone B 31-33 gastrin releasing peptide Homo sapiens 93-96 11121866-3 2001 BB, 100 nM caused increased p125(FAK) and paxillin tyrosine phosphorylation maximally after 1 min. boeravinone B 0-2 protein tyrosine kinase 2 Homo sapiens 28-37 11121866-3 2001 BB, 100 nM caused increased p125(FAK) and paxillin tyrosine phosphorylation maximally after 1 min. boeravinone B 0-2 paxillin Homo sapiens 42-50 11121866-4 2001 The effect of BB on p125(FAK) and paxillin tyrosine phosphorylation was concentration-dependent, being half maximal at 4-8 nM. boeravinone B 14-16 protein tyrosine kinase 2 Homo sapiens 20-29 11121866-4 2001 The effect of BB on p125(FAK) and paxillin tyrosine phosphorylation was concentration-dependent, being half maximal at 4-8 nM. boeravinone B 14-16 paxillin Homo sapiens 34-42 11121866-6 2001 BW2258U89, a GRP receptor antagonist, caused a dose-dependent inhibition of BB-stimulated p125(FAK) and paxillin tyrosine phosphorylation with an IC50 value of 3 microM. boeravinone B 76-78 gastrin releasing peptide Homo sapiens 13-16 11121866-6 2001 BW2258U89, a GRP receptor antagonist, caused a dose-dependent inhibition of BB-stimulated p125(FAK) and paxillin tyrosine phosphorylation with an IC50 value of 3 microM. boeravinone B 76-78 protein tyrosine kinase 2 Homo sapiens 90-99 11121866-6 2001 BW2258U89, a GRP receptor antagonist, caused a dose-dependent inhibition of BB-stimulated p125(FAK) and paxillin tyrosine phosphorylation with an IC50 value of 3 microM. boeravinone B 76-78 paxillin Homo sapiens 104-112 11121866-7 2001 Cytochalasin D (0.3 microM), which inhibits actin polymerization, reduced the ability of BB to stimulate tyrosine phosphorylation of p125(FAK) and paxillin. boeravinone B 89-91 SEC23 interacting protein Homo sapiens 133-137 11121866-7 2001 Cytochalasin D (0.3 microM), which inhibits actin polymerization, reduced the ability of BB to stimulate tyrosine phosphorylation of p125(FAK) and paxillin. boeravinone B 89-91 protein tyrosine kinase 2 Homo sapiens 138-141 11121866-7 2001 Cytochalasin D (0.3 microM), which inhibits actin polymerization, reduced the ability of BB to stimulate tyrosine phosphorylation of p125(FAK) and paxillin. boeravinone B 89-91 paxillin Homo sapiens 147-155 11121866-8 2001 Genistein (50 microM) and H-7 (50 microM), which are kinase inhibitors, reduced the tyrosine phosphorylation of p125(FAK) and paxillin stimulated by BB. boeravinone B 149-151 protein tyrosine kinase 2 Homo sapiens 112-121 11121866-8 2001 Genistein (50 microM) and H-7 (50 microM), which are kinase inhibitors, reduced the tyrosine phosphorylation of p125(FAK) and paxillin stimulated by BB. boeravinone B 149-151 paxillin Homo sapiens 126-134 10966820-1 2000 Factor B is a key component of the alternative pathway of complement and is cleaved by factor D into the Ba and Bb fragments in the presence of activated C3 (C3b or C3(H(2)O)). boeravinone B 112-114 complement C3 Homo sapiens 154-156 10966820-1 2000 Factor B is a key component of the alternative pathway of complement and is cleaved by factor D into the Ba and Bb fragments in the presence of activated C3 (C3b or C3(H(2)O)). boeravinone B 112-114 complement C3 Homo sapiens 158-161 10881050-9 2000 ACE activity in BB was higher than in phosphate buffer (PB) due, at least in part, to a greater hydrolysis of the His-Leu product in PB. boeravinone B 16-18 angiotensin I converting enzyme Rattus norvegicus 0-3 10881050-10 2000 ACE activity of lung increased 20% when BB plus Triton was used. boeravinone B 40-42 angiotensin I converting enzyme Rattus norvegicus 0-3 10881050-12 2000 These results indicate a condition whereby ACE activity can be easily and efficiently assayed in rat tissue samples homogenized in BB using a fluorimetric method with Hip-His-Leu as a substrate. boeravinone B 131-133 angiotensin I converting enzyme Rattus norvegicus 43-46 10756110-9 2000 Since the vWF-A domain after alpha-helix A7 is connected by a short link to the catalytic serine protease domain in the Bb fragment, the identification of a metal-free and a more stable metal-bound conformation for the vWF-A domain implies that the vWF-A interaction with C3b may alter its Mg(2+)-bound coordination in such a way as to induce conformational changes that may regulate the proteolytic activity of factor B. boeravinone B 120-122 von Willebrand factor Homo sapiens 10-13 11238299-5 2001 RESULTS: The ratio of MB to MM to BB was 50:40:10 on the basis of CK activity. boeravinone B 34-36 HCK proto-oncogene, Src family tyrosine kinase Homo sapiens 66-68 10980128-10 2000 Moreover, calcification of elastin implants was significantly reduced in the site-specific administration group (5.43 +/- 1.03 microg/mg Ca for BB-1101 group versus 21.71 +/- 1.19 for control group, P: < 0.001). boeravinone B 144-146 elastin Rattus norvegicus 27-34 10919858-4 2000 Lithium (Li) treatment of BB rats for 1 mo, known to reduce adenylyl cyclase (AC) activity, downregulated AQP2 protein levels (15 +/- 6%) and increased urine output (220%). boeravinone B 26-28 aquaporin 2 Rattus norvegicus 106-110 10919858-6 2000 Complete water restriction of BB rats produced only a small increase in AQP2 mRNA (235 +/- 33%) and AQP2 protein (156 +/- 22%) levels. boeravinone B 30-32 aquaporin 2 Rattus norvegicus 72-76 10876047-3 2000 Specific ((125)I-Tyr(0),Bpa(4))BB binding was inhibited with high affinity by BB, BW2258U89, GRP, GRP(14-27) and NMB (IC(50) values of 10, 2, 15, 20, and 150 nM)but not GRP(1-16) (IC(50) value of > 1000 nM). boeravinone B 31-33 gastrin releasing peptide Homo sapiens 98-101 10876047-3 2000 Specific ((125)I-Tyr(0),Bpa(4))BB binding was inhibited with high affinity by BB, BW2258U89, GRP, GRP(14-27) and NMB (IC(50) values of 10, 2, 15, 20, and 150 nM)but not GRP(1-16) (IC(50) value of > 1000 nM). boeravinone B 31-33 gastrin releasing peptide Homo sapiens 98-101 10876047-5 2000 (Tyr(0),Bpa(4))BB, 10 nM, elevated cytosolic calcium using T47D cells within 10 s. Also (Tyr(0),Bpa(4))BB, 10 nM, elevated c-fos mRNA after 45 min. boeravinone B 15-17 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 123-128 10876047-5 2000 (Tyr(0),Bpa(4))BB, 10 nM, elevated cytosolic calcium using T47D cells within 10 s. Also (Tyr(0),Bpa(4))BB, 10 nM, elevated c-fos mRNA after 45 min. boeravinone B 103-105 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 123-128 10876047-6 2000 These results indicate that (Tyr(0),Bpa(4))BB is an agonist for GRP receptors. boeravinone B 43-45 gastrin releasing peptide Homo sapiens 64-67 10666492-4 2000 The frequency of VDR alleles was as follows: bb (20.9%), Bb (60.5%), and BB (18.6%), and that of ER alleles was pp (39.5%), Pp (51.2%), and PP (9.3%). boeravinone B 45-47 vitamin D receptor Homo sapiens 17-20 10727664-9 2000 IGF-1 (10(-10)-10(-6) M) caused a dose-dependent increase in PS in myocytes from BB/DR but not BB/DP rats. boeravinone B 81-83 insulin-like growth factor 1 Rattus norvegicus 0-5 10727664-12 2000 Interestingly, IGF-1 elicited a comparable dose-dependent increase in Ca(2+) transients in myocytes from both BB/DR and BB/DP rats. boeravinone B 110-112 insulin-like growth factor 1 Rattus norvegicus 15-20 10706524-8 2000 In a multiple linear regression model of tibial lead concentrations, the VDR genotype modified the relation between age and tibial lead concentrations; subjects with the B allele had larger increases in tibial lead concentrations with increasing age (0.37, 0.48, and 0.67 microg/g per year of age in subjects with bb, Bb, and BB, respectively; the adjusted p-value for trend in slopes = 0.04). boeravinone B 314-316 vitamin D receptor Homo sapiens 73-76 10706524-8 2000 In a multiple linear regression model of tibial lead concentrations, the VDR genotype modified the relation between age and tibial lead concentrations; subjects with the B allele had larger increases in tibial lead concentrations with increasing age (0.37, 0.48, and 0.67 microg/g per year of age in subjects with bb, Bb, and BB, respectively; the adjusted p-value for trend in slopes = 0.04). boeravinone B 318-320 vitamin D receptor Homo sapiens 73-76 10706524-8 2000 In a multiple linear regression model of tibial lead concentrations, the VDR genotype modified the relation between age and tibial lead concentrations; subjects with the B allele had larger increases in tibial lead concentrations with increasing age (0.37, 0.48, and 0.67 microg/g per year of age in subjects with bb, Bb, and BB, respectively; the adjusted p-value for trend in slopes = 0.04). boeravinone B 326-328 vitamin D receptor Homo sapiens 73-76 10666492-4 2000 The frequency of VDR alleles was as follows: bb (20.9%), Bb (60.5%), and BB (18.6%), and that of ER alleles was pp (39.5%), Pp (51.2%), and PP (9.3%). boeravinone B 57-59 vitamin D receptor Homo sapiens 17-20 10666492-4 2000 The frequency of VDR alleles was as follows: bb (20.9%), Bb (60.5%), and BB (18.6%), and that of ER alleles was pp (39.5%), Pp (51.2%), and PP (9.3%). boeravinone B 73-75 vitamin D receptor Homo sapiens 17-20 10713643-1 2000 Complement activation products, such as C1rs-C1inh, specific for the activation of the classical pathway, C3b(Bb)P, specific for the activation of the alternative pathway and SC5b-9, specific for common terminal pathway of the complement cascade, were measured in healthy donors and in patients with clinically active and inactive systemic lupus erythematosus (SLE). boeravinone B 110-112 serpin family G member 1 Homo sapiens 45-50 10813109-7 2000 The relative distribution of VDR genotypes and alleles in the Slovenian population was 18.6:57.8:23.6% for BB:Bb:bb, respectively. boeravinone B 107-109 vitamin D receptor Homo sapiens 29-32 10813109-7 2000 The relative distribution of VDR genotypes and alleles in the Slovenian population was 18.6:57.8:23.6% for BB:Bb:bb, respectively. boeravinone B 110-112 vitamin D receptor Homo sapiens 29-32 10813109-7 2000 The relative distribution of VDR genotypes and alleles in the Slovenian population was 18.6:57.8:23.6% for BB:Bb:bb, respectively. boeravinone B 113-115 vitamin D receptor Homo sapiens 29-32 10713643-1 2000 Complement activation products, such as C1rs-C1inh, specific for the activation of the classical pathway, C3b(Bb)P, specific for the activation of the alternative pathway and SC5b-9, specific for common terminal pathway of the complement cascade, were measured in healthy donors and in patients with clinically active and inactive systemic lupus erythematosus (SLE). boeravinone B 110-112 endogenous retrovirus group K member 3 Homo sapiens 106-109 10219888-7 1999 PROL-CTK was the method less influenced by the presence of bb-PRL since most of the subjects with macroprolactinemia had PRL levels either within the normal range or only marginally elevated. boeravinone B 59-61 megakaryocyte-associated tyrosine kinase Homo sapiens 5-8 10462269-11 1999 A trend for association of higher prorenin levels with the DN-associated allele of this renin polymorphism was observed in a subgroup of patients with DN (bb vs Bb+BB, P=0.07). boeravinone B 155-157 renin Homo sapiens 37-42 10462269-11 1999 A trend for association of higher prorenin levels with the DN-associated allele of this renin polymorphism was observed in a subgroup of patients with DN (bb vs Bb+BB, P=0.07). boeravinone B 161-163 renin Homo sapiens 37-42 10462269-11 1999 A trend for association of higher prorenin levels with the DN-associated allele of this renin polymorphism was observed in a subgroup of patients with DN (bb vs Bb+BB, P=0.07). boeravinone B 164-166 renin Homo sapiens 37-42 10523383-6 1999 The increase in blood pressure induced by DOCA-salt treatment was attenuated in vasopressin-deficient rats, such that BB DOCA-salt-treated rats exhibited only a slight elevation of blood pressure (134+/-6 mm Hg) compared with BB-UNx rats (111+/-4 mm Hg; P<0.05). boeravinone B 118-120 arginine vasopressin Rattus norvegicus 80-91 10219888-7 1999 PROL-CTK was the method less influenced by the presence of bb-PRL since most of the subjects with macroprolactinemia had PRL levels either within the normal range or only marginally elevated. boeravinone B 59-61 prolactin Homo sapiens 62-65 9973444-7 1999 An increase in the CD4/CD8 T cell ratio was observed in both the syn- and alloMLR due to a relative weak expansion of CD8+ T cells with DC of the BB-DP rat. boeravinone B 146-148 Cd4 molecule Rattus norvegicus 19-22 9890556-10 1999 TNFalpha receptor I (p55, TNFRI) and II (p75, TNFRII) shedding was also inhibited by GI-129471 (IC50 = 1.5 and 3.1 microM, respectively) and BB-2516 (IC50 = 14 and 15 microM, respectively). boeravinone B 141-143 tumor necrosis factor Homo sapiens 0-8 9890556-10 1999 TNFalpha receptor I (p55, TNFRI) and II (p75, TNFRII) shedding was also inhibited by GI-129471 (IC50 = 1.5 and 3.1 microM, respectively) and BB-2516 (IC50 = 14 and 15 microM, respectively). boeravinone B 141-143 TNF receptor superfamily member 1A Homo sapiens 21-24 9890556-10 1999 TNFalpha receptor I (p55, TNFRI) and II (p75, TNFRII) shedding was also inhibited by GI-129471 (IC50 = 1.5 and 3.1 microM, respectively) and BB-2516 (IC50 = 14 and 15 microM, respectively). boeravinone B 141-143 TNF receptor superfamily member 1A Homo sapiens 26-31 9890556-10 1999 TNFalpha receptor I (p55, TNFRI) and II (p75, TNFRII) shedding was also inhibited by GI-129471 (IC50 = 1.5 and 3.1 microM, respectively) and BB-2516 (IC50 = 14 and 15 microM, respectively). boeravinone B 141-143 TNF receptor superfamily member 1B Homo sapiens 41-44 9890556-10 1999 TNFalpha receptor I (p55, TNFRI) and II (p75, TNFRII) shedding was also inhibited by GI-129471 (IC50 = 1.5 and 3.1 microM, respectively) and BB-2516 (IC50 = 14 and 15 microM, respectively). boeravinone B 141-143 TNF receptor superfamily member 1B Homo sapiens 46-52 9844148-9 1998 The patients with the BB pattern of VDR genotype were characterized by the lowest PTH levels both at time of transplantation and after stabilization, and lower set point values than patients with Bb and bb patterns. boeravinone B 22-24 vitamin D receptor Homo sapiens 36-39 9892221-0 1999 Recombinant human platelet-activating factor acetylhydrolase reduces the frequency of diabetes in the diabetes-prone BB rat. boeravinone B 117-119 phospholipase A2 group VII Homo sapiens 18-60 10692979-7 1999 With respect to VDR genotype, a significantly higher decrease in osteocalcin level was observed in bb as compared with BB subjects. boeravinone B 99-101 vitamin D receptor Homo sapiens 16-19 10692979-7 1999 With respect to VDR genotype, a significantly higher decrease in osteocalcin level was observed in bb as compared with BB subjects. boeravinone B 99-101 bone gamma-carboxyglutamate protein Homo sapiens 65-76 10692979-7 1999 With respect to VDR genotype, a significantly higher decrease in osteocalcin level was observed in bb as compared with BB subjects. boeravinone B 119-121 vitamin D receptor Homo sapiens 16-19 10692979-7 1999 With respect to VDR genotype, a significantly higher decrease in osteocalcin level was observed in bb as compared with BB subjects. boeravinone B 119-121 bone gamma-carboxyglutamate protein Homo sapiens 65-76 9844148-9 1998 The patients with the BB pattern of VDR genotype were characterized by the lowest PTH levels both at time of transplantation and after stabilization, and lower set point values than patients with Bb and bb patterns. boeravinone B 196-198 vitamin D receptor Homo sapiens 36-39 9844148-9 1998 The patients with the BB pattern of VDR genotype were characterized by the lowest PTH levels both at time of transplantation and after stabilization, and lower set point values than patients with Bb and bb patterns. boeravinone B 203-205 vitamin D receptor Homo sapiens 36-39 9642242-7 1998 The kcat for the cell-bound enzyme, ZymC3b,Bb was 0.0048 s-1 and that for soluble C3b,Bb was 0.0110 s-1. boeravinone B 43-45 endogenous retrovirus group K member 3 Homo sapiens 39-42 9740163-8 1998 The serum osteocalcin level was also lower in BB than in bb patients (P < 0.05). boeravinone B 46-48 bone gamma-carboxyglutamate protein Homo sapiens 10-21 9740163-8 1998 The serum osteocalcin level was also lower in BB than in bb patients (P < 0.05). boeravinone B 57-59 bone gamma-carboxyglutamate protein Homo sapiens 10-21 9719169-5 1998 RESULTS: VDR genotype BB, Bb and bb were found in 27, 49 and 24% of patients. boeravinone B 33-35 vitamin D receptor Homo sapiens 9-12 10101442-10 1998 Results from this study suggest that faster bone mineral loss and more exaggerated disturbances of vitamin D metabolism are present in haemodialyzed uraemic patients with BB than bb genotype of VDR. boeravinone B 179-181 vitamin D receptor Homo sapiens 194-197 9718491-4 1998 kappa-Casein variant B also had a positive effect (+12 g/kg in favour of BB relative to AA animals). boeravinone B 73-75 casein kappa Bos taurus 0-12 9696696-4 1998 Expression of NCX1 only slightly inhibited platelet-derived growth factor BB-induced alkalinization and did not affect hyperosmolarity- or phorbol 12-myristate 13-acetate-induced alkalinization. boeravinone B 74-76 solute carrier family 8 member A1 Homo sapiens 14-18 9639698-7 1998 The Hprt mutant frequencies in DMBA-treated BB and F344 rats were significantly increased over control values for every dose-time combination examined, while only the 130 mg/kg dose consistently produced lacI MFs that were significantly above the controls. boeravinone B 44-46 hypoxanthine phosphoribosyltransferase 1 Rattus norvegicus 4-8 9295059-6 1997 In subjects with the AB or BB genotype, the mean H2O2-induced PARP enzyme activity was significantly higher (p = 0.02, adjusted for case-control status and age) compared with that in subjects with the AA genotype. boeravinone B 27-29 poly(ADP-ribose) polymerase 1 Homo sapiens 62-66 9693975-7 1998 In a cross-sectional analysis of sera from BB rats, low levels of anti-ICA512 were present in 11/20 (55%) of non-diabetic-diabetes prone (DP) BB rats, 0/4 (0%) of diabetic DP BB rats, and 1/6 (17%) of diabetes-resistant BB rats. boeravinone B 43-45 protein tyrosine phosphatase, receptor type, N Rattus norvegicus 71-77 9595408-4 1998 In contrast, ET-1 and ET-2 significantly induced SMC migration in the presence of low concentrations of PDGF-BB (0.5 ng/mL) or Ang II (10(-9) mol/L), although ET-3 was less active (ET-1 = ET-2 > ET-3). boeravinone B 109-111 endothelin 1 Homo sapiens 13-17 9595408-4 1998 In contrast, ET-1 and ET-2 significantly induced SMC migration in the presence of low concentrations of PDGF-BB (0.5 ng/mL) or Ang II (10(-9) mol/L), although ET-3 was less active (ET-1 = ET-2 > ET-3). boeravinone B 109-111 endothelin 2 Homo sapiens 22-26 9610787-5 1998 Among controls, the BB genotype was significantly associated with higher 1,25-dihydroxyvitamin D (median = 36.2 pg/ml for the BB versus 33.9 pg/ml for the bb genotype; P = 0.02), suggesting an association of the VDR polymorphisms with VDR function. boeravinone B 20-22 vitamin D receptor Homo sapiens 212-215 9610787-5 1998 Among controls, the BB genotype was significantly associated with higher 1,25-dihydroxyvitamin D (median = 36.2 pg/ml for the BB versus 33.9 pg/ml for the bb genotype; P = 0.02), suggesting an association of the VDR polymorphisms with VDR function. boeravinone B 20-22 vitamin D receptor Homo sapiens 235-238 9437188-0 1997 Inhibition of platelet-derived growth factor BB-induced expression of glyceraldehyde-3-phosphate dehydrogenase by sodium butyrate in rat vascular smooth muscle cells. boeravinone B 45-47 glyceraldehyde-3-phosphate dehydrogenase Rattus norvegicus 70-110 9409235-5 1997 Furthermore, at high concentrations BB was able to prevent chemotaxis induced by fetal calf serum and epidermal growth factor (EGF). boeravinone B 36-38 epidermal growth factor Homo sapiens 102-125 9637357-5 1997 Oral dosing of diabetes prone BB rats with lipopolysaccharide (LPS) or the Escherichia coli extract OM-89 lead to a Th2-shift of pancreatic mRNA expression. boeravinone B 30-32 heart and neural crest derivatives expressed 2 Mus musculus 116-119 8703030-11 1996 Strikingly, the concurrent addition of IL-4 enhanced PDGF BB-induced Iepsilon binding activity, Jak1 tyrosine phosphorylation, and [3H]thymidine incorporation. boeravinone B 58-60 interleukin 4 Mus musculus 39-43 8914043-13 1996 The beneficial effect of bb genotype was independent of the prevailing PTH levels and was also observed in those patients with a baseline PTH level < 250 pg/ml (final Z score: bb, -0.42 +/- 1.3, N = 11; Bb/BB, -1.35 +/- 0.8, N = 11, P < 0.05). boeravinone B 25-27 parathyroid hormone Homo sapiens 71-74 8914043-13 1996 The beneficial effect of bb genotype was independent of the prevailing PTH levels and was also observed in those patients with a baseline PTH level < 250 pg/ml (final Z score: bb, -0.42 +/- 1.3, N = 11; Bb/BB, -1.35 +/- 0.8, N = 11, P < 0.05). boeravinone B 25-27 parathyroid hormone Homo sapiens 138-141 8914043-13 1996 The beneficial effect of bb genotype was independent of the prevailing PTH levels and was also observed in those patients with a baseline PTH level < 250 pg/ml (final Z score: bb, -0.42 +/- 1.3, N = 11; Bb/BB, -1.35 +/- 0.8, N = 11, P < 0.05). boeravinone B 206-208 parathyroid hormone Homo sapiens 138-141 8914043-13 1996 The beneficial effect of bb genotype was independent of the prevailing PTH levels and was also observed in those patients with a baseline PTH level < 250 pg/ml (final Z score: bb, -0.42 +/- 1.3, N = 11; Bb/BB, -1.35 +/- 0.8, N = 11, P < 0.05). boeravinone B 209-211 parathyroid hormone Homo sapiens 138-141 8914043-14 1996 At the end of follow-up, the histomorphometric studies showed a higher bone formation rate adjusted for PTH levels in patients with the Bb or BB genotype than in those with the favorable bb genotype (0.29 +/- 0.06 vs. 0.21 +/- 0.08 micron3/micron2/day respectively; P < 0.05). boeravinone B 136-138 parathyroid hormone Homo sapiens 104-107 8914043-14 1996 At the end of follow-up, the histomorphometric studies showed a higher bone formation rate adjusted for PTH levels in patients with the Bb or BB genotype than in those with the favorable bb genotype (0.29 +/- 0.06 vs. 0.21 +/- 0.08 micron3/micron2/day respectively; P < 0.05). boeravinone B 142-144 parathyroid hormone Homo sapiens 104-107 8889857-8 1996 The association of VDR genotype with BMD at the femoral neck appeared to be modified by calcium intake (BB and Bb: 0.797 +/- 0.11 g/cm2 vs. 0.844 +/- 0.11 g/cm2, interaction term, p = 0.06) for low (< 1036 mg/day) and high (> or = 1036 mg/day; upper quartile) calcium intakes, respectively. boeravinone B 104-106 vitamin D receptor Homo sapiens 19-22 8889857-8 1996 The association of VDR genotype with BMD at the femoral neck appeared to be modified by calcium intake (BB and Bb: 0.797 +/- 0.11 g/cm2 vs. 0.844 +/- 0.11 g/cm2, interaction term, p = 0.06) for low (< 1036 mg/day) and high (> or = 1036 mg/day; upper quartile) calcium intakes, respectively. boeravinone B 111-113 vitamin D receptor Homo sapiens 19-22 9288532-4 1997 In d BB rats, the 24 h mean value of SBP (132 +/- 0.15 mm-Hg) was significantly increased compared to nd BB rats (125 +/- 0.18 mmHg). boeravinone B 5-7 spermine binding protein Rattus norvegicus 37-40 8816966-6 1996 We observed that in DP-BB and in treated DR-BB rats, the levels of TCR beta, IFN-gamma and IL-12p40 mRNA increase with disease progression. boeravinone B 23-25 T-cell receptor beta chain Rattus norvegicus 67-75 8675695-7 1996 The addition of BB-2275 to rheumatoid synovial membrane cell cultures totally inhibited MMP activity and also significantly reduced the levels of soluble TNF alpha (P < 0.006), p55 sTNF-R (P < 0.006), and p75 sTNF-R (P < 0.004). boeravinone B 16-18 tumor necrosis factor Homo sapiens 154-163 8675695-7 1996 The addition of BB-2275 to rheumatoid synovial membrane cell cultures totally inhibited MMP activity and also significantly reduced the levels of soluble TNF alpha (P < 0.006), p55 sTNF-R (P < 0.006), and p75 sTNF-R (P < 0.004). boeravinone B 16-18 TNF receptor superfamily member 1A Homo sapiens 180-183 8816966-6 1996 We observed that in DP-BB and in treated DR-BB rats, the levels of TCR beta, IFN-gamma and IL-12p40 mRNA increase with disease progression. boeravinone B 23-25 interferon gamma Rattus norvegicus 77-86 8616834-7 1996 Dividing the BCC cases into groups of 92 patients with 1 lesion and 194 patients with 2-35 lesions showed that the frequencies of GSTM3 BB (2.6%) and GSTM1 A/B (1.3%) in the group with 2-35 tumors were almost significantly lower than in the group with 1 lesion (7.6%, exact P = 0.0601, chi 2(1) = 3.390; 6.5%, exact P = 0.055, chi 2(1) = 4.946, respectively). boeravinone B 136-138 glutathione S-transferase mu 3 Homo sapiens 130-135 8787784-1 1995 The inhibitory effect of 3-butylidene-4,5-dihydroxyphthalide (BP-42) on platelet derived growth factor (PDGF)-BB-induced DNA synthesis was investigated in synchronized smooth muscle cells (SMC) in primary culture of rat aorta. boeravinone B 110-112 Blood pressure QTL 42 Rattus norvegicus 62-67 8845602-6 1996 The frequency distribution of the VDR genotype was: bb, 20.6%; Bb, 39.1%; and BB, 40.2%. boeravinone B 52-54 vitamin D receptor Homo sapiens 34-37 8845602-6 1996 The frequency distribution of the VDR genotype was: bb, 20.6%; Bb, 39.1%; and BB, 40.2%. boeravinone B 63-65 vitamin D receptor Homo sapiens 34-37 8845602-6 1996 The frequency distribution of the VDR genotype was: bb, 20.6%; Bb, 39.1%; and BB, 40.2%. boeravinone B 78-80 vitamin D receptor Homo sapiens 34-37 8991066-5 1996 In contrast, BB mice given 50 and 150 mg/kg B[a]P displayed induced hprt frequencies of 0.9 +/- 0.6 and 9.1 +/- 1.5 x 10(-6). boeravinone B 13-15 hypoxanthine guanine phosphoribosyl transferase Mus musculus 68-72 8787784-1 1995 The inhibitory effect of 3-butylidene-4,5-dihydroxyphthalide (BP-42) on platelet derived growth factor (PDGF)-BB-induced DNA synthesis was investigated in synchronized smooth muscle cells (SMC) in primary culture of rat aorta. boeravinone B 110-112 myotrophin Rattus norvegicus 89-102 8787784-7 1995 BP-421 (3-heptylidene-4,5-dihydroxyphthalide) and BP-422 (3-benzylidene-4,5-dihydroxyphthalide) had 3-fold greater inhibitory potencies than BP-42 for the PDGF-BB-induced competence activity. boeravinone B 160-162 Blood pressure QTL 42 Rattus norvegicus 0-5 8553473-2 1995 The increase of uptake rate for Ca2+ by BB membrane preparations together with the enhancement of the process of L-phenylalanine passive diffusion and suppression of Na(+)-dependent transport of this amino acid was established. boeravinone B 40-42 carbonic anhydrase 2 Rattus norvegicus 32-35 8824710-4 1995 Since we have further demonstrated that poly I:C administration to BB rats increases NK cell number and levels of inducers of NK cell activity, interferon-alpha and IL-6 which is described therein, we tested the hypothesis that NK cell activity plays an important role in poly I:C accelerated disease. boeravinone B 67-69 interleukin 6 Rattus norvegicus 165-169 7638756-9 1995 WF pancreas transplants result in the appearance of RT6.2+ T cells in BB-Ac recipients, an RT allele that BB rats lack. boeravinone B 70-72 ADP-ribosyltransferase 2b Rattus norvegicus 52-57 7673427-6 1995 The increase in serum osteocalcin levels in the BB group was significantly less than that in the bb group (11% vs. 32%, P = 0.01). boeravinone B 48-50 bone gamma-carboxyglutamate protein Homo sapiens 22-33 7810696-4 1994 In association with the appearance in both models of significant renal hypertrophy, TGF-beta 1 mRNA levels were increased threefold in the kidney of the diabetic BB rat after 3 days of diabetes and also threefold after 7-9 days in the NOD mouse. boeravinone B 162-164 transforming growth factor, beta 1 Rattus norvegicus 84-94 7860767-9 1995 The expression of the G6Pase gene is also dramatically elevated in BB diabetic rats, again higher than the enzyme elevation, and its relative induction after partial hepatectomy is blunted in these animals. boeravinone B 67-69 glucose-6-phosphatase catalytic subunit 1 Rattus norvegicus 22-28 7830488-0 1995 Endothelins urinary excretion is increased in spontaneously diabetic rats: BB/BB. boeravinone B 75-77 endothelin 1 Rattus norvegicus 0-11 7830488-0 1995 Endothelins urinary excretion is increased in spontaneously diabetic rats: BB/BB. boeravinone B 78-80 endothelin 1 Rattus norvegicus 0-11 7830488-4 1995 BB/BB diabetic rats showed elevated urinary excretion of endothelins as compared to BB/WB control rats, starting two weeks after diabetes onset, and up to twelve weeks. boeravinone B 0-2 endothelin 1 Rattus norvegicus 57-68 7830488-4 1995 BB/BB diabetic rats showed elevated urinary excretion of endothelins as compared to BB/WB control rats, starting two weeks after diabetes onset, and up to twelve weeks. boeravinone B 3-5 endothelin 1 Rattus norvegicus 57-68 8294472-1 1994 The troponin I (TnI) inhibitory region (residues 104-115) was synthesized with alpha-14C-labeled Gly-104 and a covalently linked benzoylbenzoyl (BB) moiety at the N terminus to yield a photoactivatable radioactive peptide (BBIp). boeravinone B 145-147 troponin I, fast skeletal muscle Oryctolagus cuniculus 4-14 8163929-7 1994 Reactivity of IgG antibodies with the octapeptide sequence PPPGMRPP was also found in 30% of anti-Sm/U1snRNP positive (SWR x SJL)F1 mice that precipitated BB" peptides. boeravinone B 155-157 RNA binding region (RNP1, RRM) containing 3 Homo sapiens 101-108 7946007-7 1994 Whereas the molecular weight of BB isoform (58 kd) of liver was in proximity to the weight of BB form (44 kd) of skeletal muscle mMDH. boeravinone B 32-34 malate dehydrogenase 2, NAD (mitochondrial) Mus musculus 129-133 7946007-7 1994 Whereas the molecular weight of BB isoform (58 kd) of liver was in proximity to the weight of BB form (44 kd) of skeletal muscle mMDH. boeravinone B 94-96 malate dehydrogenase 2, NAD (mitochondrial) Mus musculus 129-133 8088308-4 1994 CVF is a potent activator of the alternative pathway of complement by forming the C3-convertase CVF, Bb which cannot be downregulated by the natural inhibitor factors H and I and thereby leads to generation of the anaphylatoxins C3a and C5a and formation of the membrane attack complex (MAC). boeravinone B 101-103 complement C5 Rattus norvegicus 237-240 8294472-1 1994 The troponin I (TnI) inhibitory region (residues 104-115) was synthesized with alpha-14C-labeled Gly-104 and a covalently linked benzoylbenzoyl (BB) moiety at the N terminus to yield a photoactivatable radioactive peptide (BBIp). boeravinone B 145-147 troponin I, fast skeletal muscle Oryctolagus cuniculus 16-19 8294472-7 1994 The results indicated that Met-155 of TnC was cross-linked to the BB moiety of BBIp in either the presence or absence of Ca2+. boeravinone B 66-68 tenascin Oryctolagus cuniculus 38-41 8238505-2 1993 PKC specific activities were increased in the membraneous fraction of retina from streptozotocin (STZ)-induced diabetic rats and the genetically determined diabetic BB rats, respectively, after 1 or 2 wk of diabetes, compared with control. boeravinone B 165-167 protein kinase C, gamma Rattus norvegicus 0-3 8061161-5 1994 However, IL-1 induced significantly higher blood glucose concentrations in the prediabetic period (p < 0.00005) and at diabetes onset (p < 0.00005) in the DP BB rats and caused episodes of blood glucose concentrations > 11 mmol/l in the prediabetic period in 11/20 DP BB rats compared to 4/27 diabetes-resistant (DR) BB rats and 4/28 Wistar Furth (WF) rats (both p < 0.004), compared to DP BB). boeravinone B 164-166 interleukin 1 beta Homo sapiens 9-13 8430604-0 1993 Manidipine affects rPDGF-BB-induced gene transcription of low-density lipoprotein receptors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in human mesangial cells. boeravinone B 25-27 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 96-143 7688327-1 1993 The inducible NO synthase (iNOS) was found to be expressed in pancreatic lesions of adult diabetes-prone BB rats. boeravinone B 105-107 nitric oxide synthase 2 Rattus norvegicus 4-25 7688327-1 1993 The inducible NO synthase (iNOS) was found to be expressed in pancreatic lesions of adult diabetes-prone BB rats. boeravinone B 105-107 nitric oxide synthase 2 Rattus norvegicus 27-31 1438315-5 1992 The increases in membranous PKC specific activity and DAG level are observed in both spontaneous diabetes-prone diabetic BB rats as well as in STZ-induced diabetic BB and Sprague-Dawley rats, which persisted for up to 5 weeks. boeravinone B 121-123 protein kinase C, gamma Rattus norvegicus 28-31 1438315-5 1992 The increases in membranous PKC specific activity and DAG level are observed in both spontaneous diabetes-prone diabetic BB rats as well as in STZ-induced diabetic BB and Sprague-Dawley rats, which persisted for up to 5 weeks. boeravinone B 164-166 protein kinase C, gamma Rattus norvegicus 28-31 1321794-1 1992 C3 nephritic factor (NEF) is an IgG autoantibody directed against neoantigenic determinants of the alternative C3 convertase (C3b.Bb). boeravinone B 130-132 endogenous retrovirus group K member 3 Homo sapiens 126-129 1483294-3 1992 The bioactivity of sera and fractions containing BB-PRL was evaluated and the fractions analysed by affinity chromatography and electrophoresis. boeravinone B 49-51 prolactin Homo sapiens 52-55 1483294-14 1992 During gel chromatography either a change in the structure of BB-PRL and/or a removal of substances which potentiate the bioactivity of PRL occurs, explaining the lower bioactivity of fractions containing BB-PRL in comparison with the serum. boeravinone B 62-64 prolactin Homo sapiens 65-68 1402554-3 1992 Saline-treated diabetic BB rats had decreased plasma concentrations of IGF-I and osteocalcin (OC) (OC, 3.7 +/- 0.3 vs 13.1 +/- 0.8 (S.E.M.) boeravinone B 24-26 insulin-like growth factor 1 Rattus norvegicus 71-76 1402554-3 1992 Saline-treated diabetic BB rats had decreased plasma concentrations of IGF-I and osteocalcin (OC) (OC, 3.7 +/- 0.3 vs 13.1 +/- 0.8 (S.E.M.) boeravinone B 24-26 bone gamma-carboxyglutamate protein Rattus norvegicus 81-92 1541051-2 1992 During these experiments, we unexpectedly found that in vivo production of TNF stimulated by a single injection of lipopolysaccharide was enhanced approximately 10 times in the long-term diabetic BB rats (P less than 0.0001), whose mean duration of diabetes with more than 16.8 mM (300 mg/dl) of nonfasting blood glucose level was 26.2 +/- 2.1 days, as compared to that in the rats of nondiabetes and in the rats at the onset of diabetes, whose mean duration of diabetes was 1.4 +/- 0.6 days. boeravinone B 196-198 tumor necrosis factor Rattus norvegicus 75-78 1551314-1 1992 Elevated levels of immunoreactive hypothalamic neuropeptide Y have recently been reported both in streptozotocin-induced diabetic rats and in the spontaneously diabetic BB rat. boeravinone B 169-171 neuropeptide Y Rattus norvegicus 47-61 1551314-3 1992 In the hypothalami of both the spontaneously diabetic BB/E and the streptozotocin-diabetic animals, neuropeptide Y mRNA showed significant elevations (to 204 +/- 13% (+/- SE) and 387 +/- 48% of control values, respectively, p less than 0.01 for both). boeravinone B 54-56 neuropeptide Y Rattus norvegicus 100-114 1834379-0 1991 Deficiency of purine nucleoside phosphorylase activity in thymocytes from the immunodeficient diabetic BB rat. boeravinone B 103-105 purine nucleoside phosphorylase Rattus norvegicus 14-45 1576084-5 1992 Cardioselective beta-adrenergic receptor blockade, metoprolol HC1 (BB, 1.0 mg/kg, n = 8), significantly (p less than 0.01) reduced the heart-rate conditional response (peak HR change: control 66.8 +/- 6; BB 25.1 +/- 3.8 beats/min) to the same extent as noted during RSGx. boeravinone B 67-69 CYCS pseudogene 39 Homo sapiens 62-65 1576084-5 1992 Cardioselective beta-adrenergic receptor blockade, metoprolol HC1 (BB, 1.0 mg/kg, n = 8), significantly (p less than 0.01) reduced the heart-rate conditional response (peak HR change: control 66.8 +/- 6; BB 25.1 +/- 3.8 beats/min) to the same extent as noted during RSGx. boeravinone B 204-206 CYCS pseudogene 39 Homo sapiens 62-65 1824247-5 1991 Plasma levels of alternative pathway components Ba and Bb also increased, 8.0- and 5.0-fold, respectively, during IL-2 treatment. boeravinone B 55-57 interleukin 2 Homo sapiens 114-118 2066650-0 1991 Growth hormone-enhanced lipolysis in the spontaneously diabetic BB rat. boeravinone B 64-66 gonadotropin releasing hormone receptor Rattus norvegicus 0-14 1917978-3 1991 The dissociation rate constants of BB CBG for cortisol (4.42 nM) and corticosterone (1.43 nM) are both about 50% higher than those associated with Wistar CBG, but no obvious difference in the steroid binding specificity of BB and Wistar CBGs was detected. boeravinone B 35-37 serpin family A member 6 Rattus norvegicus 38-41 1917978-3 1991 The dissociation rate constants of BB CBG for cortisol (4.42 nM) and corticosterone (1.43 nM) are both about 50% higher than those associated with Wistar CBG, but no obvious difference in the steroid binding specificity of BB and Wistar CBGs was detected. boeravinone B 35-37 serpin family A member 6 Rattus norvegicus 154-157 2269476-6 1990 IL-6 was produced by 64 +/- 8% or 71 +/- 9% (means +/- SD) of the non-IVIg-exposed monocytes after LPS or Bb stimulation, respectively (n = 12). boeravinone B 106-108 interleukin 6 Homo sapiens 0-4 2005382-0 1991 Reconstitution of C5 convertase of the alternative complement pathway with isolated C3b dimer and factors B and D. C5 convertase of the alternative complement pathway is a trimolecular complex consisting of two molecules of C3b and one molecule of Bb. boeravinone B 248-250 endogenous retrovirus group K member 3 Homo sapiens 84-87 2005382-1 1991 We previously proposed a model of the alternative pathway C5 convertase in which the second C3b molecule binds covalently to the first C3b molecule bearing Bb, and the C5 molecule binds to each C3b molecule of the covalently linked C3b dimer, resulting in its appropriate presentation to the catalytic site on Bb. boeravinone B 156-158 endogenous retrovirus group K member 3 Homo sapiens 92-95 2005382-1 1991 We previously proposed a model of the alternative pathway C5 convertase in which the second C3b molecule binds covalently to the first C3b molecule bearing Bb, and the C5 molecule binds to each C3b molecule of the covalently linked C3b dimer, resulting in its appropriate presentation to the catalytic site on Bb. boeravinone B 156-158 endogenous retrovirus group K member 3 Homo sapiens 135-138 2005382-1 1991 We previously proposed a model of the alternative pathway C5 convertase in which the second C3b molecule binds covalently to the first C3b molecule bearing Bb, and the C5 molecule binds to each C3b molecule of the covalently linked C3b dimer, resulting in its appropriate presentation to the catalytic site on Bb. boeravinone B 156-158 endogenous retrovirus group K member 3 Homo sapiens 135-138 2005382-1 1991 We previously proposed a model of the alternative pathway C5 convertase in which the second C3b molecule binds covalently to the first C3b molecule bearing Bb, and the C5 molecule binds to each C3b molecule of the covalently linked C3b dimer, resulting in its appropriate presentation to the catalytic site on Bb. boeravinone B 156-158 endogenous retrovirus group K member 3 Homo sapiens 135-138 2005382-1 1991 We previously proposed a model of the alternative pathway C5 convertase in which the second C3b molecule binds covalently to the first C3b molecule bearing Bb, and the C5 molecule binds to each C3b molecule of the covalently linked C3b dimer, resulting in its appropriate presentation to the catalytic site on Bb. boeravinone B 310-312 endogenous retrovirus group K member 3 Homo sapiens 92-95 2054597-2 1991 In spontaneously diabetic (BB) rats and streptozotocin (STZ)-induced diabetic rats, models of insulin-dependent diabetes mellitus, an elevated concentration of NPY was detected in the paraventricular nucleus (PVN) and arcuate nucleus (ARH) of the hypothalamus. boeravinone B 27-29 neuropeptide Y Rattus norvegicus 160-163 1700997-7 1990 However, the incorporated DAF increased the amount of Bb generated from B in the presence of D indicating that accelerated decay of the convertase was the primary effect of DAF. boeravinone B 54-56 CD55 molecule (Cromer blood group) Homo sapiens 26-29 1700997-8 1990 Similarly, treatment of intact human E with anti-DAF decreased the amount of Bb generated by the alternative pathway convertase. boeravinone B 77-79 CD55 molecule (Cromer blood group) Homo sapiens 49-52 1703989-2 1990 Purified DAF and Factor H, in 0.1% NP-40, were assayed by measuring the amount required to release 50% of the radiolabelled Bb in 10 min from C3b,Bb on Zym or cross-linked erythrocytes. boeravinone B 124-126 complement decay-accelerating factor Bos taurus 9-12 1703989-3 1990 The relative effectiveness (i.e. the restriction index, RI) of DAF for accelerating the decay of C3b,Bb on the various particles was: ES (1.0), ER (0.04) and Zym (0.03). boeravinone B 101-103 complement decay-accelerating factor Bos taurus 63-66 1703989-5 1990 The rate of decay of C3b,Bb induced by DAF and Factor H showed similar restriction. boeravinone B 25-27 complement decay-accelerating factor Bos taurus 39-42 2269476-8 1990 In these cultures 24 +/- 12% or 29 +/- 12% of the monocytes made IL-6 in response to LPS or Bb. boeravinone B 92-94 interleukin 6 Homo sapiens 65-69 2269476-11 1990 LPS or Bb stimulation resulted in 47 +/- 18% or 69 +/- 7% TNF-alpha producing cells versus 48 +/- 9% or 59 +/- 8% in IVIg-supplemented cultures. boeravinone B 7-9 tumor necrosis factor Homo sapiens 58-67 2135398-3 1990 Concentration-dependent increases in [Ca2+]i, c-fos expression, and [3H]thymidine incorporation were observed with both BB and AA PDGF isoforms. boeravinone B 120-122 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 46-51 2169435-7 1990 Phosphorylation of Bb to yield Bb* is concluded to reduce the Km of B-CK dimers for CP by about 50%. boeravinone B 19-21 creatine kinase B Gallus gallus 68-72 2169435-7 1990 Phosphorylation of Bb to yield Bb* is concluded to reduce the Km of B-CK dimers for CP by about 50%. boeravinone B 31-33 creatine kinase B Gallus gallus 68-72 2135398-7 1990 Conversely, in cells made deficient in protein kinase C (PKC) activity by prolonged treatment with phorbol ester, BB and AA PDGF-induced c-fos expression was inhibited by 75-80%, while PDGF-induced increases in [Ca2+]i and DNA synthesis were unaffected or enhanced. boeravinone B 114-116 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 137-142 1697173-4 1990 ; CEA VS BB + MT = N.S.) boeravinone B 9-11 CEA cell adhesion molecule 3 Homo sapiens 2-5 1973671-9 1990 Although a possible role for large granular lymphocytes cannot be excluded, the results demonstrate that in the BB rat, the beta-cell destruction can be induced by CD4 T lymphocytes. boeravinone B 112-114 Cd4 molecule Rattus norvegicus 164-167 1971747-1 1990 In past studies, we have demonstrated that in streptozotocin-induced diabetic or spontaneously diabetic (BB) animal models, low Km cAMP phosphodiesterase and calmodulin are decreased while a low MW inhibitor of calmodulin is increased. boeravinone B 105-107 calmodulin 1 Rattus norvegicus 158-168 1971747-1 1990 In past studies, we have demonstrated that in streptozotocin-induced diabetic or spontaneously diabetic (BB) animal models, low Km cAMP phosphodiesterase and calmodulin are decreased while a low MW inhibitor of calmodulin is increased. boeravinone B 105-107 calmodulin 1 Rattus norvegicus 211-221 1971747-3 1990 We found markedly decreased rates of synthesis of calmodulin in the fully diabetic BB rat. boeravinone B 83-85 calmodulin 1 Rattus norvegicus 50-60 1695911-4 1990 IL-1 production in response to lipopolysaccharide was significantly lower in LL, BL, BB, and BT patients than in normal controls. boeravinone B 85-87 interleukin 1 alpha Homo sapiens 0-4 1966886-3 1990 In this study, similar defects in insulin receptor of aortic endothelial cells cultured from diabetic BB rats were found. boeravinone B 102-104 insulin receptor Rattus norvegicus 34-50 2307481-1 1990 Long-term treatment with recombinant interleukin-2 (IL-2) of diabetes-prone BB rats had contrasting effects in two different BB rat sublines. boeravinone B 76-78 interleukin 2 Rattus norvegicus 37-50 2307481-1 1990 Long-term treatment with recombinant interleukin-2 (IL-2) of diabetes-prone BB rats had contrasting effects in two different BB rat sublines. boeravinone B 76-78 interleukin 2 Rattus norvegicus 52-56 2307481-1 1990 Long-term treatment with recombinant interleukin-2 (IL-2) of diabetes-prone BB rats had contrasting effects in two different BB rat sublines. boeravinone B 125-127 interleukin 2 Rattus norvegicus 37-50 2307481-1 1990 Long-term treatment with recombinant interleukin-2 (IL-2) of diabetes-prone BB rats had contrasting effects in two different BB rat sublines. boeravinone B 125-127 interleukin 2 Rattus norvegicus 52-56 34833355-6 2021 The prophylactic administration of BB in the murine model of UC reduced histological damage, decreased the expression of IL-1beta (61.12%), IL-6 (94.70%), and TNF-alpha (68.88%), and increased the expression of INF-gamma (177.06%), IL-4 (541.36%), and IL-10 (531.97%). boeravinone B 35-37 interleukin 1 alpha Mus musculus 121-129 2306658-0 1990 Activation of bovine monocytes and neutrophils by the Bb fragment of complement factor B: demonstration by the uptake of 3H-deoxyglucose. boeravinone B 54-56 complement factor B Bos taurus 69-88 2306658-1 1990 The Bb fragment is the enzymatically active split product of bovine complement factor B. boeravinone B 4-6 complement factor B Bos taurus 68-87 34833355-6 2021 The prophylactic administration of BB in the murine model of UC reduced histological damage, decreased the expression of IL-1beta (61.12%), IL-6 (94.70%), and TNF-alpha (68.88%), and increased the expression of INF-gamma (177.06%), IL-4 (541.36%), and IL-10 (531.97%). boeravinone B 35-37 interleukin 6 Mus musculus 140-144 34833355-6 2021 The prophylactic administration of BB in the murine model of UC reduced histological damage, decreased the expression of IL-1beta (61.12%), IL-6 (94.70%), and TNF-alpha (68.88%), and increased the expression of INF-gamma (177.06%), IL-4 (541.36%), and IL-10 (531.97%). boeravinone B 35-37 tumor necrosis factor Mus musculus 159-168 34833355-6 2021 The prophylactic administration of BB in the murine model of UC reduced histological damage, decreased the expression of IL-1beta (61.12%), IL-6 (94.70%), and TNF-alpha (68.88%), and increased the expression of INF-gamma (177.06%), IL-4 (541.36%), and IL-10 (531.97%). boeravinone B 35-37 interleukin 4 Mus musculus 232-236 34833355-6 2021 The prophylactic administration of BB in the murine model of UC reduced histological damage, decreased the expression of IL-1beta (61.12%), IL-6 (94.70%), and TNF-alpha (68.88%), and increased the expression of INF-gamma (177.06%), IL-4 (541.36%), and IL-10 (531.97%). boeravinone B 35-37 interleukin 10 Mus musculus 252-257 34193669-10 2021 BB regulated the expression of glycine (Gly), glutamic acid (Glu), taurine (Tau), aspartic acid (Asp) and gamma-aminobutyric acid (GABA) and enhanced the activity of Na+, K+ ATPase and Ca2+ ATPase. boeravinone B 0-2 carbonic anhydrase 2 Rattus norvegicus 185-196 34386392-11 2021 HbA1c <8% was significantly more in those aged 3-8 yrs, mean duration <=4.1 yrs, those using pens and BB regimen. boeravinone B 102-104 hemoglobin subunit alpha 1 Homo sapiens 0-4 34193671-11 2021 BB treatment considerably (p < 0.001) reduced the levels of lipid peroxidation (LPO) and increased the level of superoxide dismutase (SOD), glutathione (GSH), glutathione peroxidase (GPx), catalase (CAT) in DMBA/croton-induced skin cancer. boeravinone B 0-2 catalase Mus musculus 189-197 34193671-11 2021 BB treatment considerably (p < 0.001) reduced the levels of lipid peroxidation (LPO) and increased the level of superoxide dismutase (SOD), glutathione (GSH), glutathione peroxidase (GPx), catalase (CAT) in DMBA/croton-induced skin cancer. boeravinone B 0-2 catalase Mus musculus 199-202 34193671-13 2021 BB treatment considerably reduced the cytokines include tumor necrosis factor-alpha (TNF-alpha), interleukin-18 (IL-18), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and inflammatory parameters such as transforming growth factor beta 1 (TGF-beta1), prostaglandin E2 (PGE2), nuclear kappa B factor (NF-kappaB) and cycloxgenase-2 (COX-2) in DMBA/croton-induced skin cancer mice. boeravinone B 0-2 tumor necrosis factor Mus musculus 56-83 34193671-13 2021 BB treatment considerably reduced the cytokines include tumor necrosis factor-alpha (TNF-alpha), interleukin-18 (IL-18), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and inflammatory parameters such as transforming growth factor beta 1 (TGF-beta1), prostaglandin E2 (PGE2), nuclear kappa B factor (NF-kappaB) and cycloxgenase-2 (COX-2) in DMBA/croton-induced skin cancer mice. boeravinone B 0-2 tumor necrosis factor Mus musculus 85-94 34193671-13 2021 BB treatment considerably reduced the cytokines include tumor necrosis factor-alpha (TNF-alpha), interleukin-18 (IL-18), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and inflammatory parameters such as transforming growth factor beta 1 (TGF-beta1), prostaglandin E2 (PGE2), nuclear kappa B factor (NF-kappaB) and cycloxgenase-2 (COX-2) in DMBA/croton-induced skin cancer mice. boeravinone B 0-2 interleukin 18 Mus musculus 97-111 34193671-13 2021 BB treatment considerably reduced the cytokines include tumor necrosis factor-alpha (TNF-alpha), interleukin-18 (IL-18), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and inflammatory parameters such as transforming growth factor beta 1 (TGF-beta1), prostaglandin E2 (PGE2), nuclear kappa B factor (NF-kappaB) and cycloxgenase-2 (COX-2) in DMBA/croton-induced skin cancer mice. boeravinone B 0-2 interleukin 18 Mus musculus 113-118 34193671-13 2021 BB treatment considerably reduced the cytokines include tumor necrosis factor-alpha (TNF-alpha), interleukin-18 (IL-18), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and inflammatory parameters such as transforming growth factor beta 1 (TGF-beta1), prostaglandin E2 (PGE2), nuclear kappa B factor (NF-kappaB) and cycloxgenase-2 (COX-2) in DMBA/croton-induced skin cancer mice. boeravinone B 0-2 interleukin 1 beta Mus musculus 121-138 34193671-13 2021 BB treatment considerably reduced the cytokines include tumor necrosis factor-alpha (TNF-alpha), interleukin-18 (IL-18), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and inflammatory parameters such as transforming growth factor beta 1 (TGF-beta1), prostaglandin E2 (PGE2), nuclear kappa B factor (NF-kappaB) and cycloxgenase-2 (COX-2) in DMBA/croton-induced skin cancer mice. boeravinone B 0-2 interleukin 1 alpha Mus musculus 140-148 34193671-13 2021 BB treatment considerably reduced the cytokines include tumor necrosis factor-alpha (TNF-alpha), interleukin-18 (IL-18), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and inflammatory parameters such as transforming growth factor beta 1 (TGF-beta1), prostaglandin E2 (PGE2), nuclear kappa B factor (NF-kappaB) and cycloxgenase-2 (COX-2) in DMBA/croton-induced skin cancer mice. boeravinone B 0-2 interleukin 6 Mus musculus 151-164 34193671-13 2021 BB treatment considerably reduced the cytokines include tumor necrosis factor-alpha (TNF-alpha), interleukin-18 (IL-18), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and inflammatory parameters such as transforming growth factor beta 1 (TGF-beta1), prostaglandin E2 (PGE2), nuclear kappa B factor (NF-kappaB) and cycloxgenase-2 (COX-2) in DMBA/croton-induced skin cancer mice. boeravinone B 0-2 interleukin 6 Mus musculus 166-170 34193671-13 2021 BB treatment considerably reduced the cytokines include tumor necrosis factor-alpha (TNF-alpha), interleukin-18 (IL-18), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and inflammatory parameters such as transforming growth factor beta 1 (TGF-beta1), prostaglandin E2 (PGE2), nuclear kappa B factor (NF-kappaB) and cycloxgenase-2 (COX-2) in DMBA/croton-induced skin cancer mice. boeravinone B 0-2 transforming growth factor, beta 1 Mus musculus 208-241 34193671-13 2021 BB treatment considerably reduced the cytokines include tumor necrosis factor-alpha (TNF-alpha), interleukin-18 (IL-18), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and inflammatory parameters such as transforming growth factor beta 1 (TGF-beta1), prostaglandin E2 (PGE2), nuclear kappa B factor (NF-kappaB) and cycloxgenase-2 (COX-2) in DMBA/croton-induced skin cancer mice. boeravinone B 0-2 transforming growth factor, beta 1 Mus musculus 243-252 34193671-13 2021 BB treatment considerably reduced the cytokines include tumor necrosis factor-alpha (TNF-alpha), interleukin-18 (IL-18), interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and inflammatory parameters such as transforming growth factor beta 1 (TGF-beta1), prostaglandin E2 (PGE2), nuclear kappa B factor (NF-kappaB) and cycloxgenase-2 (COX-2) in DMBA/croton-induced skin cancer mice. boeravinone B 0-2 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 304-313 2806905-3 1989 Studies of heat stability with kidney homogenates revealed that the relative stabilities of GPI-1 dimers was AA greater than AB greater than BB greater than AC greater than or equal to BC greater than CC. boeravinone B 141-143 glucose-6-phosphate isomerase 1 Mus musculus 92-97 35067717-4 2022 In basal eukaryotes, the coiled-coil domain proteins Lrrcc1 and Ccdc61 were shown to be required for proper BB construction and function. boeravinone B 108-110 leucine rich repeat and coiled-coil centrosomal protein 1 L homeolog Xenopus laevis 53-59 35067717-4 2022 In basal eukaryotes, the coiled-coil domain proteins Lrrcc1 and Ccdc61 were shown to be required for proper BB construction and function. boeravinone B 108-110 coiled-coil domain containing 61 L homeolog Xenopus laevis 64-70 2544091-3 1989 The authors assessed the ability of insulin to stimulate the Vmax of a low Km cAMP phosphodiesterase (PDE) in adipose tissue of control, streptozotocin diabetic (STZ-DM) rats, and spontaneous diabetic BB rats (SDR). boeravinone B 201-203 insulin Homo sapiens 36-43 2544091-12 1989 However, both animal models of diabetes, ie, STZ-DM and BB, like man, respond to insulin therapy. boeravinone B 56-58 insulin Homo sapiens 81-88 2783957-6 1989 In spontaneously diabetic BB rats, plasma osteocalcin concentrations were severely decreased compared with those in non-diabetic rats, more than would have been expected from their decreased 1,25-(OH)2D3 concentrations. boeravinone B 26-28 bone gamma-carboxyglutamate protein Rattus norvegicus 42-53 2784784-5 1989 Analysis of the sequence data reveals that the first domain of RT1.D beta and RT1.B beta chain of the BB rat are different from other rat or mouse class II sequences. boeravinone B 102-104 RT1 class II, locus Db1 Rattus norvegicus 63-73 2703699-1 1989 Cathepsin B activity is demonstrated histochemically with a post-coupling method using Z-Arg-Arg-4-methoxy-2-naphthylamide as substrate and Fast Blue BB as coupling reagent in unfixed and undecalcified cryostat sections of whole rat knee joints. boeravinone B 150-152 cathepsin B Rattus norvegicus 0-11 2783323-8 1989 These Ba and Bb preparations at 10 and 50 micrograms/ml, respectively, induced IL-1 production in the presence of 5 micrograms/ml polymyxin B (PMB). boeravinone B 13-15 interleukin 1 beta Homo sapiens 79-83 2783323-9 1989 However, Ba and Bb preparations purified by affinity chromatography and HPLC contained lower levels of endotoxin contamination and displayed IL-1-inducing activities at Ba and Bb concentrations of 50 and 100 micrograms/ml, respectively, that were almost completely inhibited by PMB. boeravinone B 16-18 interleukin 1 beta Homo sapiens 141-145 3142800-6 1988 In the diabetic and nondiabetic BB rats greater than 75 days old, the RT1.D alpha and RT1.D beta transcripts were found at lower normal levels, similar to that of WF rats. boeravinone B 32-34 RT1 class II, locus Da Rattus norvegicus 70-81 3142800-6 1988 In the diabetic and nondiabetic BB rats greater than 75 days old, the RT1.D alpha and RT1.D beta transcripts were found at lower normal levels, similar to that of WF rats. boeravinone B 32-34 RT1 class II, locus Db1 Rattus norvegicus 86-96 2964038-3 1988 However, the activity of the serum control protein of the alternative complement pathway, factor H, in controlling streptococcus-bound C3b and C3b,Bb was 6-8 times stronger on M+ organisms than on M- organisms. boeravinone B 147-149 complement factor H Homo sapiens 90-98 3183384-4 1988 Thus, the alternative pathway C5 convertase could be described as a trimolecular complex in which Bb binds noncovalently to a covalently linked C3b dimer. boeravinone B 98-100 complement C3 Homo sapiens 144-147 3065088-8 1988 The number of IL 2R cells is also diminished in the endocrine pancreas of unsuccessfully treated BB rats. boeravinone B 97-99 interleukin 2 receptor, alpha chain Mus musculus 14-19 2964038-3 1988 However, the activity of the serum control protein of the alternative complement pathway, factor H, in controlling streptococcus-bound C3b and C3b,Bb was 6-8 times stronger on M+ organisms than on M- organisms. boeravinone B 147-149 endogenous retrovirus group K member 3 Homo sapiens 135-138 2964038-3 1988 However, the activity of the serum control protein of the alternative complement pathway, factor H, in controlling streptococcus-bound C3b and C3b,Bb was 6-8 times stronger on M+ organisms than on M- organisms. boeravinone B 147-149 endogenous retrovirus group K member 3 Homo sapiens 143-146 3448834-2 1987 The content of CPK BB in different brain structures was unequal: from 0.5 mcg/mg of protein in the occipital lobe and tuber cinereum to 4.5 mcg/mg in the frontal lobe. boeravinone B 19-21 phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha Homo sapiens 15-18 3277033-0 1988 Hepatic cytochrome P-450j induction in the spontaneously diabetic BB rat. boeravinone B 66-68 cytochrome P450, family 2, subfamily e, polypeptide 1 Rattus norvegicus 8-25 3448834-3 1987 In the regional localization of CPK BB in the postmortem brain of schizophrenia patients, some changes in isoenzyme content were found as compared to the control group. boeravinone B 36-38 phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha Homo sapiens 32-35 3643213-3 1987 Whereas Bb, in complex with C3b, has proteolytic specificity toward native C3, the function of the Ba moiety in the formation and/or decay of alternative complement pathway C3 convertase is uncertain. boeravinone B 8-10 complement C3 Homo sapiens 28-31 3597252-5 1987 PT and W decreased at higher velocities in M and BB but not in F; consequently, the correlation between CSA and PT and W was lower at 300 degrees/s (r = 0.58, 0.60) than 30 degrees/s (r = 0.80, 0.79). boeravinone B 49-51 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 104-107 3644748-4 1987 Two of these antibodies markedly inhibited the activity of purified C3b,Bb deposited on rabbit erythrocytes. boeravinone B 72-74 complement C3 Homo sapiens 68-71 3644748-7 1987 It is likely that such antibodies induce in Bb conformational changes which increase the C3b,Bb complex stability but may also hinder its catalytic site. boeravinone B 44-46 complement C3 Homo sapiens 89-92 3648093-5 1987 Interestingly, both purified lupus inhibitor and Bb inhibited the chemotactic activity exhibited by mixtures of C5a des Arg and its cochemotaxin. boeravinone B 49-51 complement C5a receptor 1 Homo sapiens 112-115 3109992-1 1987 Aldose reductase was purified from testis of non-diabetic BB rats using DEAE cellulose, hydroxylapatite and sephadex G-100 column chromatography. boeravinone B 58-60 aldo-keto reductase family 1 member B1 Rattus norvegicus 0-16 3026876-0 1987 Inhibitor of calmodulin and cAMP phosphodiesterase activity in BB rats. boeravinone B 63-65 calmodulin 1 Rattus norvegicus 13-23 3643213-9 1987 Due to avidity effects, each of these interactions could be of relatively low intrinsic affinity, and the characteristic unidirectionality of alternative complement pathway C3 convertase decay may simply result from the low intrinsic association of "univalent" Bb for the C3b subunit. boeravinone B 261-263 complement C3 Homo sapiens 272-275 3124832-1 1987 Polyclonal rabbit anti-human isophosphorylases inhibit selectively the isoenzyme activities of the BB and MM isoenzyme of the human glycogen phosphorylase b with high sensitivity and without crossreactivities. boeravinone B 99-101 glycogen phosphorylase B Homo sapiens 132-156 2419425-7 1986 DAF binds to Bb with a 50% higher affinity than to C3b, and to C4b,C2a with a 1000-fold higher affinity than to C4b alone. boeravinone B 13-15 CD55 molecule (Cromer blood group) Homo sapiens 0-3 2430467-2 1986 To characterize this type of insulin resistance, autophosphorylation and kinase activity of the insulin receptor on liver was studied with streptozotocin (STZ)-induced and BB diabetic rats. boeravinone B 172-174 insulin receptor Rattus norvegicus 96-112 2430467-8 1986 In the BB rat, autophosphorylation and kinase activity of the insulin receptor were both decreased in the diabetic state and partially normalized by insulin treatment. boeravinone B 7-9 insulin receptor Rattus norvegicus 62-78 3038761-2 1987 The generation of these lysophosphatidylcholine-like molecules appears to represent an essential step in the activation of the oxidative burst of the PMNL triggered by PMA since inhibition of phospholipase A2 (PLA2) by p-bromophenacylbromide (BB) or mepacrine results in an inhibition of the O-2 release. boeravinone B 243-245 phospholipase A2 group IB Homo sapiens 192-208 3038761-2 1987 The generation of these lysophosphatidylcholine-like molecules appears to represent an essential step in the activation of the oxidative burst of the PMNL triggered by PMA since inhibition of phospholipase A2 (PLA2) by p-bromophenacylbromide (BB) or mepacrine results in an inhibition of the O-2 release. boeravinone B 243-245 phospholipase A2 group IB Homo sapiens 210-214 3638964-11 1986 It was slightly less stable (t1/2 = 77 +/- 3 s) and exhibited only half the activity of C3b,Bb (kcat./Km = 16.3 X 10(4) +/- 1.0 X 10(4) M-1 X s-1). boeravinone B 92-94 complement C3 Homo sapiens 88-91 2422866-6 1986 Patients diagnosed as having MS with clinical exacerbation had significantly higher values of CSF-MBP/CSF-BB ratio than control subjects. boeravinone B 106-108 colony stimulating factor 2 Homo sapiens 102-105 2419425-9 1986 The affinity of DAF for CVF,Bb was similar to its affinity for Bb alone, suggesting that DAF does not recognize conformational determinants unique to Bb in C3 convertases. boeravinone B 28-30 CD55 molecule (Cromer blood group) Homo sapiens 16-19 3159752-3 1985 C3b,Bb formation was measured by the concentration of Ba, released when C3b,B is activated. boeravinone B 4-6 complement C3 Homo sapiens 72-75 3089951-1 1986 When human serum was incubated at 45 degrees C for 30 min, C3 and B were converted to C3b and Bb. boeravinone B 94-96 complement C3 Homo sapiens 59-67 3159752-4 1985 Incubation of normal human serum (NHS) with C3NeF accelerates C3b amplification loop turnover with the formation of large quantities of C3b,Bb. boeravinone B 140-142 complement C3 Homo sapiens 136-139 6693386-4 1984 Stability to inactivation by heat, urea, and proteolysis was in each case: LDH-Bb4 greater than LDH-Ba/Bb greater than LDH-Ba4. boeravinone B 79-81 L-lactate dehydrogenase A chain Fundulus heteroclitus 75-78 3919090-4 1985 These findings suggest that BB immune insulitis is not MHC restricted and may be directed against islet transplants from non-RT1/u animals. boeravinone B 28-30 RT1 class II, locus Da Rattus norvegicus 125-130 3844438-4 1985 Some conversion of macrophage factor B to Bb-sized fragments occurred spontaneously in the conditioned culture medium after several hours. boeravinone B 42-44 complement factor B Mus musculus 30-38 6512413-5 1984 With sodium dodecylsulfate-polyacrylamide gel electrophoresis it was observed that the spontaneously diabetic BB and nondiabetic littermate rat VLDL contained higher percentages of apoE relative to total apoC when compared with control Wistar rats. boeravinone B 110-112 apolipoprotein E Rattus norvegicus 181-185 6512413-7 1984 Apolipoprotein A-I of the control rat HDL showed four isoforms that focused at pI 5.8 (17.3%), 5.75 (30.6%), 5.65 (31.8%), and 5.55 (20.5%); however, the spontaneously diabetic BB and nondiabetic littermate rat HDL apoA-I was mainly represented by two isoforms that focused at pI 5.8 and 5.75. boeravinone B 177-179 apolipoprotein A1 Rattus norvegicus 0-18 6512413-8 1984 VLDL of both diabetic and nondiabetic BB rats contained higher levels of acidic apoE isoforms compared to their counterparts in control Wistar rats. boeravinone B 38-40 apolipoprotein E Rattus norvegicus 80-84 6329861-4 1984 Both BB and BBN rats are indistinguishable RT1u by serologic methods. boeravinone B 5-7 RT1 class II, locus Da Rattus norvegicus 43-47 6558419-1 1983 Fluid-phase heparin prevents generation of the C3 amplification convertase of human complement, C3b, Bb most likely by inhibiting the formation of the bimolecular complex between cell-bound C3b and B. boeravinone B 101-103 complement C3 Homo sapiens 96-99 6689022-7 1983 Comparison of the mouse and human factor B sequence reveals extensive regional homology at the catalytic residues and in the NH2-terminal portion of the Bb fragment. boeravinone B 153-155 complement factor B Mus musculus 34-42 6558419-1 1983 Fluid-phase heparin prevents generation of the C3 amplification convertase of human complement, C3b, Bb most likely by inhibiting the formation of the bimolecular complex between cell-bound C3b and B. boeravinone B 101-103 complement C3 Homo sapiens 190-199 6554279-4 1983 When C5 is activated by CVF,Bb in the presence of complement component C6, the C5b,6 complex is formed. boeravinone B 28-30 complement C5 Homo sapiens 79-82 6553050-3 1983 It has been shown previously that C3b,Bb formed with Ni2+ rather than Mg2+ exhibits enhanced stability. boeravinone B 38-40 endogenous retrovirus group K member 3 Homo sapiens 34-37 6680304-8 1983 This constant reflects the Bb association with C3b and is (2,4 +/- 0,1) x 10(7) mole-1 l. Blastolysin is effective both in the C1q binding and initiation of the alternative pathway of complement activation. boeravinone B 27-29 endogenous retrovirus group K member 3 Homo sapiens 47-50 6680304-8 1983 This constant reflects the Bb association with C3b and is (2,4 +/- 0,1) x 10(7) mole-1 l. Blastolysin is effective both in the C1q binding and initiation of the alternative pathway of complement activation. boeravinone B 27-29 complement C1q A chain Homo sapiens 127-130 6342609-0 1983 Amino acid sequence of the Bb fragment from human complement Factor B. boeravinone B 27-29 complement factor B Homo sapiens 50-69 6222136-10 1983 The half-life at 22 degrees C of C3b,Bb on PNH erythrocytes was threefold greater than on normal human erythrocytes and similar to that of the enzyme bound to particles that do not possess Factor H-like activity. boeravinone B 37-39 endogenous retrovirus group K member 3 Homo sapiens 33-36 6870906-3 1983 Cytochrome P-450 A fractions appeared to be unmodified by the inducers, whereas the specifically induced cytochrome P-450 forms were always recovered in Bb fractions. boeravinone B 153-155 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 105-121 6601526-2 1983 The spreading reaction induced by Bb has previously been shown to depend upon the enzymatic activity of Bb and to be inhibited by Fab" antibody fragments directed to C5 (but not anti-C3 Fab"). boeravinone B 34-36 FA complementation group B Homo sapiens 130-133 6586103-6 1983 C3(H2O),Bb produces only three to five metastable C3b molecules per enzyme before being inactivated by regulatory proteins. boeravinone B 8-10 complement C3 Homo sapiens 50-53 6342610-0 1983 Amino acid sequence of the Bb fragment from complement Factor B. boeravinone B 27-29 complement factor B Homo sapiens 44-63 6923908-1 1982 We demonstrate that nickel++ (Ni) can replace Mg in the formation of the C3b,Bb enzyme, and that Ni is more efficient in enzyme formation than Mg. boeravinone B 77-79 complement C3 Homo sapiens 73-76 6923908-5 1982 The C3b,Bb formed with Ni (C3b,Bb(Ni)) had a 5 to 10 times longer half-life at different temperatures than the enzyme formed with Mg (C3b,Bb(Mg)). boeravinone B 8-10 complement C3 Homo sapiens 4-7 6923908-5 1982 The C3b,Bb formed with Ni (C3b,Bb(Ni)) had a 5 to 10 times longer half-life at different temperatures than the enzyme formed with Mg (C3b,Bb(Mg)). boeravinone B 8-10 complement C3 Homo sapiens 27-37 6923908-5 1982 The C3b,Bb formed with Ni (C3b,Bb(Ni)) had a 5 to 10 times longer half-life at different temperatures than the enzyme formed with Mg (C3b,Bb(Mg)). boeravinone B 8-10 complement C3 Homo sapiens 27-30 6923908-5 1982 The C3b,Bb formed with Ni (C3b,Bb(Ni)) had a 5 to 10 times longer half-life at different temperatures than the enzyme formed with Mg (C3b,Bb(Mg)). boeravinone B 31-33 complement C3 Homo sapiens 4-7 6923908-5 1982 The C3b,Bb formed with Ni (C3b,Bb(Ni)) had a 5 to 10 times longer half-life at different temperatures than the enzyme formed with Mg (C3b,Bb(Mg)). boeravinone B 31-33 complement C3 Homo sapiens 27-30 6461667-1 1982 H (beta 1H) controls the C3b amplification loop by its ability to displace Bb from the alternative pathway convertase, C3b,Bb, and acts as a cofactor with I (C3b inactivator) to produce inactive C3b. boeravinone B 75-77 complement factor H Homo sapiens 3-10 7051949-3 1982 On activating surfaces of the alternative pathway, C3b, Bb is relatively resistant to regulation by H. In contrast, non-activating surfaces exhibit surface characteristics such as high content in membrane-associated sialic acid or heparin-related material which increase the interaction of H with cell-bound C3b. boeravinone B 56-58 complement C3 Homo sapiens 51-54 7051949-3 1982 On activating surfaces of the alternative pathway, C3b, Bb is relatively resistant to regulation by H. In contrast, non-activating surfaces exhibit surface characteristics such as high content in membrane-associated sialic acid or heparin-related material which increase the interaction of H with cell-bound C3b. boeravinone B 56-58 complement C3 Homo sapiens 308-311 6461667-1 1982 H (beta 1H) controls the C3b amplification loop by its ability to displace Bb from the alternative pathway convertase, C3b,Bb, and acts as a cofactor with I (C3b inactivator) to produce inactive C3b. boeravinone B 75-77 complement C3 Homo sapiens 25-28 6461667-1 1982 H (beta 1H) controls the C3b amplification loop by its ability to displace Bb from the alternative pathway convertase, C3b,Bb, and acts as a cofactor with I (C3b inactivator) to produce inactive C3b. boeravinone B 75-77 complement C3 Homo sapiens 119-122 6461667-1 1982 H (beta 1H) controls the C3b amplification loop by its ability to displace Bb from the alternative pathway convertase, C3b,Bb, and acts as a cofactor with I (C3b inactivator) to produce inactive C3b. boeravinone B 75-77 complement C3 Homo sapiens 119-122 6912276-4 1981 In the C3b,Bb complex, Bb exhibits restricted substrate specificity for C3 and C5. boeravinone B 11-13 complement C3 Homo sapiens 7-10 6459381-4 1982 C3b bound to cells that had been treated with virus, and P-stabilized amplification convertase sites P,C3b,Bb formed on these cells, exhibited increased resistance to the action of the regulatory proteins beta-1H and C3b Ina compared with C3b and P,C3b,Bb on untreated, nonactivating cells. boeravinone B 107-109 complement factor H Homo sapiens 205-212 6459381-4 1982 C3b bound to cells that had been treated with virus, and P-stabilized amplification convertase sites P,C3b,Bb formed on these cells, exhibited increased resistance to the action of the regulatory proteins beta-1H and C3b Ina compared with C3b and P,C3b,Bb on untreated, nonactivating cells. boeravinone B 107-109 complement factor I Homo sapiens 217-224 6459381-4 1982 C3b bound to cells that had been treated with virus, and P-stabilized amplification convertase sites P,C3b,Bb formed on these cells, exhibited increased resistance to the action of the regulatory proteins beta-1H and C3b Ina compared with C3b and P,C3b,Bb on untreated, nonactivating cells. boeravinone B 253-255 endogenous retrovirus group K member 3 Homo sapiens 0-3 6912276-4 1981 In the C3b,Bb complex, Bb exhibits restricted substrate specificity for C3 and C5. boeravinone B 23-25 complement C3 Homo sapiens 7-10 6912276-10 1981 It was found that anti-C5 Fab" inhibited by up to 100% the 3-h human monocyte spreading reaction induced by Bb; in contrast, anti-C3 Fab" or anti-C4 Fab" inhibited by less than 10%. boeravinone B 108-110 FA complementation group B Homo sapiens 26-29 6912276-11 1981 That the inhibitory effect of anti-C5 Fab" was exerted directly on the monocyte was established when it was found that the 3-h monocyte spreading reaction was significantly inhibited by pretreating monocytes with anti-C5 Fab" for 20 min and then washing before the addition of Bb. boeravinone B 277-279 FA complementation group B Homo sapiens 38-41 6912276-11 1981 That the inhibitory effect of anti-C5 Fab" was exerted directly on the monocyte was established when it was found that the 3-h monocyte spreading reaction was significantly inhibited by pretreating monocytes with anti-C5 Fab" for 20 min and then washing before the addition of Bb. boeravinone B 277-279 FA complementation group B Homo sapiens 221-224 448075-3 1979 It was found that although fluid phase C3b,Bb(C3NeF) is fully capable of binding 125I-C1q, it is not able to activate 125I-C1 even at concentrations of 1.3 x 10(12) C3bBb(C3NeF) complexs/ml. boeravinone B 43-45 complement C1q A chain Homo sapiens 86-89 7378210-9 1980 Two non-acute myocardial infarction patients, who were resuscitated after cardiac arrest, had increased serum CK B values caused by the transient presence of CK isoenzyme BB in serum. boeravinone B 171-173 creatine kinase B Homo sapiens 110-114 379217-3 1979 The capability of C3NeF to bind to C3b,Bb was used as a means for purifying C3NeF to homogeneity. boeravinone B 39-41 endogenous retrovirus group K member 3 Homo sapiens 35-38 379217-4 1979 The investigation described in this report suggests that binding of C3NeF to C3b,Bb occurs via the Fab portion of the molecule. boeravinone B 81-83 endogenous retrovirus group K member 3 Homo sapiens 77-80 379217-4 1979 The investigation described in this report suggests that binding of C3NeF to C3b,Bb occurs via the Fab portion of the molecule. boeravinone B 81-83 FA complementation group B Homo sapiens 99-102 379217-7 1979 The decrease in functional activity could be attributed to the accelerated rate of dissociation of 125I-F(ab")2 and 125I-Fab fragments from stabilized cell-bound C3b,Bb. boeravinone B 166-168 FA complementation group B Homo sapiens 121-124 77846-5 1978 Cell-bound beta1H was also dissociated by the action of B (or Bb). boeravinone B 62-64 complement factor H Homo sapiens 11-17 390986-2 1979 C3b, Bb formed in the fluid phase or on a non-activating surface for the alternative pathway undergoes decay-dissociation through release of Bi, and the residual C3b undergoes cleavage inactivation by the C3b inactivator (C3bINA). boeravinone B 5-7 complement C3 Homo sapiens 0-3 390986-2 1979 C3b, Bb formed in the fluid phase or on a non-activating surface for the alternative pathway undergoes decay-dissociation through release of Bi, and the residual C3b undergoes cleavage inactivation by the C3b inactivator (C3bINA). boeravinone B 5-7 complement factor I Homo sapiens 205-220 390986-2 1979 C3b, Bb formed in the fluid phase or on a non-activating surface for the alternative pathway undergoes decay-dissociation through release of Bi, and the residual C3b undergoes cleavage inactivation by the C3b inactivator (C3bINA). boeravinone B 5-7 complement factor I Homo sapiens 222-228 390986-6 1979 Sialic acid residues on C3b-bearing particles augment binding of beta 1H to favor competition with B, inactivation of C3b and decay-dissociation of C3b, Bb. boeravinone B 153-155 complement C3 Homo sapiens 24-27 390986-6 1979 Sialic acid residues on C3b-bearing particles augment binding of beta 1H to favor competition with B, inactivation of C3b and decay-dissociation of C3b, Bb. boeravinone B 153-155 complement factor H Homo sapiens 65-72 77846-7 1978 The C3b site-bearing cell could bind beta1H on the C3c region of C3b molecules facilitating the C3bINA action on C3b, and beta1H shared the same binding site with B (or Bb) inhibiting the generation of the alternative pathway convertases competitively. boeravinone B 169-171 complement C3 Homo sapiens 4-7 77846-7 1978 The C3b site-bearing cell could bind beta1H on the C3c region of C3b molecules facilitating the C3bINA action on C3b, and beta1H shared the same binding site with B (or Bb) inhibiting the generation of the alternative pathway convertases competitively. boeravinone B 169-171 complement C3 Homo sapiens 65-68 77846-7 1978 The C3b site-bearing cell could bind beta1H on the C3c region of C3b molecules facilitating the C3bINA action on C3b, and beta1H shared the same binding site with B (or Bb) inhibiting the generation of the alternative pathway convertases competitively. boeravinone B 169-171 complement factor I Homo sapiens 96-102 77846-7 1978 The C3b site-bearing cell could bind beta1H on the C3c region of C3b molecules facilitating the C3bINA action on C3b, and beta1H shared the same binding site with B (or Bb) inhibiting the generation of the alternative pathway convertases competitively. boeravinone B 169-171 complement C3 Homo sapiens 65-68 77846-7 1978 The C3b site-bearing cell could bind beta1H on the C3c region of C3b molecules facilitating the C3bINA action on C3b, and beta1H shared the same binding site with B (or Bb) inhibiting the generation of the alternative pathway convertases competitively. boeravinone B 169-171 complement factor H Homo sapiens 122-128 33998227-1 2021 Here we report the highly enantio- and syn-selective synthesis of beta-hydroxy alpha-amino acids from glycine imine derivatives under Bronsted base (BB) catalysis. boeravinone B 149-151 synemin Homo sapiens 39-42 893680-6 1977 At a very high plasma HCO(3) (>50 meq/liter), BB rats raised urine pH, urine HCO(3) concentration, and U-B P(CO2) to the same levels seen in normals. boeravinone B 49-51 complement C2 Homo sapiens 110-115 34028176-9 2021 BB treatment significantly (P < .001) diminished the level of heart markers such as lactate dehydrogenase (LDH), troponin (TnT), creatine kinase (CK) and creatine kinase isoenzymes MB (CK-MB). boeravinone B 0-2 troponin T3, fast skeletal type Rattus norvegicus 123-126 33617395-4 2021 BB doses of 1-5 Gy were used to generate a calibration curve in order to estimate the biological MRT valley dose using the gammaH2AX assay. boeravinone B 0-2 H2A.X variant histone Mus musculus 123-132 33851450-10 2021 Nobiletin and UH did not show any effects, whereas low-dose BB treatment increased drebrin cluster densities. boeravinone B 60-62 drebrin 1 Rattus norvegicus 83-90 33512783-12 2021 The cells and the wound tissues treated with BB showed highest Nrf2 activation and HO-1 expression than PVP-I and CHG. BB was highly efficient in wound infection control while delayed wound healing. boeravinone B 45-47 NFE2 like bZIP transcription factor 2 Homo sapiens 63-67 33512783-12 2021 The cells and the wound tissues treated with BB showed highest Nrf2 activation and HO-1 expression than PVP-I and CHG. BB was highly efficient in wound infection control while delayed wound healing. boeravinone B 45-47 heme oxygenase 1 Homo sapiens 83-87 33512783-12 2021 The cells and the wound tissues treated with BB showed highest Nrf2 activation and HO-1 expression than PVP-I and CHG. BB was highly efficient in wound infection control while delayed wound healing. boeravinone B 119-121 NFE2 like bZIP transcription factor 2 Homo sapiens 63-67 33512783-12 2021 The cells and the wound tissues treated with BB showed highest Nrf2 activation and HO-1 expression than PVP-I and CHG. BB was highly efficient in wound infection control while delayed wound healing. boeravinone B 119-121 heme oxygenase 1 Homo sapiens 83-87 32146419-6 2020 Overexpressing KCNQ1OT1 suppressed PDFG-BB-induced VSMC proliferation, migration, and secretion of inflammatory factors. boeravinone B 40-42 KCNQ1 overlapping transcript 1 Mus musculus 15-23 32564499-5 2020 RESULTS: Perceived pain (NRS) was significantly reduced in BB intervention (5.6+-2.3 to 3.4+-2.6, p<0.001), compared to SS (5.2+-2.1 to 4.8+-2.3, p=0.78), during the first 30-minute phase, as well as at the week"s end (to 3.9+-2.5 compared to 5.5+-2.6 respectively, p<0.001). boeravinone B 59-61 sphingolipid transporter 1 (putative) Homo sapiens 25-28 32435796-4 2020 Sas4 is necessary for BB assembly and cortical microtubule organization, and Sas4 loss disrupts cell division furrow positioning and DNA segregation. boeravinone B 22-24 centromere protein J Homo sapiens 0-4 32368886-4 2020 A BB/PEG/ICG grafted poly(aspartic acid) comb-like functional polymer was firstly synthesized and conjugated with transferrin to form a transferrin-polymer-drug conjugate (Tf-P(BB)), which showed 120 % increase in HepG2 hepatoma (Tf receptor overexpression) cell uptake compared to non-targeting protein-polymer-drug conjugate (HRP-P(BB)). boeravinone B 2-4 transferrin Homo sapiens 114-125 32350068-7 2020 A second Tetrahymena POC5-like gene, SFR1, is similarly implicated in modulating BB production. boeravinone B 81-83 POC5 centriolar protein Homo sapiens 21-25 32368886-4 2020 A BB/PEG/ICG grafted poly(aspartic acid) comb-like functional polymer was firstly synthesized and conjugated with transferrin to form a transferrin-polymer-drug conjugate (Tf-P(BB)), which showed 120 % increase in HepG2 hepatoma (Tf receptor overexpression) cell uptake compared to non-targeting protein-polymer-drug conjugate (HRP-P(BB)). boeravinone B 2-4 transferrin Homo sapiens 136-147 32332827-8 2020 The rhythm of the visual stimulation elicited 10-Hz oscillations in occipital MEG sensors which were of similar magnitude for both BB frequencies. boeravinone B 131-133 protein tyrosine phosphatase non-receptor type 4 Homo sapiens 78-81 30501451-6 2020 RESULTS: There was a 2.6-fold increase in ATP13A4 expression (p < 0.001) in BB 44 from subjects with schizophrenia. boeravinone B 79-81 ATPase 13A4 Homo sapiens 42-49 31956959-2 2020 We also speculated that the baicalin-berberine (BB) combination produced vasorelaxant effects by activating the NO/cGMP pathway, and the BKCa channel and the DAG/PKC/CPI-17 pathway were involved. boeravinone B 48-50 potassium calcium-activated channel subfamily M alpha 1 Rattus norvegicus 137-141 32207314-3 2020 Silencing CEMIP suppressed PDGF-BB-induced cell migration and proliferation in VSMCs, as determined using a Cell Counting Kit-8 assays, 5-ethynyl-2"-deocyuridine (EDU) assays, flow cytometry, wound healing assays, and Transwell assays. boeravinone B 32-34 cell migration inducing hyaluronidase 1 Homo sapiens 10-15 31956959-2 2020 We also speculated that the baicalin-berberine (BB) combination produced vasorelaxant effects by activating the NO/cGMP pathway, and the BKCa channel and the DAG/PKC/CPI-17 pathway were involved. boeravinone B 48-50 protein phosphatase 1, regulatory (inhibitor) subunit 14A Rattus norvegicus 166-172 31028244-5 2019 Biophysical experiments confirmed that TIP1 specifically binds to the BB loop of the TLR4-TIR domain. boeravinone B 70-72 Tax1 (human T cell leukemia virus type I) binding protein 3 Mus musculus 39-43 31672639-11 2020 Rno-miR-27a and miR-25 were upregulated 7- to 8-fold in the rodents who underwent LCHS/CS+BB compared with LCHS/CS alone, and this correlated with reduced bone marrow expression of IL-1beta, tumor necrosis factor-alpha, IL-6, nitric oxide, and reduced plasma C-reactive protein in the LCHS/CS+BB group. boeravinone B 90-92 microRNA 27a Rattus norvegicus 0-11 31672639-11 2020 Rno-miR-27a and miR-25 were upregulated 7- to 8-fold in the rodents who underwent LCHS/CS+BB compared with LCHS/CS alone, and this correlated with reduced bone marrow expression of IL-1beta, tumor necrosis factor-alpha, IL-6, nitric oxide, and reduced plasma C-reactive protein in the LCHS/CS+BB group. boeravinone B 90-92 microRNA 25 Rattus norvegicus 16-22 31672639-11 2020 Rno-miR-27a and miR-25 were upregulated 7- to 8-fold in the rodents who underwent LCHS/CS+BB compared with LCHS/CS alone, and this correlated with reduced bone marrow expression of IL-1beta, tumor necrosis factor-alpha, IL-6, nitric oxide, and reduced plasma C-reactive protein in the LCHS/CS+BB group. boeravinone B 90-92 interleukin 1 alpha Rattus norvegicus 181-189 31672639-11 2020 Rno-miR-27a and miR-25 were upregulated 7- to 8-fold in the rodents who underwent LCHS/CS+BB compared with LCHS/CS alone, and this correlated with reduced bone marrow expression of IL-1beta, tumor necrosis factor-alpha, IL-6, nitric oxide, and reduced plasma C-reactive protein in the LCHS/CS+BB group. boeravinone B 90-92 tumor necrosis factor Rattus norvegicus 191-218 31672639-11 2020 Rno-miR-27a and miR-25 were upregulated 7- to 8-fold in the rodents who underwent LCHS/CS+BB compared with LCHS/CS alone, and this correlated with reduced bone marrow expression of IL-1beta, tumor necrosis factor-alpha, IL-6, nitric oxide, and reduced plasma C-reactive protein in the LCHS/CS+BB group. boeravinone B 90-92 interleukin 6 Rattus norvegicus 220-224 31672639-11 2020 Rno-miR-27a and miR-25 were upregulated 7- to 8-fold in the rodents who underwent LCHS/CS+BB compared with LCHS/CS alone, and this correlated with reduced bone marrow expression of IL-1beta, tumor necrosis factor-alpha, IL-6, nitric oxide, and reduced plasma C-reactive protein in the LCHS/CS+BB group. boeravinone B 90-92 C-reactive protein Rattus norvegicus 259-277 31672639-11 2020 Rno-miR-27a and miR-25 were upregulated 7- to 8-fold in the rodents who underwent LCHS/CS+BB compared with LCHS/CS alone, and this correlated with reduced bone marrow expression of IL-1beta, tumor necrosis factor-alpha, IL-6, nitric oxide, and reduced plasma C-reactive protein in the LCHS/CS+BB group. boeravinone B 293-295 microRNA 27a Rattus norvegicus 0-11 31672639-11 2020 Rno-miR-27a and miR-25 were upregulated 7- to 8-fold in the rodents who underwent LCHS/CS+BB compared with LCHS/CS alone, and this correlated with reduced bone marrow expression of IL-1beta, tumor necrosis factor-alpha, IL-6, nitric oxide, and reduced plasma C-reactive protein in the LCHS/CS+BB group. boeravinone B 293-295 microRNA 25 Rattus norvegicus 16-22 31672639-13 2020 The use of BB after severe trauma can help mitigate persistent inflammation by upregulating Rno-miR-27a and miR-25 and reducing inflammatory cytokines in those who remain critically ill. boeravinone B 11-13 microRNA 27a Rattus norvegicus 92-103 31672639-13 2020 The use of BB after severe trauma can help mitigate persistent inflammation by upregulating Rno-miR-27a and miR-25 and reducing inflammatory cytokines in those who remain critically ill. boeravinone B 11-13 microRNA 25 Rattus norvegicus 108-114 31478669-5 2019 Bovine serum albumin (BSA) adsorption on HA-BB coated surfaces was 0.2 ng/cm2, which was 60 times lower than BB or HA alone and 25 times lower than the commonly accepted ultralow adsorption limit (<5 ng/cm2), demonstrating the synergistic effect of HA and BB against nonspecific protein adsorption. boeravinone B 44-46 albumin Homo sapiens 7-20 30772901-8 2019 An in vitro study using the serum showed that BB supplementation attenuated lipopolysaccharide (LPS)-induced nitrite and tumor necrosis factor-alpha, and cognitive performance was associated with innate anti-inflammatory capability. boeravinone B 46-48 tumor necrosis factor Rattus norvegicus 121-148 31097020-11 2019 RESULTS: Both BB.z-NK and 2B4.z-NK exhibited specific cytotoxicity against CD5+ malignant cells in vitro and prolonged the survival of T-ALL xenograft mice. boeravinone B 14-16 CD5 antigen Mus musculus 75-78 30026131-18 2019 Similarly, MG lowered the expression of Baculoviral IAP repeat (Bir1) which is the inhibitor of apoptosis while CA and BB aided the over expression of Bir1. boeravinone B 119-121 survivin Saccharomyces cerevisiae S288C 151-155 31332999-7 2019 Patients with BB genotype had the lowest MBL level in serum compared to other genotypes with a very high significant difference (P=0.001). boeravinone B 14-16 mannose binding lectin 2 Homo sapiens 41-44 30430798-2 2018 OBJECTIVES: To determine short-term adherence of type 2 diabetes mellitus (T2DM) patients discharged from internal medicine wards with recommendation for BB insulin treatment. boeravinone B 154-156 insulin Homo sapiens 157-164 30270567-9 2019 The daily insulin dosage among GLP-1RA/insulin users was 30.3 IU/day (95% CI, -41.2 to -19.3; P < 0.001; I2 = 94%), lower than with BP/BB. boeravinone B 139-141 insulin Homo sapiens 10-17 30662661-7 2018 RESULTS: Exposure of HT-29 cells with Boeravinone B suppressed constitutive as well as ligand mediated phosphorylation of ErbB2, ErbB3 and EGFR. boeravinone B 38-51 erb-b2 receptor tyrosine kinase 2 Homo sapiens 122-127 30662661-7 2018 RESULTS: Exposure of HT-29 cells with Boeravinone B suppressed constitutive as well as ligand mediated phosphorylation of ErbB2, ErbB3 and EGFR. boeravinone B 38-51 erb-b2 receptor tyrosine kinase 3 Homo sapiens 129-134 30662661-7 2018 RESULTS: Exposure of HT-29 cells with Boeravinone B suppressed constitutive as well as ligand mediated phosphorylation of ErbB2, ErbB3 and EGFR. boeravinone B 38-51 epidermal growth factor receptor Homo sapiens 139-143 30662661-11 2018 Boeravinone B caused nuclear translocation of apoptosis-inducing factor (AIF) and caused proteolytic processing of PARP along with caspase-3, confirming Boeravinone B may induce caspase-independent apoptosis in HT-29 cells. boeravinone B 0-13 collagen type XI alpha 2 chain Homo sapiens 115-119 30662661-11 2018 Boeravinone B caused nuclear translocation of apoptosis-inducing factor (AIF) and caused proteolytic processing of PARP along with caspase-3, confirming Boeravinone B may induce caspase-independent apoptosis in HT-29 cells. boeravinone B 0-13 caspase 3 Homo sapiens 131-140 30662661-12 2018 CONCLUSION: The findings of present study provide first ever evidences for Boeravinone B suggesting anticancer activity via internalization and destruction of EGFR family receptors i.e. ErbB2 and EGFR in HT-29 cell lines. boeravinone B 75-88 epidermal growth factor receptor Homo sapiens 159-163 30662661-12 2018 CONCLUSION: The findings of present study provide first ever evidences for Boeravinone B suggesting anticancer activity via internalization and destruction of EGFR family receptors i.e. ErbB2 and EGFR in HT-29 cell lines. boeravinone B 75-88 erb-b2 receptor tyrosine kinase 2 Homo sapiens 186-191 30662661-12 2018 CONCLUSION: The findings of present study provide first ever evidences for Boeravinone B suggesting anticancer activity via internalization and destruction of EGFR family receptors i.e. ErbB2 and EGFR in HT-29 cell lines. boeravinone B 75-88 epidermal growth factor receptor Homo sapiens 196-200 30058766-6 2018 In Spanish individuals, VDR BsmI gene polymorphism was associated with CRF: Recessive model (BB vs. Bb + bb): OR = 1.60, 95% CI: 1.09-2.35, P = 0.016; Additive model (BB + bb vs. Bb): OR = 1.60, 95% CI: 1.21-2.12, P = 0.001). boeravinone B 93-95 vitamin D receptor Homo sapiens 24-27 30058766-6 2018 In Spanish individuals, VDR BsmI gene polymorphism was associated with CRF: Recessive model (BB vs. Bb + bb): OR = 1.60, 95% CI: 1.09-2.35, P = 0.016; Additive model (BB + bb vs. Bb): OR = 1.60, 95% CI: 1.21-2.12, P = 0.001). boeravinone B 100-102 vitamin D receptor Homo sapiens 24-27 30058766-6 2018 In Spanish individuals, VDR BsmI gene polymorphism was associated with CRF: Recessive model (BB vs. Bb + bb): OR = 1.60, 95% CI: 1.09-2.35, P = 0.016; Additive model (BB + bb vs. Bb): OR = 1.60, 95% CI: 1.21-2.12, P = 0.001). boeravinone B 105-107 vitamin D receptor Homo sapiens 24-27 30058766-6 2018 In Spanish individuals, VDR BsmI gene polymorphism was associated with CRF: Recessive model (BB vs. Bb + bb): OR = 1.60, 95% CI: 1.09-2.35, P = 0.016; Additive model (BB + bb vs. Bb): OR = 1.60, 95% CI: 1.21-2.12, P = 0.001). boeravinone B 167-169 vitamin D receptor Homo sapiens 24-27 30058766-6 2018 In Spanish individuals, VDR BsmI gene polymorphism was associated with CRF: Recessive model (BB vs. Bb + bb): OR = 1.60, 95% CI: 1.09-2.35, P = 0.016; Additive model (BB + bb vs. Bb): OR = 1.60, 95% CI: 1.21-2.12, P = 0.001). boeravinone B 172-174 vitamin D receptor Homo sapiens 24-27 30058766-6 2018 In Spanish individuals, VDR BsmI gene polymorphism was associated with CRF: Recessive model (BB vs. Bb + bb): OR = 1.60, 95% CI: 1.09-2.35, P = 0.016; Additive model (BB + bb vs. Bb): OR = 1.60, 95% CI: 1.21-2.12, P = 0.001). boeravinone B 179-181 vitamin D receptor Homo sapiens 24-27 30430798-11 2018 CONCLUSIONS: Short-term adherence with discharge recommendation for BB insulin treatment is associated with pre-hospitalization patient characteristics. boeravinone B 68-70 insulin Homo sapiens 71-78 30260972-10 2018 miR-146a-5p was elevated in the pancreas of diabetes-prone BB-DP rats at diabetes onset, suggesting that miR-146a-5p could play a role in type 1 diabetes development. boeravinone B 59-61 membrane associated ring-CH-type finger 8 Rattus norvegicus 0-3 30260972-10 2018 miR-146a-5p was elevated in the pancreas of diabetes-prone BB-DP rats at diabetes onset, suggesting that miR-146a-5p could play a role in type 1 diabetes development. boeravinone B 59-61 membrane associated ring-CH-type finger 8 Rattus norvegicus 105-108 30248148-10 2018 Starting BB early after HTx surgery might be beneficial. boeravinone B 9-11 Zic family member 3 Homo sapiens 24-27 29914886-4 2018 CPDP 9R34, which included AB loop, beta-strand B, and N-terminal BB loop residues, inhibited TLR9 signaling most potently. boeravinone B 65-67 toll-like receptor 9 Mus musculus 93-97 30248148-1 2018 OBJECTIVES: Heart transplant (HTx) recipients have a high heart rate (HR), because of graft denervation and are frequently started on beta-blockade (BB). boeravinone B 149-151 Zic family member 3 Homo sapiens 30-33 30248148-5 2018 RESULTS: In adjusted analyses, HF1, HF2 and CKD273 (p <= 0.024) were higher in BB users than non-users with a similar trend for ACSP75 (p = 0.06). boeravinone B 82-84 complement factor H Homo sapiens 31-34 30248148-5 2018 RESULTS: In adjusted analyses, HF1, HF2 and CKD273 (p <= 0.024) were higher in BB users than non-users with a similar trend for ACSP75 (p = 0.06). boeravinone B 82-84 complement factor H Homo sapiens 36-39 30248148-6 2018 Patients started on BB within 1 year after HTx and non-users had similar HF1 and HF2 levels (p >= 0.098), whereas starting BB later was associated with higher HF1 and HF2 compared with non-users (p <= 0.014). boeravinone B 20-22 Zic family member 3 Homo sapiens 43-46 30248148-6 2018 Patients started on BB within 1 year after HTx and non-users had similar HF1 and HF2 levels (p >= 0.098), whereas starting BB later was associated with higher HF1 and HF2 compared with non-users (p <= 0.014). boeravinone B 20-22 complement factor H Homo sapiens 73-76 30248148-6 2018 Patients started on BB within 1 year after HTx and non-users had similar HF1 and HF2 levels (p >= 0.098), whereas starting BB later was associated with higher HF1 and HF2 compared with non-users (p <= 0.014). boeravinone B 20-22 complement factor H Homo sapiens 81-84 30248148-6 2018 Patients started on BB within 1 year after HTx and non-users had similar HF1 and HF2 levels (p >= 0.098), whereas starting BB later was associated with higher HF1 and HF2 compared with non-users (p <= 0.014). boeravinone B 126-128 complement factor H Homo sapiens 162-165 30248148-6 2018 Patients started on BB within 1 year after HTx and non-users had similar HF1 and HF2 levels (p >= 0.098), whereas starting BB later was associated with higher HF1 and HF2 compared with non-users (p <= 0.014). boeravinone B 126-128 complement factor H Homo sapiens 170-173 29956736-10 2018 DCA at 10 mM promoted apoptosis and the upregulation of activated caspase-3 in PASMCs pre-treated with 20 ng/ml PDGF-homeodimer BB (BB). boeravinone B 128-130 caspase 3 Homo sapiens 66-75 29956736-10 2018 DCA at 10 mM promoted apoptosis and the upregulation of activated caspase-3 in PASMCs pre-treated with 20 ng/ml PDGF-homeodimer BB (BB). boeravinone B 132-134 caspase 3 Homo sapiens 66-75 29555202-10 2018 Logistic regression analysis revealed that BB + Bb genotypes of the VDR BsmI had significantly increased the odds ratio (OR) of hypertriglyceridemia when compared with the bb genotype (OR 1.87; 95% CI 1.10-3.19, p = 0.022). boeravinone B 43-45 vitamin D receptor Homo sapiens 68-71 29975683-2 2018 RNA-binding protein of multiple splice forms 2, or Rbpms2, interacts with molecules that are essential to reproduction and egg patterning, including bucky ball, a key factor for Bb formation. boeravinone B 178-180 RNA binding protein, mRNA processing factor 2b Danio rerio 51-57 29791873-3 2018 PDGF-BB treatment induced the activation of RhoA, ROCK, PDGF-Rbeta, and the expression of PDGF-Rbeta in HA-VSMCs (human aortic vascular smooth muscle cells). boeravinone B 5-7 ras homolog family member A Homo sapiens 44-48 29791873-3 2018 PDGF-BB treatment induced the activation of RhoA, ROCK, PDGF-Rbeta, and the expression of PDGF-Rbeta in HA-VSMCs (human aortic vascular smooth muscle cells). boeravinone B 5-7 platelet derived growth factor receptor beta Homo sapiens 56-66 29791873-3 2018 PDGF-BB treatment induced the activation of RhoA, ROCK, PDGF-Rbeta, and the expression of PDGF-Rbeta in HA-VSMCs (human aortic vascular smooth muscle cells). boeravinone B 5-7 platelet derived growth factor receptor beta Homo sapiens 90-100 29555202-10 2018 Logistic regression analysis revealed that BB + Bb genotypes of the VDR BsmI had significantly increased the odds ratio (OR) of hypertriglyceridemia when compared with the bb genotype (OR 1.87; 95% CI 1.10-3.19, p = 0.022). boeravinone B 48-50 vitamin D receptor Homo sapiens 68-71 29682419-5 2018 Results: NOS2KO exhibit exacerbated BB, starting four weeks of age, and increased repetitive movements compared to wild-type mice (WT). boeravinone B 36-38 nitric oxide synthase 2, inducible Mus musculus 9-13 29682419-6 2018 The expression of BB was attenuated by repeated treatment with clomipramine, a clinically approved drug to treat TTM in humans, or memantine, an antagonist of NMDA receptors, as well as partial rescue of NOS2 expression in haploinsufficient animals. boeravinone B 18-20 nitric oxide synthase 2 Homo sapiens 204-208 29415666-8 2018 This was consistent with the observed higher levels of median parathyroid hormone, fibroblast growth factor 23 and mean phosphate in patients with Bb genotype. boeravinone B 147-149 fibroblast growth factor 23 Homo sapiens 83-110 28942315-8 2018 The chemically produced HO2 was largely converted to OH by the reactions with NO (HO2+NO=OH+NO2) from BB emissions. boeravinone B 102-104 heme oxygenase 2 Homo sapiens 24-27 28942315-8 2018 The chemically produced HO2 was largely converted to OH by the reactions with NO (HO2+NO=OH+NO2) from BB emissions. boeravinone B 102-104 heme oxygenase 2 Homo sapiens 82-85 28766166-8 2018 miR-363 mimic downregulated the levels of p-PI3K/Akt, miR-363 inhibitor upregulated the levels of p-PI3K/Akt, and miR-363 mimic and PI3K/Akt pathway inhibitor LY294002 reversed the positive effect of rhPDGF-BB on the proliferation of hADSCs, which suggested that rhPDGF-BB promoted the proliferation of hADSCs via miR-363/PI3K/Akt pathway. boeravinone B 207-209 microRNA 363 Homo sapiens 0-7 29079655-2 2018 We aimed to improve this killing by substituting the CD28 costimulatory endodomain (28.z) with 4-1BB (BB.z), as 28.z CD5 CAR T cells rapidly differentiated into short-lived effector cells. boeravinone B 98-100 CD5 molecule Homo sapiens 117-120 29079655-4 2018 Here, we found BB.z CD5 CAR T cells had impaired growth compared with 28.z CD5.CAR T cells, due to increased T-cell-T-cell fratricide. boeravinone B 15-17 CD5 molecule Homo sapiens 20-23 29403548-4 2018 In addition, miR-31 proliferation was detected by Cell Counting Kit-8 and EdU assays; proliferation was significantly promoted in platelet-derived growth factor (PDGF)-BB-induced human ASMCs (HASMCs) (P<0.001). boeravinone B 168-170 microRNA 31 Homo sapiens 13-19 29174517-7 2018 Positive associations were also observed for C3a (beta=0.64 [0.31; 0.97]), FD (beta=1.00 [0.59; 1.42]), FH (beta=1.17 [0.82; 1.53]), and properdin (beta=0.60 [0.28; 0.92]), but not for Bb, C5a or sC5b-9. boeravinone B 185-187 complement C3 Homo sapiens 45-48 29174517-7 2018 Positive associations were also observed for C3a (beta=0.64 [0.31; 0.97]), FD (beta=1.00 [0.59; 1.42]), FH (beta=1.17 [0.82; 1.53]), and properdin (beta=0.60 [0.28; 0.92]), but not for Bb, C5a or sC5b-9. boeravinone B 185-187 complement factor H Homo sapiens 104-106 28766166-8 2018 miR-363 mimic downregulated the levels of p-PI3K/Akt, miR-363 inhibitor upregulated the levels of p-PI3K/Akt, and miR-363 mimic and PI3K/Akt pathway inhibitor LY294002 reversed the positive effect of rhPDGF-BB on the proliferation of hADSCs, which suggested that rhPDGF-BB promoted the proliferation of hADSCs via miR-363/PI3K/Akt pathway. boeravinone B 207-209 AKT serine/threonine kinase 1 Homo sapiens 49-52 28766166-8 2018 miR-363 mimic downregulated the levels of p-PI3K/Akt, miR-363 inhibitor upregulated the levels of p-PI3K/Akt, and miR-363 mimic and PI3K/Akt pathway inhibitor LY294002 reversed the positive effect of rhPDGF-BB on the proliferation of hADSCs, which suggested that rhPDGF-BB promoted the proliferation of hADSCs via miR-363/PI3K/Akt pathway. boeravinone B 207-209 microRNA 363 Homo sapiens 54-61 28766166-8 2018 miR-363 mimic downregulated the levels of p-PI3K/Akt, miR-363 inhibitor upregulated the levels of p-PI3K/Akt, and miR-363 mimic and PI3K/Akt pathway inhibitor LY294002 reversed the positive effect of rhPDGF-BB on the proliferation of hADSCs, which suggested that rhPDGF-BB promoted the proliferation of hADSCs via miR-363/PI3K/Akt pathway. boeravinone B 207-209 microRNA 363 Homo sapiens 54-61 28766166-8 2018 miR-363 mimic downregulated the levels of p-PI3K/Akt, miR-363 inhibitor upregulated the levels of p-PI3K/Akt, and miR-363 mimic and PI3K/Akt pathway inhibitor LY294002 reversed the positive effect of rhPDGF-BB on the proliferation of hADSCs, which suggested that rhPDGF-BB promoted the proliferation of hADSCs via miR-363/PI3K/Akt pathway. boeravinone B 207-209 microRNA 363 Homo sapiens 54-61 29046665-0 2017 Boeravinone B, A Novel Dual Inhibitor of NorA Bacterial Efflux Pump of Staphylococcus aureus and Human P-Glycoprotein, Reduces the Biofilm Formation and Intracellular Invasion of Bacteria. boeravinone B 0-13 ATP binding cassette subfamily B member 1 Homo sapiens 103-117 28392355-7 2017 VDR genotyping yielded: FokI: 57.1% FF and 38.9% Ff, BsmI: 29.8% bb and 51.5% Bb, while TaqI showed 39.4% TT and 43.4% Tt. boeravinone B 65-67 vitamin D receptor Homo sapiens 0-3 28392355-7 2017 VDR genotyping yielded: FokI: 57.1% FF and 38.9% Ff, BsmI: 29.8% bb and 51.5% Bb, while TaqI showed 39.4% TT and 43.4% Tt. boeravinone B 78-80 vitamin D receptor Homo sapiens 0-3 29123515-10 2017 Directly upon the 6-day OT phase, FF/Bb intervention enhanced cecal content levels of propionic and butyric acid in PepMix-fed mice and the former was positively correlated with Foxp3+ cell numbers in the colon. boeravinone B 37-39 forkhead box P3 Mus musculus 178-183 29123515-11 2017 In the PP of PepMix+FF/Bb-exposed mice, IL-22 mRNA expression increased and IL-10 followed the same tendency, while the Foxp3 expression was increased over GATA3 and RorgammaT. boeravinone B 23-25 interleukin 22 Mus musculus 40-45 29123515-11 2017 In the PP of PepMix+FF/Bb-exposed mice, IL-22 mRNA expression increased and IL-10 followed the same tendency, while the Foxp3 expression was increased over GATA3 and RorgammaT. boeravinone B 23-25 interleukin 10 Mus musculus 76-81 29123515-11 2017 In the PP of PepMix+FF/Bb-exposed mice, IL-22 mRNA expression increased and IL-10 followed the same tendency, while the Foxp3 expression was increased over GATA3 and RorgammaT. boeravinone B 23-25 forkhead box P3 Mus musculus 120-125 29123515-11 2017 In the PP of PepMix+FF/Bb-exposed mice, IL-22 mRNA expression increased and IL-10 followed the same tendency, while the Foxp3 expression was increased over GATA3 and RorgammaT. boeravinone B 23-25 GATA binding protein 3 Mus musculus 156-161 29046665-11 2017 Boeravinone B effectively inhibited P-gp with half maximal inhibitory concentration (IC50) of 64.85 muM. boeravinone B 0-13 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 28438710-9 2017 Thus, more accurate local SAR supervision schemes are required which could lead to a further improvement of BB DANTE vessel wall imaging at 7T. boeravinone B 108-110 sarcosine dehydrogenase Homo sapiens 26-29 28880872-11 2017 We thus tested if Macf1a functions via its actin binding domain (ABD) and plectin repeat domain (PRD) to integrate cortical actin and Bb CK, respectively, to mediate Bb dissociation at the oocyte cortex. boeravinone B 134-136 microtubule actin crosslinking factor 1a Danio rerio 18-24 28880872-13 2017 Our analysis shows that Macf1a functions via its ABD to mediate Bb granule dissociation and nuclear positioning, while the PRD is dispensable. boeravinone B 64-66 microtubule actin crosslinking factor 1a Danio rerio 24-30 28880872-14 2017 We propose that Macf1a does not function via its canonical mechanism of linking two cytoskeletal systems together in dissociating the Bb. boeravinone B 134-136 microtubule actin crosslinking factor 1a Danio rerio 16-22 28739909-0 2017 Solution structure of the TLR adaptor MAL/TIRAP reveals an intact BB loop and supports MAL Cys91 glutathionylation for signaling. boeravinone B 66-68 mal, T cell differentiation protein Homo sapiens 38-41 28739909-0 2017 Solution structure of the TLR adaptor MAL/TIRAP reveals an intact BB loop and supports MAL Cys91 glutathionylation for signaling. boeravinone B 66-68 TIR domain containing adaptor protein Homo sapiens 42-47 28605596-5 2017 Finally, detailed time-resolved spectral analysis of P, carotenoid, and BB (Phi in the M182HL mutant) reveals that the triplet state of the carotenoid is coupled fairly strongly to the bridging intermediate BB in wild-type and Phi in the M182HL mutant, a fact that is probably responsible for the lack of any obvious intermediate 3BB/3Phi transient formation during triplet energy transfer. boeravinone B 72-74 glucose-6-phosphate isomerase Homo sapiens 76-79 27669189-12 2017 However, the DBP elicited significantly greater BB activity vs. the SMBP and BBP, respectively. boeravinone B 48-50 D-box binding PAR bZIP transcription factor Homo sapiens 13-16 28495789-7 2017 GF/Bb reduced allergic symptoms and enhanced serum galectin-9 levels, while suppressing activation, restoring phagocytic capacity, and normalizing CD103 expression of SI-LP DCs of OVA-allergic mice. boeravinone B 3-5 lectin, galactose binding, soluble 9 Mus musculus 51-61 28495789-7 2017 GF/Bb reduced allergic symptoms and enhanced serum galectin-9 levels, while suppressing activation, restoring phagocytic capacity, and normalizing CD103 expression of SI-LP DCs of OVA-allergic mice. boeravinone B 3-5 integrin alpha E, epithelial-associated Mus musculus 147-152 28445285-6 2017 RESULTS: A significant difference was observed between VDR BsmI polymorphism and pediatric BMD levels of the lumbar spine (LS) in the corecessive model (bb vs BB + Bb: WMD = -0.23, 95% CI [-0.35, -0.11], P < 0.01). boeravinone B 153-155 vitamin D receptor Homo sapiens 55-58 28495789-10 2017 Dietary intervention with GF/Bb enhances galectin-9 and suppresses allergic symptoms of OVA-allergic mice in association with reduced intestinal DC and Th2 activation and increased Treg frequency in these mice. boeravinone B 29-31 lectin, galactose binding, soluble 9 Mus musculus 41-51 28662037-8 2017 Intracoronary Bb increased immediately after AXCL, and the levels were directly correlated with peripheral blood levels of cardiac troponin I, an established biomarker of myocardial necrosis (Spearman coefficient = 0.465, P < 0.01). boeravinone B 14-16 troponin I, cardiac 3 Mus musculus 123-141 27879961-3 2017 beta1-adrenoceptor blockers (beta-blockers, BB) reduced mortality in left heart failure, but they do not explored much at clinical level. boeravinone B 44-46 adrenoceptor beta 1 Homo sapiens 0-18 28445285-6 2017 RESULTS: A significant difference was observed between VDR BsmI polymorphism and pediatric BMD levels of the lumbar spine (LS) in the corecessive model (bb vs BB + Bb: WMD = -0.23, 95% CI [-0.35, -0.11], P < 0.01). boeravinone B 159-161 vitamin D receptor Homo sapiens 55-58 28445285-6 2017 RESULTS: A significant difference was observed between VDR BsmI polymorphism and pediatric BMD levels of the lumbar spine (LS) in the corecessive model (bb vs BB + Bb: WMD = -0.23, 95% CI [-0.35, -0.11], P < 0.01). boeravinone B 164-166 vitamin D receptor Homo sapiens 55-58 27867273-0 2016 Soyasaponin Bb Protects Rat Hepatocytes from Alcohol-Induced Oxidative Stress by Inducing Heme Oxygenase-1. boeravinone B 12-14 heme oxygenase 1 Rattus norvegicus 90-106 28333970-15 2017 Moreover, BB treatment not only displayed the activation Akt in liver tissue and skeletal muscle, but also in C2C12 myotube to cause an increase in phosphorylation of Akt in the absence of insulin. boeravinone B 10-12 thymoma viral proto-oncogene 1 Mus musculus 167-170 28333970-16 2017 These results demonstrated that BB act as an activator of AMPK and /or regulation of insulin pathway (Akt), and the antioxidant activity within the pancreas. boeravinone B 32-34 thymoma viral proto-oncogene 1 Mus musculus 102-105 28099381-12 2017 LCHS/CS + BB significantly reduced plasma EPO levels and increased plasma hepcidin levels on day 7. boeravinone B 10-12 erythropoietin Homo sapiens 42-45 28099381-12 2017 LCHS/CS + BB significantly reduced plasma EPO levels and increased plasma hepcidin levels on day 7. boeravinone B 10-12 hepcidin antimicrobial peptide Homo sapiens 74-82 28333970-4 2017 Treatment with BB led to reduced levels of blood glucose, HbA1C, triglycerides and leptin and to increased levels of insulin and adiponectin compared with the vehicle-treated STZ group. boeravinone B 15-17 adiponectin, C1Q and collagen domain containing Mus musculus 129-140 28333970-7 2017 The membrane levels of skeletal muscular glucose transporter 4 (GLUT4) were significantly higher in BB-treated mice. boeravinone B 100-102 solute carrier family 2 (facilitated glucose transporter), member 4 Mus musculus 64-69 28333970-10 2017 BB-treated mice increased expression of fatty acid oxidation enzymes, including peroxisome proliferator-activated receptor alpha (PPARalpha) and mRNA levels of carnitine palmitoyl transferase Ia (CPT1a). boeravinone B 0-2 peroxisome proliferator activated receptor alpha Mus musculus 80-128 28333970-10 2017 BB-treated mice increased expression of fatty acid oxidation enzymes, including peroxisome proliferator-activated receptor alpha (PPARalpha) and mRNA levels of carnitine palmitoyl transferase Ia (CPT1a). boeravinone B 0-2 peroxisome proliferator activated receptor alpha Mus musculus 130-139 28333970-10 2017 BB-treated mice increased expression of fatty acid oxidation enzymes, including peroxisome proliferator-activated receptor alpha (PPARalpha) and mRNA levels of carnitine palmitoyl transferase Ia (CPT1a). boeravinone B 0-2 carnitine palmitoyltransferase 1a, liver Mus musculus 196-201 28333970-13 2017 BB-treated mice also expressed lower levels of PPARgamma and FAS protein. boeravinone B 0-2 peroxisome proliferator activated receptor gamma Mus musculus 47-56 28333970-13 2017 BB-treated mice also expressed lower levels of PPARgamma and FAS protein. boeravinone B 0-2 fatty acid synthase Mus musculus 61-64 28333970-15 2017 Moreover, BB treatment not only displayed the activation Akt in liver tissue and skeletal muscle, but also in C2C12 myotube to cause an increase in phosphorylation of Akt in the absence of insulin. boeravinone B 10-12 thymoma viral proto-oncogene 1 Mus musculus 57-60 28167503-3 2017 In the case of BB, cleavage leads to destabilization by the RING E3 ligase PROTEOLYSIS 1 (PRT1) of the N-end rule pathway. boeravinone B 15-17 proteolysis 1 Arabidopsis thaliana 75-88 28167503-3 2017 In the case of BB, cleavage leads to destabilization by the RING E3 ligase PROTEOLYSIS 1 (PRT1) of the N-end rule pathway. boeravinone B 15-17 proteolysis 1 Arabidopsis thaliana 90-94 28035919-13 2017 CONCLUSIONS: BB treatment was beneficial for the improvement of learning and memory of AD, and these effects might be related to the regulation of BDNF. boeravinone B 13-15 brain derived neurotrophic factor Mus musculus 147-151 27867273-9 2016 SUMMARY: Effects of soyasaponin Bb was investigated on oxidative stress in rat hepatocytesCell viability and antioxidant capacities were evaluated to determine the effectsThe expression level of HO-1 was measured to reveal the proptective mechanisms. boeravinone B 32-34 heme oxygenase 1 Rattus norvegicus 195-199 27573463-7 2016 The BB alignment was disrupted by disturbing apical microtubules with nocodazole and by a BF-depleting Odf2 mutation. boeravinone B 4-6 outer dense fiber of sperm tails 2 Mus musculus 103-107 27005845-0 2016 Soyasaponin Bb inhibits the recruitment of toll-like receptor 4 (TLR4) into lipid rafts and its signaling pathway by suppressing the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-dependent generation of reactive oxygen species. boeravinone B 12-14 toll like receptor 4 Homo sapiens 43-63 27125758-10 2016 Among individuals with bb, the INSUF/DEF group showed higher levels of triglycerides and VLDL cholesterol. boeravinone B 23-25 UTP25 small subunit processome component Homo sapiens 37-40 27347121-11 2016 Since the inhibition of the Akt signaling pathway markedly reduced PDGF-BB-induced migration in AsPC-1 cells, the present results strongly suggest that arsenite inhibits PDGF-BB-induced migration by suppressing the Akt signaling pathway in AsPC-1 cells. boeravinone B 72-74 AKT serine/threonine kinase 1 Homo sapiens 28-31 27005845-0 2016 Soyasaponin Bb inhibits the recruitment of toll-like receptor 4 (TLR4) into lipid rafts and its signaling pathway by suppressing the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-dependent generation of reactive oxygen species. boeravinone B 12-14 toll like receptor 4 Homo sapiens 65-69 26809149-6 2016 PATIENT SAMPLE: We assessed 243 patients treated with either Bb or SC brace to prevent the progression of AIS. boeravinone B 61-63 IS1 Homo sapiens 106-109 27146198-9 2016 We found that imidazole and pyrimidine rings of 6-ClG undergo expansion and contraction, respectively, following photoexcitation to the Bb state. boeravinone B 136-138 pleckstrin homology and RhoGEF domain containing G2 Homo sapiens 50-53 26472014-5 2016 Frequency of BB genotype that possess 2-6 activating KIR genes was predominant in cases compared to controls (OR=2.55, p=<0.001). boeravinone B 13-15 killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4 Homo sapiens 53-56 26003185-9 2016 The diet containing FFBB reduced IL-6, IFN-gamma, IL-4 and IL-10 concentrations, whereas the combination of galacto-oligosaccharides and long-chain fructo-oligosaccharides with BB was less potent in this model. boeravinone B 22-24 interleukin 10 Mus musculus 59-64 27909504-4 2016 We analyzed our seven year follow-up of patients, treated for PAF with first (CB1) and second generation (CB2), with demonstration of LA-PV disconnection with bidirectional block (BB) after adenosine (AD). boeravinone B 180-182 cannabinoid receptor 2 Homo sapiens 106-109 27068453-3 2016 On day 15, the release of osteocalcin, was significant in the TCP-Fu-Ch scaffold, when compared with that in the TCP-Ch scaffold, and the level of release was approximately 8 and 6 ng/ml in osteogenic and normal media supplemented with PDGF-BB, respectively. boeravinone B 241-243 bone gamma-carboxyglutamate protein Homo sapiens 26-37 26826772-1 2016 INTRODUCTION: The aim of this review was to assess the effectiveness to reduce clinical adverse events and safety of insulin administered in basal-bolus-corrector or basal-corrector regimens (BB) versus a sliding scale scheme (SS) in patients with diabetes or newly diagnosed hyperglycemia admitted to a conventional (not critical) medical or surgical hospital ward. boeravinone B 192-194 insulin Homo sapiens 117-124 26647836-6 2016 These results suggested that hesperetin may inhibit PDGFa-BB-induced PASMC proliferation via the AKT/GSK3beta signaling pathway, and that it may possess therapeutic potential for the treatment of pulmonary vascular remodeling diseases. boeravinone B 58-60 platelet derived growth factor subunit A Homo sapiens 52-57 25410165-11 2016 Infiltration of polymorphonuclear cells, increased myeloperoxidase activity and increased expression of iNOS was observed in the fundic mucosa and muscularis propria of 70-day-old and 220-day-old BB-DP rats. boeravinone B 196-198 nitric oxide synthase 2 Rattus norvegicus 104-108 26647836-6 2016 These results suggested that hesperetin may inhibit PDGFa-BB-induced PASMC proliferation via the AKT/GSK3beta signaling pathway, and that it may possess therapeutic potential for the treatment of pulmonary vascular remodeling diseases. boeravinone B 58-60 AKT serine/threonine kinase 1 Homo sapiens 97-100 26647836-6 2016 These results suggested that hesperetin may inhibit PDGFa-BB-induced PASMC proliferation via the AKT/GSK3beta signaling pathway, and that it may possess therapeutic potential for the treatment of pulmonary vascular remodeling diseases. boeravinone B 58-60 glycogen synthase kinase 3 beta Homo sapiens 101-109 26839610-6 2015 In addition, the RPE-overall showed a significant (p<0.05) relationship with %EMG BB (r=0.55) and %EMG BF (r=0.50). boeravinone B 85-87 ribulose-5-phosphate-3-epimerase Homo sapiens 17-20 26492243-6 2015 Moreover, visceral fat weights were enhanced in HFD-fed mice, accompanied by increased blood leptin concentrations and decreased adiponectin levels, which were reversed by treatment with BB. boeravinone B 187-189 adiponectin, C1Q and collagen domain containing Mus musculus 129-140 26427796-5 2015 The degree of platelet-derived growth factor-BB-induced increase in intracellular Ca(2+) was smaller in Fura2-labeled Epac1(-/-)-ASMCs than in Epac1(+/+)-ASMCs. boeravinone B 45-47 Rap guanine nucleotide exchange factor (GEF) 3 Mus musculus 118-123 26427796-5 2015 The degree of platelet-derived growth factor-BB-induced increase in intracellular Ca(2+) was smaller in Fura2-labeled Epac1(-/-)-ASMCs than in Epac1(+/+)-ASMCs. boeravinone B 45-47 Rap guanine nucleotide exchange factor (GEF) 3 Mus musculus 143-148 26165414-7 2015 The BB genotype of the VDR polymorphism, BsmI, was associated with a greater decrease in FCA than the Bb/bb genotype. boeravinone B 102-104 vitamin D receptor Homo sapiens 23-26 26165414-7 2015 The BB genotype of the VDR polymorphism, BsmI, was associated with a greater decrease in FCA than the Bb/bb genotype. boeravinone B 105-107 vitamin D receptor Homo sapiens 23-26 26492243-7 2015 Muscular membrane protein levels of glucose transporter 4 (GLUT4) were reduced in HFD-fed mice and significantly enhanced upon administration of BB, Rosi, and Feno. boeravinone B 145-147 solute carrier family 2 (facilitated glucose transporter), member 4 Mus musculus 36-57 26492243-7 2015 Muscular membrane protein levels of glucose transporter 4 (GLUT4) were reduced in HFD-fed mice and significantly enhanced upon administration of BB, Rosi, and Feno. boeravinone B 145-147 solute carrier family 2 (facilitated glucose transporter), member 4 Mus musculus 59-64 26492243-9 2015 BB also decreased hepatic mRNA levels of phosphenolpyruvate carboxykinase (PEPCK), which are associated with a decrease in hepatic glucose production. boeravinone B 0-2 phosphoenolpyruvate carboxykinase 1, cytosolic Mus musculus 41-73 26492243-9 2015 BB also decreased hepatic mRNA levels of phosphenolpyruvate carboxykinase (PEPCK), which are associated with a decrease in hepatic glucose production. boeravinone B 0-2 phosphoenolpyruvate carboxykinase 1, cytosolic Mus musculus 75-80 26492243-10 2015 BB-exerted hypotriglyceridemic activity may be partly associated with increased mRNA levels of peroxisome proliferator activated receptor alpha (PPARalpha), and with reduced hepatic glycerol-3-phosphate acyltransferase (GPAT) mRNA levels in the liver, which decreased triacylglycerol synthesis. boeravinone B 0-2 peroxisome proliferator activated receptor alpha Mus musculus 95-143 26492243-10 2015 BB-exerted hypotriglyceridemic activity may be partly associated with increased mRNA levels of peroxisome proliferator activated receptor alpha (PPARalpha), and with reduced hepatic glycerol-3-phosphate acyltransferase (GPAT) mRNA levels in the liver, which decreased triacylglycerol synthesis. boeravinone B 0-2 peroxisome proliferator activated receptor alpha Mus musculus 145-154 26492243-10 2015 BB-exerted hypotriglyceridemic activity may be partly associated with increased mRNA levels of peroxisome proliferator activated receptor alpha (PPARalpha), and with reduced hepatic glycerol-3-phosphate acyltransferase (GPAT) mRNA levels in the liver, which decreased triacylglycerol synthesis. boeravinone B 0-2 glycerol-3-phosphate acyltransferase, mitochondrial Mus musculus 182-218 26492243-10 2015 BB-exerted hypotriglyceridemic activity may be partly associated with increased mRNA levels of peroxisome proliferator activated receptor alpha (PPARalpha), and with reduced hepatic glycerol-3-phosphate acyltransferase (GPAT) mRNA levels in the liver, which decreased triacylglycerol synthesis. boeravinone B 0-2 glycerol-3-phosphate acyltransferase, mitochondrial Mus musculus 220-224 26291555-4 2015 METHODS AND RESULTS: We showed that the expression and activity of glucose-6-phosphate dehydrogenase (G6PD) are promoted in platelet-derived growth factor (PDGF)-BB-induced proliferative VSMCs. boeravinone B 162-164 glucose-6-phosphate dehydrogenase Homo sapiens 67-100 26291555-4 2015 METHODS AND RESULTS: We showed that the expression and activity of glucose-6-phosphate dehydrogenase (G6PD) are promoted in platelet-derived growth factor (PDGF)-BB-induced proliferative VSMCs. boeravinone B 162-164 glucose-6-phosphate dehydrogenase Homo sapiens 102-106 25440369-11 2014 Microvessels stained by CD31 and macrophages stained by CD68 were more frequently observed in the high-BB-SIR plaques. boeravinone B 103-105 platelet and endothelial cell adhesion molecule 1 Homo sapiens 24-28 25870276-5 2015 Examination of the human TLR2 TIR domain crystal structure revealed a pocket adjacent to the highly conserved P681 and G682 BB loop residues. boeravinone B 124-126 toll like receptor 2 Homo sapiens 25-29 25870276-14 2015 Our data provide proof of principle that targeting the BB loop pocket is an effective approach for identification of TLR2 signaling inhibitors. boeravinone B 55-57 toll like receptor 2 Homo sapiens 117-121 25948249-8 2015 The BB mutation-induced attenuation of BMPR1B signaling led to an increased density of the FSHR and LHR and a concurrent reduction in apoptosis to increase the ovulation rate. boeravinone B 4-6 bone morphogenetic protein receptor type-1B Ovis aries 39-45 25948249-8 2015 The BB mutation-induced attenuation of BMPR1B signaling led to an increased density of the FSHR and LHR and a concurrent reduction in apoptosis to increase the ovulation rate. boeravinone B 4-6 follicle-stimulating hormone receptor Ovis aries 91-95 25948249-8 2015 The BB mutation-induced attenuation of BMPR1B signaling led to an increased density of the FSHR and LHR and a concurrent reduction in apoptosis to increase the ovulation rate. boeravinone B 4-6 lutropin-choriogonadotropic hormone receptor Ovis aries 100-103 25948473-3 2015 Here, we identify three amino acid residues (714P in the BB loop, 696L in the alphaA helix and 721N in the alphaB sheet) conserved in all MyD88-recruited TLRs, but not the TLR3 TIR domain, as being critical for TLR4 responsiveness to LPS. boeravinone B 57-59 MYD88 innate immune signal transduction adaptor Homo sapiens 138-143 25948473-3 2015 Here, we identify three amino acid residues (714P in the BB loop, 696L in the alphaA helix and 721N in the alphaB sheet) conserved in all MyD88-recruited TLRs, but not the TLR3 TIR domain, as being critical for TLR4 responsiveness to LPS. boeravinone B 57-59 toll like receptor 4 Homo sapiens 211-215 29296411-9 2015 The locations of the BB markers were visualized and analyzed with respect to the MLC aperture in the treatment plan similar to the Winston-Lutz (WL) test. boeravinone B 21-23 modulator of VRAC current 1 Homo sapiens 81-84 25440369-11 2014 Microvessels stained by CD31 and macrophages stained by CD68 were more frequently observed in the high-BB-SIR plaques. boeravinone B 103-105 CD68 molecule Homo sapiens 56-60 24819208-7 2014 The AB/BB genotype (53.3%) in the MBL-2 gene was found to be significantly higher in the AL patients compared with control groups. boeravinone B 7-9 mannose binding lectin 2 Homo sapiens 34-39 24782549-11 2014 RESULTS: Functional anatomical VD was higher in bidirectional breathing (BB) (overall: 207.4 +- 7.9 mL; MMB: 232.5 +- 72.7 mL; NNB: 182.2 +- 75 mL) compared to UB (overall: 178.1 +- 87.2 mL; NMB: 176.9 +- 91.3 mL; MNB: 179.3 +- 83.2 mL) (P < .001). boeravinone B 73-75 neuromedin B Homo sapiens 191-194 24311451-3 2014 RESULTS: Although body weight was reduced similarly in both groups, the BB group showed greater HbA1c and systolic blood pressure reductions (HbA1c: -4.62% vs. -1.46%, p = 0.047; SBP -9.58 vs. -2.43 mmHg; p = 0.04). boeravinone B 72-74 selenium binding protein 1 Homo sapiens 179-182 24197068-0 2014 Src tyrosine kinase mediates platelet-derived growth factor BB-induced and redox-dependent migration in metanephric mesenchymal cells. boeravinone B 60-62 Rous sarcoma oncogene Mus musculus 0-3 24356965-10 2014 We used molecular docking to propose how A46 interacts with the BB loop of the TRAM TIR domain. boeravinone B 64-66 TIR domain containing adaptor molecule 2 Homo sapiens 79-83 24275656-9 2014 A comparison between the TcpB and TIRAP crystal structures reveals substantial conformational differences in the region that encompasses the BB loop. boeravinone B 141-143 TIR domain containing adaptor protein Homo sapiens 34-39 24197068-16 2014 Inhibition of Src with siRNA reduced PDGF BB-induced ROS generation as assessed by 2",7"-dichlorodihydrofluorescein diacetate fluorescence. boeravinone B 42-44 Rous sarcoma oncogene Mus musculus 14-17 24600979-12 2014 The PON1 phenotype which is known to have high activity towards the substrate paraoxon, but low antioxidant activity (BB phenotype) was observed significantly more in PEX patients compared to controls. boeravinone B 118-120 paraoxonase 1 Homo sapiens 4-8 25994638-0 2014 Docking modes of BB-3497 into the PDF active site--a comparison of the pure MM and QM/MM based docking strategies. boeravinone B 17-19 peptide deformylase, mitochondrial Homo sapiens 34-37 25994638-3 2014 In this work, the known peptidic inhibitor BB-3497 and its various ionization and tautomeric states are evaluated for their inhibition efficiency against PDF using a molecular mechanics (MM) approach as well as a mixed quantum mechanics/molecular mechanics (QM/MM) approach, with an aim to understand the interactions in the binding site. boeravinone B 43-45 peptide deformylase, mitochondrial Homo sapiens 154-157 23626692-3 2013 In this study, we found three amino acid residues, two (663L and 688N) outside and one (681P) inside the BB loop, which were conserved in all of the TLRs, except for the TLR3 toll/IL-1R(TIR) domain. boeravinone B 105-107 toll like receptor 3 Homo sapiens 170-174 24133120-7 2013 Similarly, Cav2 appeared at the apical pole of PCs after DDAVP treatment of BB, Sprague-Dawley, and Long-Evans rats. boeravinone B 76-78 caveolin 2 Rattus norvegicus 11-15 23677468-7 2013 Activation of the alternative pathway on activated platelets occurs when properdin is on the surface and recruits C3b or C3(H2O) to form C3b,Bb or a novel cell-bound C3 convertase [C3(H2O),Bb], which normally is present only in the fluid phase. boeravinone B 141-143 complement C3 Homo sapiens 114-117 24668707-6 2014 Moreover, in the patient group, C3 levels were positively correlated with WBC and PLT counts, and Bb levels were positively correlated with AST, ALT and LDH activities. boeravinone B 98-100 solute carrier family 17 member 5 Homo sapiens 140-143 23626692-9 2013 Thus, our data demonstrated that the 663L and 688N residues outside of the BB loop were essential for the responsiveness of TLR2/2, TLR2/1 and TLR2/6, but the 681P residue inside of the BB loop exhibited divergent roles in TLR2/2, TLR2/1 and TLR2/6 signalling transduction, thereby providing clues regarding the specific signalling transduction of TLR2/2, TLR2/1 and TLR2/6. boeravinone B 75-77 toll like receptor 2 Homo sapiens 124-130 23626692-9 2013 Thus, our data demonstrated that the 663L and 688N residues outside of the BB loop were essential for the responsiveness of TLR2/2, TLR2/1 and TLR2/6, but the 681P residue inside of the BB loop exhibited divergent roles in TLR2/2, TLR2/1 and TLR2/6 signalling transduction, thereby providing clues regarding the specific signalling transduction of TLR2/2, TLR2/1 and TLR2/6. boeravinone B 75-77 toll like receptor 2 Homo sapiens 132-138 23626692-9 2013 Thus, our data demonstrated that the 663L and 688N residues outside of the BB loop were essential for the responsiveness of TLR2/2, TLR2/1 and TLR2/6, but the 681P residue inside of the BB loop exhibited divergent roles in TLR2/2, TLR2/1 and TLR2/6 signalling transduction, thereby providing clues regarding the specific signalling transduction of TLR2/2, TLR2/1 and TLR2/6. boeravinone B 75-77 toll like receptor 2 Homo sapiens 143-149 23626692-9 2013 Thus, our data demonstrated that the 663L and 688N residues outside of the BB loop were essential for the responsiveness of TLR2/2, TLR2/1 and TLR2/6, but the 681P residue inside of the BB loop exhibited divergent roles in TLR2/2, TLR2/1 and TLR2/6 signalling transduction, thereby providing clues regarding the specific signalling transduction of TLR2/2, TLR2/1 and TLR2/6. boeravinone B 75-77 toll like receptor 2 Homo sapiens 223-229 23626692-9 2013 Thus, our data demonstrated that the 663L and 688N residues outside of the BB loop were essential for the responsiveness of TLR2/2, TLR2/1 and TLR2/6, but the 681P residue inside of the BB loop exhibited divergent roles in TLR2/2, TLR2/1 and TLR2/6 signalling transduction, thereby providing clues regarding the specific signalling transduction of TLR2/2, TLR2/1 and TLR2/6. boeravinone B 75-77 toll like receptor 2 Homo sapiens 231-237 23626692-9 2013 Thus, our data demonstrated that the 663L and 688N residues outside of the BB loop were essential for the responsiveness of TLR2/2, TLR2/1 and TLR2/6, but the 681P residue inside of the BB loop exhibited divergent roles in TLR2/2, TLR2/1 and TLR2/6 signalling transduction, thereby providing clues regarding the specific signalling transduction of TLR2/2, TLR2/1 and TLR2/6. boeravinone B 75-77 toll like receptor 2 Homo sapiens 124-128 23626692-9 2013 Thus, our data demonstrated that the 663L and 688N residues outside of the BB loop were essential for the responsiveness of TLR2/2, TLR2/1 and TLR2/6, but the 681P residue inside of the BB loop exhibited divergent roles in TLR2/2, TLR2/1 and TLR2/6 signalling transduction, thereby providing clues regarding the specific signalling transduction of TLR2/2, TLR2/1 and TLR2/6. boeravinone B 75-77 toll like receptor 2 Homo sapiens 223-229 23626692-9 2013 Thus, our data demonstrated that the 663L and 688N residues outside of the BB loop were essential for the responsiveness of TLR2/2, TLR2/1 and TLR2/6, but the 681P residue inside of the BB loop exhibited divergent roles in TLR2/2, TLR2/1 and TLR2/6 signalling transduction, thereby providing clues regarding the specific signalling transduction of TLR2/2, TLR2/1 and TLR2/6. boeravinone B 75-77 toll like receptor 2 Homo sapiens 231-237 23626692-9 2013 Thus, our data demonstrated that the 663L and 688N residues outside of the BB loop were essential for the responsiveness of TLR2/2, TLR2/1 and TLR2/6, but the 681P residue inside of the BB loop exhibited divergent roles in TLR2/2, TLR2/1 and TLR2/6 signalling transduction, thereby providing clues regarding the specific signalling transduction of TLR2/2, TLR2/1 and TLR2/6. boeravinone B 75-77 toll like receptor 2 Homo sapiens 242-248 23335922-1 2012 Properdin, the only positive regulatory protein of the complement system, acts as both a stabilizer of the alternative pathway (AP) convertases and as a selective pattern recognition molecule of certain microorganisms and host cells (i.e., apoptotic/necrotic cells) by serving as a platform for de novo C3b,Bb assembly. boeravinone B 307-309 complement factor properdin Homo sapiens 0-9 23307841-8 2013 Metabolic enzymes involved in glycolysis (glycogen phosphorylase, phosphoglycerate mutase) and the citric acid cycle (aconitase 2, oxoglutarate dehydrogenase) were increased in AA- vs. BB-sired steers. boeravinone B 185-187 aconitase 2 Bos taurus 118-157 23535492-9 2013 In lymphoblasts, ADORA2A protein expression (p = 0.024), as well as cellular cAMP production (p = 0.0006), was significantly higher in AA than BB diplotype. boeravinone B 143-145 adenosine A2a receptor Homo sapiens 17-24 23570599-6 2013 The expression of PPARgamma increased and ColI and PDGF-B decreased in BB, DSHX and BB+DSHX groups as compared to model group (P < 0.05). boeravinone B 71-73 peroxisome proliferator-activated receptor gamma Rattus norvegicus 18-27 23570599-6 2013 The expression of PPARgamma increased and ColI and PDGF-B decreased in BB, DSHX and BB+DSHX groups as compared to model group (P < 0.05). boeravinone B 71-73 platelet derived growth factor subunit B Rattus norvegicus 51-57 22922150-5 2012 It accelerates the decomposition of C2a into C4b and the displacement of Bb from C3b. boeravinone B 73-75 complement C3 Homo sapiens 81-84 25621308-10 2013 When BB was administered beyond 1 hour after LCHS, its protective effects on cellularity, BM HPC growth, HPC mobilization, and plasma G-CSF levels were greatly diminished. boeravinone B 5-7 colony stimulating factor 3 Rattus norvegicus 134-139 23305498-11 2013 BB MS was related to high CD4+IL13 cell levels (ls=0.90), as well as to high CD14+IL6 cells percentage (ls=0.80). boeravinone B 0-2 interleukin 13 Homo sapiens 30-34 23305498-11 2013 BB MS was related to high CD4+IL13 cell levels (ls=0.90), as well as to high CD14+IL6 cells percentage (ls=0.80). boeravinone B 0-2 CD14 molecule Homo sapiens 77-81 22229637-11 2012 RESULTS: Galectin-9 expression by intestinal epithelial cells and serum galectin-9 levels were increased in mice and humans following dietary intervention with GF/Bb and correlated with reduced acute allergic skin reaction and mast cell degranulation. boeravinone B 163-165 lectin, galactose binding, soluble 9 Mus musculus 9-19 22624173-12 2004 (9) prepared a rat monoclonal autoantibody (IC2) with lymphocytes isolated from the spleen and lymph nodes of a spontaneously diabetic BB rat. boeravinone B 135-137 dynein cytoplasmic 1 intermediate chain 2 Homo sapiens 44-47 22624175-12 2004 (9) prepared a rat monoclonal autoantibody (IC2) with lymphocytes isolated from the spleen and lymph nodes of a spontaneously diabetic BB rat. boeravinone B 135-137 dynein cytoplasmic 1 intermediate chain 2 Homo sapiens 44-47 22290286-4 2012 At locus LEP/HinfI animals of AA genotype had lower test daily gain than that of BB (P < 0.01) or AB genotype (P < 0.05). boeravinone B 81-83 leptin Sus scrofa 9-12 22505424-3 2012 In previous studies, it was found that T3 binds to the bb" fragment of PDI. boeravinone B 55-57 prolyl 4-hydroxylase subunit beta Rattus norvegicus 71-74 22245613-5 2012 We conclude that the allele B (BB or Bb genotype) in vitamin D receptor gene is correlated with large amount albuminuria in the Han Chinese population with type 2 diabetes, and is probably a risk factor for early-onset diabetic nephropathy. boeravinone B 31-33 vitamin D receptor Homo sapiens 53-71 22245613-5 2012 We conclude that the allele B (BB or Bb genotype) in vitamin D receptor gene is correlated with large amount albuminuria in the Han Chinese population with type 2 diabetes, and is probably a risk factor for early-onset diabetic nephropathy. boeravinone B 37-39 vitamin D receptor Homo sapiens 53-71 24710421-3 2012 Fourteen patients with confirmed LNB and 103 patients with non-LNB were included, and the numbers of spontaneous and Bb-induced IFN-gamma-secreting cells were assayed by the ELISPOT test. boeravinone B 117-119 interferon gamma Homo sapiens 128-137 22229637-11 2012 RESULTS: Galectin-9 expression by intestinal epithelial cells and serum galectin-9 levels were increased in mice and humans following dietary intervention with GF/Bb and correlated with reduced acute allergic skin reaction and mast cell degranulation. boeravinone B 163-165 lectin, galactose binding, soluble 9 Mus musculus 72-82 22229637-12 2012 In addition, GF/Bb enhanced T(h)1- and T(reg)-cell differentiation in MLN and in PBMC cultures exposed to galectin-9. boeravinone B 16-18 galectin 9 Homo sapiens 106-116 22229637-13 2012 CONCLUSIONS: Dietary supplementation with GF/Bb enhances serum galectin-9 levels, which associates with the prevention of allergic symptoms. boeravinone B 45-47 galectin 9 Homo sapiens 63-73 21703046-8 2011 An age adjusted logistic regression limited to controls and patients not receiving bisphosphonate therapy showed that higher corrected serum calcium and the VDR Bb/BB genotypes independently increased the risk of prostate cancer. boeravinone B 161-163 vitamin D receptor Homo sapiens 157-160 22382187-8 2012 Insulin dose increment at 12 wk was significantly more in the BB regimen 0.46 +- 0.32 U/kg/day compared to 0.15 +- 0.21 U/kg/day in the BHI regimen (P<0.001). boeravinone B 62-64 insulin Homo sapiens 0-7 22848400-0 2012 Therapeutic inhibition of pro-inflammatory signaling and toxicity to staphylococcal enterotoxin B by a synthetic dimeric BB-loop mimetic of MyD88. boeravinone B 121-123 myeloid differentiation primary response gene 88 Mus musculus 140-145 21533832-2 2011 Recent studies have shown that the TIR/BB-Loop mimetic (AS-1) disrupted the interaction of MyD88 with the IL-1R, resulting in blunting of NF-kappaB activation. boeravinone B 39-41 prostaglandin D2 receptor Homo sapiens 56-60 21533832-2 2011 Recent studies have shown that the TIR/BB-Loop mimetic (AS-1) disrupted the interaction of MyD88 with the IL-1R, resulting in blunting of NF-kappaB activation. boeravinone B 39-41 MYD88 innate immune signal transduction adaptor Homo sapiens 91-96 21533832-2 2011 Recent studies have shown that the TIR/BB-Loop mimetic (AS-1) disrupted the interaction of MyD88 with the IL-1R, resulting in blunting of NF-kappaB activation. boeravinone B 39-41 interleukin 1 receptor type 1 Homo sapiens 106-111 22319800-13 2004 (6) prepared a rat monoclonal autoantibody (IC2) with lymphocytes isolated from the spleen and lymph nodes of a spontaneously diabetic BB rat. boeravinone B 135-137 dynein cytoplasmic 1 intermediate chain 2 Homo sapiens 44-47 22213323-7 2012 Comparison of the frequencies of the VDR genotypes in sunlight-exposed vs. not sunlight-exposed skin areas revealed BB 30.1% vs. 7.1% respectively in BCCs and BB 28.1% vs. 0.0% respectively in SCCs, indicating that vitamin D signalling may be of importance for photocarcinogenesis of the skin. boeravinone B 116-118 vitamin D receptor Homo sapiens 37-40 22213323-7 2012 Comparison of the frequencies of the VDR genotypes in sunlight-exposed vs. not sunlight-exposed skin areas revealed BB 30.1% vs. 7.1% respectively in BCCs and BB 28.1% vs. 0.0% respectively in SCCs, indicating that vitamin D signalling may be of importance for photocarcinogenesis of the skin. boeravinone B 159-161 vitamin D receptor Homo sapiens 37-40 22694192-5 2012 Finally, direct comparison of the main features shown by the AA interface in the human 5-HT(3A)-R with those of the BB interface in the homopentameric human 5-HT(3B)-R provides interesting clues about the possible reasons that cause the 5-HT(3B)-R not to be functional. boeravinone B 116-118 5-hydroxytryptamine receptor 3B Homo sapiens 157-164 22291790-5 2011 RESULTS: Glutathione-S-transferase GSTM3 gene frequencies were 89% for AA, 10% for AB and 1% for BB. boeravinone B 97-99 glutathione S-transferase mu 3 Homo sapiens 35-40 21427361-8 2011 The proteome of the NHERF2 null mouse small intestinal BB demonstrates up- and downregulation of multiple transport proteins, signaling molecules, cytoskeletal proteins, tight junctional and adherens junction proteins, and proteins involved in metabolism, suggesting involvement of NHERF2 in multiple apical regulatory processes and interactions with luminal contents. boeravinone B 55-57 solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 2 Mus musculus 20-26 21427361-8 2011 The proteome of the NHERF2 null mouse small intestinal BB demonstrates up- and downregulation of multiple transport proteins, signaling molecules, cytoskeletal proteins, tight junctional and adherens junction proteins, and proteins involved in metabolism, suggesting involvement of NHERF2 in multiple apical regulatory processes and interactions with luminal contents. boeravinone B 55-57 solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 2 Mus musculus 282-288 21703046-8 2011 An age adjusted logistic regression limited to controls and patients not receiving bisphosphonate therapy showed that higher corrected serum calcium and the VDR Bb/BB genotypes independently increased the risk of prostate cancer. boeravinone B 164-166 vitamin D receptor Homo sapiens 157-160 20822478-6 2011 The results suggest that phosphorylation of Tyr86 leads to conformational changes in the BB loop of MAL, and this conformational switch forms the interface for binding with MyD88. boeravinone B 89-91 TIR domain containing adaptor protein Homo sapiens 100-103 21329755-8 2011 RESULTS: IL6 expression was significantly increased in IBU-BB compared to BB group both in VW (VW: fold-change (FC)=4.9, p=0.0009) and ST (ST: FC=8.7, p=0.0003). boeravinone B 59-61 interleukin-6 Ovis aries 9-12 20822478-6 2011 The results suggest that phosphorylation of Tyr86 leads to conformational changes in the BB loop of MAL, and this conformational switch forms the interface for binding with MyD88. boeravinone B 89-91 MYD88 innate immune signal transduction adaptor Homo sapiens 173-178 20801162-3 2011 The objective of the present study was to characterize the role(s) of GRP and its receptor antagonist (D-Tpi6, Leu13 psi[CH2NH]-Leu14) BB((6-14)) (RC-3095) in fear-related responses using two animal models of conditioned fear. boeravinone B 135-137 gastrin releasing peptide Rattus norvegicus 70-73 21150475-1 2011 Phosphorylation of extracellular-signal-regulated kinase 1/2 (p-ERK 1/2) was investigated by immunohistochemistry at 30 min, 1 h, and 48 h after nerve transection in the sciatic nerve of healthy and diabetic [streptozotocin (STZ)-induced diabetes mellitus and BioBreeding (BB; i.e. DR.lyp/lyp or BBDP)] rats. boeravinone B 273-275 mitogen activated protein kinase 3 Rattus norvegicus 19-60 21264981-11 2011 The a(cb) /a(cc) ratio clearly differentiated between fetsues with BB and those with second-degree AVB, including during midgestation, when it was difficult to distinguish these fetuses. boeravinone B 67-69 acetyl-CoA carboxylase alpha Homo sapiens 11-16 20736165-1 2010 The small intestinal BB Na(+)/H(+) antiporter NHE3 accounts for the majority of intestinal sodium and water absorption. boeravinone B 21-23 solute carrier family 9 member A3 Homo sapiens 46-50 20473502-6 2010 The distribution of VDR genotyping in patients with SLE was 23.3% for BB, 60% for Bb and 16.7% for bb and in the control group was 33.3% for BB, 46.7% for Bb and 20% for bb (P = 0.334). boeravinone B 70-72 vitamin D receptor Homo sapiens 20-23 20697762-13 2010 A predominance of Bb genotype of the VDR gene was evident in this group of postmenopausal Turkish women. boeravinone B 18-20 vitamin D receptor Homo sapiens 37-40 20473502-6 2010 The distribution of VDR genotyping in patients with SLE was 23.3% for BB, 60% for Bb and 16.7% for bb and in the control group was 33.3% for BB, 46.7% for Bb and 20% for bb (P = 0.334). boeravinone B 82-84 vitamin D receptor Homo sapiens 20-23 20473502-6 2010 The distribution of VDR genotyping in patients with SLE was 23.3% for BB, 60% for Bb and 16.7% for bb and in the control group was 33.3% for BB, 46.7% for Bb and 20% for bb (P = 0.334). boeravinone B 99-101 vitamin D receptor Homo sapiens 20-23 19902381-7 2010 Furthermore, an HP-induced decrease in cell injury was reversed by berberine chloride (BB), the inhibitor of AR. boeravinone B 87-89 aldo-keto reductase family 1 member B1 Rattus norvegicus 109-111 20622116-8 2010 Expression of Rck protected bacteria from alternative pathway-mediated killing and was associated with a reduction in C3b, Bb, and membrane attack complex deposition. boeravinone B 123-125 resistance to complement killing Salmonella enterica subsp. enterica serovar Typhimurium 14-17 20024783-7 2010 Chickens inheriting the BB genotype at A-FABP, along with the CD genotype at H-FABP, produced muscles with a much higher content of IMF when compared with all other genotypes. boeravinone B 24-26 adipocyte fatty acid binding protein Gallus gallus 39-45 20424303-11 2010 B allele frequency of the codon 192 polymorphism in paraoxonase gene was higher in cases as compared to controls and odds ratio of developing the MI with BB genotype versus AA genotype was 2.37, (P=0.044). boeravinone B 154-156 paraoxonase 1 Homo sapiens 52-63 21180298-8 2010 The main mode of action of BB in treating systolic HF is inhibition of chronic beta-1 stimulation-induced myocardial apoptosis/necrosis/inflammation. boeravinone B 27-29 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 79-85 20510028-16 2010 (3) Compared with those in SB group, myocardial tissue endothelin-1 content of rats in BB group increased significantly at PIM 10, 60, 180 (F = 2.85, P < 00.05 or P < 0.01), and NO content increased significantly at PIM 60, 180 (F = 1.87, with P values all below 0.05). boeravinone B 87-89 endothelin 1 Rattus norvegicus 55-67 20034570-6 2010 In this study, the anti-NNV mechanism of barramundi Mx protein (BMx) was elucidated in cBB cells which were derived from BB cell line after serial treatments by NNV-specific antiserum and then became an NNV-free cell line. boeravinone B 88-90 LOW QUALITY PROTEIN: interferon-induced GTP-binding protein Mx-like Lates calcarifer 52-62 20034570-6 2010 In this study, the anti-NNV mechanism of barramundi Mx protein (BMx) was elucidated in cBB cells which were derived from BB cell line after serial treatments by NNV-specific antiserum and then became an NNV-free cell line. boeravinone B 88-90 BMX non-receptor tyrosine kinase Homo sapiens 64-67 20024783-7 2010 Chickens inheriting the BB genotype at A-FABP, along with the CD genotype at H-FABP, produced muscles with a much higher content of IMF when compared with all other genotypes. boeravinone B 24-26 IF Gallus gallus 132-135 19787719-6 2009 BB correction decreased CBF by a factor of 4.7 +/- 0.4, but did not affect precision. boeravinone B 0-2 CCAAT enhancer binding protein zeta Homo sapiens 24-27 19887834-4 2010 RESULTS: The total allelic frequency of VDR polymorphism was: 16% BB, 49% Bb and 35% bb. boeravinone B 66-68 vitamin D receptor Homo sapiens 40-43 19887834-4 2010 RESULTS: The total allelic frequency of VDR polymorphism was: 16% BB, 49% Bb and 35% bb. boeravinone B 74-76 vitamin D receptor Homo sapiens 40-43 19887834-4 2010 RESULTS: The total allelic frequency of VDR polymorphism was: 16% BB, 49% Bb and 35% bb. boeravinone B 85-87 vitamin D receptor Homo sapiens 40-43 19890040-1 2009 Complement factor B (fB) circulates in plasma as a proenzyme that, upon binding to C3b in the presence of Mg(2+), is cleaved by factor D to produce Ba and Bb fragments. boeravinone B 155-157 complement factor B Homo sapiens 0-19 19890040-2 2009 Activated Bb remains bound to C3b organizing the alternative pathway C3 convertase (C3bBb). boeravinone B 10-12 complement C3 Homo sapiens 30-33 19787719-10 2009 CONCLUSION: Corrections for AIF PV and nonlinear BB relaxivity improve bolus MRI-based CBF maps. boeravinone B 49-51 CCAAT enhancer binding protein zeta Homo sapiens 87-90 19619630-6 2009 RESULTS: BB and CB contained markedly different types and quantities of bile acid conjugates and phospholipids, although the potencies of BB and CB to activate pancreatic lipase were not significantly different. boeravinone B 138-140 pancreatic lipase Bos taurus 160-177 19619630-7 2009 The potency of BB to activate pancreatic lipase was reconstituted by the major bile acid conjugates and phospholipids found in BB. boeravinone B 15-17 pancreatic lipase Bos taurus 30-47 19619630-7 2009 The potency of BB to activate pancreatic lipase was reconstituted by the major bile acid conjugates and phospholipids found in BB. boeravinone B 127-129 pancreatic lipase Bos taurus 30-47 19700700-11 2009 Basal insulin concentrations were higher in HF (1.58 +/- 0.40 microU/mL) than in BB calves (0.35 +/- 0.09 mmol/L). boeravinone B 81-83 insulin Bos taurus 6-13 19625781-3 2009 In the present study, we revealed that BB, a new synthetic quinonazoline derivative, was a potent EGFR inhibitor. boeravinone B 39-41 epidermal growth factor receptor Mus musculus 98-102 19625781-4 2009 BB selectively inhibited EGFR with a IC(50) value of 50 +/- 37 nM, at least 32-fold more potent than suppressed all other ten tested receptor tyrosine kinases including the same family member ErbB2 (IC(50) = 5.6 +/- 3.2 microM). boeravinone B 0-2 epidermal growth factor receptor Mus musculus 25-29 19625781-4 2009 BB selectively inhibited EGFR with a IC(50) value of 50 +/- 37 nM, at least 32-fold more potent than suppressed all other ten tested receptor tyrosine kinases including the same family member ErbB2 (IC(50) = 5.6 +/- 3.2 microM). boeravinone B 0-2 erb-b2 receptor tyrosine kinase 2 Mus musculus 192-197 19625781-5 2009 BB effectively abrogated autophosphorylation of the EGF-stimulated EGFR and phosphorylation of its key downstream signaling molecules ERK and AKT in A549 cells. boeravinone B 0-2 epidermal growth factor receptor Mus musculus 67-71 19625781-5 2009 BB effectively abrogated autophosphorylation of the EGF-stimulated EGFR and phosphorylation of its key downstream signaling molecules ERK and AKT in A549 cells. boeravinone B 0-2 Eph receptor B2 Mus musculus 134-137 19625781-5 2009 BB effectively abrogated autophosphorylation of the EGF-stimulated EGFR and phosphorylation of its key downstream signaling molecules ERK and AKT in A549 cells. boeravinone B 0-2 thymoma viral proto-oncogene 1 Mus musculus 142-145 19625781-9 2009 Most importantly, BB prominently inhibited in vivo tumorigenesis of NIH3T3 cells specifically driven by the activation-mutated EGFR genes. boeravinone B 18-20 epidermal growth factor receptor Mus musculus 127-131 19625781-13 2009 Taken together, the data indicate that BB is a new selective EGFR inhibitor with potent antitumor activity, revealing its potential as a promising anticancer candidate. boeravinone B 39-41 epidermal growth factor receptor Mus musculus 61-65 19473288-8 2009 The frequency of the eNOS gene intron 4 genotype was found as bb: 55 (67.1%), ab: 26 (31.7%), and aa: 1 (1.2%) in the controls and bb: 43 (67.2%), ab: 19 (29.7%), and aa: 2 (3.1%) in the patient group. boeravinone B 62-64 nitric oxide synthase 3 Homo sapiens 21-25 19535329-7 2009 NHERF3 short hairpin RNA knockdown (>50%) in Caco-2BBe cells significantly reduced basal NHE3 activity by decreasing BB NHE3 amount. boeravinone B 54-56 solute carrier family 9 member A3 Homo sapiens 123-127 19556717-6 2009 After B and BB meals, type 1 diabetic patients with high HMW-adiponectin consistently had lower triglyceride and RLP-triglyceride concentrations for up to 180 min than those with low HMW-adiponectin (p<0.01); however, apoB48 did not differ between these two groups. boeravinone B 12-14 adiponectin, C1Q and collagen domain containing Homo sapiens 61-72 19535329-6 2009 Similarly, in Caco-2BBe cells, NHERF3 and NHE3 colocalized in the BB under basal conditions but after elevation of [Ca(2+)](i) by carbachol, this overlap was abolished. boeravinone B 20-22 PDZ domain containing 1 Homo sapiens 31-37 19535329-6 2009 Similarly, in Caco-2BBe cells, NHERF3 and NHE3 colocalized in the BB under basal conditions but after elevation of [Ca(2+)](i) by carbachol, this overlap was abolished. boeravinone B 20-22 solute carrier family 9 member A3 Homo sapiens 42-46 19535329-7 2009 NHERF3 short hairpin RNA knockdown (>50%) in Caco-2BBe cells significantly reduced basal NHE3 activity by decreasing BB NHE3 amount. boeravinone B 54-56 PDZ domain containing 1 Homo sapiens 0-6 19535329-7 2009 NHERF3 short hairpin RNA knockdown (>50%) in Caco-2BBe cells significantly reduced basal NHE3 activity by decreasing BB NHE3 amount. boeravinone B 54-56 solute carrier family 9 member A3 Homo sapiens 92-96 19136636-3 2009 Ba dissociates from the complex, while Bb remains bound to C3b, forming the active alternative pathway convertase, C3bBb. boeravinone B 39-41 endogenous retrovirus group K member 3 Homo sapiens 59-62 19034627-4 2009 RESULTS: In human primary hepatocytes, real-time PCR analysis showed induction of CYP2B6, CYP3A4, UGT1A1, MDR1, and MRP2 by EGb 761, ginkgolide A (GA) and ginkgolide B (GB), but not by bilobalide (BB) or the flavonoids (quercetin, kaempferol and tamarixetin) of GBE. boeravinone B 197-199 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 82-88 19034627-4 2009 RESULTS: In human primary hepatocytes, real-time PCR analysis showed induction of CYP2B6, CYP3A4, UGT1A1, MDR1, and MRP2 by EGb 761, ginkgolide A (GA) and ginkgolide B (GB), but not by bilobalide (BB) or the flavonoids (quercetin, kaempferol and tamarixetin) of GBE. boeravinone B 197-199 ATP binding cassette subfamily B member 1 Homo sapiens 106-110 19136636-6 2009 However, the C3b-bound fB structure was easily interpreted after independently fitting the atomic structures of the isolated Bb and Ba fragments. boeravinone B 125-127 endogenous retrovirus group K member 3 Homo sapiens 13-16 18521006-2 2008 ATF3-stained sensory neurons in dorsal root ganglia and Schwann cells at compression site were more frequent in diabetic BB rats. boeravinone B 121-123 activating transcription factor 3 Rattus norvegicus 0-4 19492922-4 2009 RESULTS: BB (21%), Bb (38%) and bb (41%) genotypes showed similar osteocalcin serum levels. boeravinone B 9-11 bone gamma-carboxyglutamate protein Homo sapiens 66-77 19492922-4 2009 RESULTS: BB (21%), Bb (38%) and bb (41%) genotypes showed similar osteocalcin serum levels. boeravinone B 19-21 bone gamma-carboxyglutamate protein Homo sapiens 66-77 19492922-4 2009 RESULTS: BB (21%), Bb (38%) and bb (41%) genotypes showed similar osteocalcin serum levels. boeravinone B 32-34 bone gamma-carboxyglutamate protein Homo sapiens 66-77 18098185-7 2008 At 1W, a significant decrease of inflammatory response was observed for IBU-BB relative to BB in terms of number of lymphocytes and of immunohistochemical staining for CD172a, MHC-II, CD3, and CD4. boeravinone B 76-78 T-cell surface glycoprotein CD4 Ovis aries 193-196 18008080-10 2008 Similarly this result was demonstrated, in combined AB + BB genotypes of IL-1RA with HPV 18 (OR = 0.12, 95% CI= 0.05-0.30, p = 0.0000000) and HPV type 16 + 18 (OR = 0.18,95% CI = 0.08-0.38, p = 0.000005). boeravinone B 57-59 interleukin 1 receptor antagonist Homo sapiens 73-79 18507868-2 2008 However, BB therapy needs multiple insulin injections per a day. boeravinone B 9-11 insulin Homo sapiens 35-42 18769790-9 2008 The prevalence of these VDR gene polymorphisms in women with fractures were 16% BB, 69% Bb, 15% bb for Bsm-l; 30% AA, 46% Aa, 14% aa for Apa-1; 17% TT, 34 Tt, 8% tt for Taq-1 and 43%FF, 41% Ff, 16% ff for Fok-1. boeravinone B 80-82 vitamin D receptor Homo sapiens 24-27 18328492-3 2008 The most recently accepted notation for the LSER equation, proposed by Abraham is given as follows: SP= c+eE+sS+aA+bB+vV where SP is any free energy related property of a solute, such as log K, and each term in the equation represents a specific type of chemical interaction. boeravinone B 115-117 surfactant protein C Homo sapiens 100-105 18769790-9 2008 The prevalence of these VDR gene polymorphisms in women with fractures were 16% BB, 69% Bb, 15% bb for Bsm-l; 30% AA, 46% Aa, 14% aa for Apa-1; 17% TT, 34 Tt, 8% tt for Taq-1 and 43%FF, 41% Ff, 16% ff for Fok-1. boeravinone B 88-90 vitamin D receptor Homo sapiens 24-27 18551994-8 2008 Analysis of the gene polymorphism revealed that the frequency of the eNOS gene variant containing a 27-bp repeat in intron 4 is similar between control subjects (aa:ab:bb = 0%:21.8%:78.2%), and patients with CVD (aa:ab:bb = 3.3%:21.7%:75.0%). boeravinone B 168-170 nitric oxide synthase 3 Homo sapiens 69-73 18177825-8 2008 In case-only analysis, carriers of the AA genotype of GSTM3 among tobacco users were at elevated risk of cervical cancer (P = .024, OR 2.1, 95% CI, 1.0 to 4.1) as compared with AB and BB genotypes. boeravinone B 184-186 glutathione S-transferase mu 3 Homo sapiens 54-59 18551994-8 2008 Analysis of the gene polymorphism revealed that the frequency of the eNOS gene variant containing a 27-bp repeat in intron 4 is similar between control subjects (aa:ab:bb = 0%:21.8%:78.2%), and patients with CVD (aa:ab:bb = 3.3%:21.7%:75.0%). boeravinone B 219-221 nitric oxide synthase 3 Homo sapiens 69-73 17640418-9 2008 In livers, SOD activities were significantly greater in groups BC, BB and CX, and glutathione reductase activities were significantly greater in groups BB and CX than in group CC. boeravinone B 152-154 glutathione-disulfide reductase Rattus norvegicus 82-103 18309714-9 2007 SOD activity in BB, BL and LL groups as compared to TT and in the LL group as compared to BT were significantly different. boeravinone B 16-18 superoxide dismutase 1 Homo sapiens 0-3 17846653-6 2007 The estimates of bm represented substantial fractions of bp, whereas those of bb,m were the dominant component of bbp. boeravinone B 78-80 transmembrane protein 158 Homo sapiens 114-117